Cryo-system comprising nanoparticles for treating body part of individual by cryotherapy

The freezing system with a cooled probe and tethered nanoparticles improves cryotherapy efficacy by enhancing cooling volume and reducing toxicity, addressing inefficiencies and safety concerns of conventional methods.

JP2024167215APending Publication Date: 2024-12-03NANOBACTERIE

Patent Information

Application Number
JP2024126004
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-03-24
Filing Date
2024-08-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Conventional cryotherapy methods without nanoparticles are inefficient and may cause toxicity and temperature gradients, limiting their effectiveness and safety in treating body parts.

Method used

A freezing system comprising a cooled probe and nanoparticles, where the nanoparticles are bound via a tethering material, enhances cooling efficacy by local temperature capture and reduces toxicity through controlled temperature gradients.

Benefits of technology

The system achieves more effective and safer cryotherapy by increasing cooling volume, reducing temperature gradients, and minimizing toxicity, allowing for targeted and controlled temperature distribution within body parts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167215000007
    Figure 2024167215000007
  • Figure 2024167215000008
    Figure 2024167215000008
  • Figure 2024167215000009
    Figure 2024167215000009
Patent Text Reader

Abstract

To provide a cryotherapy for treating a body part of an individual.SOLUTION: A cryo-system for treating a body part of an individual by cryotherapy, comprises two parts: (A) a first part that is a cryo-probe, where (1) the cryo-probe includes a penetrating segment that is in communication with a cryogen source, is at least smaller than one tenth of a maximum volume of the body part and / or has at least one dimension not larger than 1 cm, so as to be suitable for an internal cooling action, and (2) the cryo-probe includes a non-penetrating segment in communication with a cryogen source so as to be suitable for an external cooling action; and (B) a second part that is any of (1) an assembly of at least two nanoparticles, the nanoparticles characterized in that the assembly includes at least two nanoparticles bound to each other or bonded to each other via a binding or bonding material, and (2) at least one nanoparticle including iron and at least one other metal other than the iron, where the assembly of at least two nanoparticles or the at least one nanoparticle is cooled by the cryo-probe.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a cryoprobe and at least one cryotherapy probe for the treatment of a body part of an individual by cryotherapy. The present invention relates to a freezing system comprising nanoparticles of the present invention. [Background technology]

[0002] The use of cryotherapy has been proposed for a number of medical applications (Non-Patent Reference 1). , which works by cooling the body parts of living organisms in the absence of nanoparticles. To improve the effectiveness of cryotherapy, a cooling probe and at least one other metal other than iron are used. We present a frozen system consisting of at least one nanoparticle containing Two cryotherapy methods that work without or sequentially are presented and are currently in use. This provides some improvement in the effectiveness of cryotherapy compared to conventional cryotherapy. [Prior art documents] [Non-patent literature]

[0003] Yiu et al, Int. J. Angiol., 16, January 2008 January 1, 2008 Summary of the Invention

[0004] The present invention relates to a freezing system for treating a body part of an individual, specifically comprising two parts: This relates to the freezing system used. A) The first part is a cooled tip, 1) a cooling probe in communication with a cryogenic source, the cryogenic probe being capable of absorbing at least 10% of the maximum volume of the body part; 1 or at least one dimension of the penetration is 1 cm or less, Suitable for local cooling or 2) The cooling probe has a non-penetrating portion that communicates with the refrigeration source and is suitable for external cooling. , and B) The second part is either: 1) An assembly of at least two nanoparticles, which bind together, and The nanoparticles are characterized by comprising at least two nanoparticles bound together via a tether or binding material. It is a sign. or 2) at least one nanoparticle comprising: a) iron and at least one other metal other than iron; and b) contains more than 50% by mass of iron or iron oxide; Here, the at least two nanoparticles or the at least one nanoparticle aggregate are cooled probes. It means that it is cooled by the needle. Here, the aggregate of at least two nanoparticles or at least one nanoparticle is in particular α) cooled probe or β) cooled by switching on or activating the cooled probe means.

[0005] The at least two nanoparticles or the at least one collection of nanoparticles are in particular: α) cryoprobes; Do not use the needle or β) switch off or do not activate the cooling probe. This means to warm up.

[0006] The present freezing system specifically does not involve the application of a magnetic field or ice-breaking source. In some cases, the present freezing system may have at least one common feature with the nanoparticles and / or the cooled tip. Both can have one characteristic.

[0007] In some other cases, the nanoparticles and / or the cooled probe have little in common with the frozen system. A scalar may have at least one characteristic.

[0008] In some cases, the freezing system may exhibit slightly different properties from those of the nanoparticle and / or the cooled tip. It can have at least one characteristic.

[0009] In some other cases, the nanoparticles and / or the cooled probe are different from the properties of the frozen system. They may have at least one characteristic that is different.

[0010] In some cases, the cryogenic freezing system may be internal or external to the body part. In some other cases, the freezing system may be at least one of the freezing systems or methods according to the present invention. The freezing system may be a freezing system during at least one step of the method. It may be designated as a freeze-up system.

[0011] In some other cases, the cryogenic system is a freezing system selected from the group consisting of: could be: i) Cryogenic systems or cryogenic systems before administration or positioning on a body part Also called the system ii) The freezing system during administration or positioning of a body part or the freezing system during administration or positioning of a body part Also known as the ketsu system, iii) Freezing systems after administration or positioning of body parts or after administration or positioning It's called a freezing system. iv) the freezing system or pre-freezing system prior to at least one step or treatment of the method; Also called a non-operating freezing system, v) A freezing system during at least one step of a method or treatment, and also during operation. Also called the stem vi) The freezing system after at least one step of the method or treatment, and also the post-freezing system Also called a non-operating frozen system.

[0012] In one embodiment of the present invention, the nanoparticles have at least one of the following properties: i) they capture or store cold temperatures locally; ii) They compare the volume cooled by the freezing system with the cooling probe in the absence of nanoparticles. This allows for an increase in the volume cooled by the needle. iii) They are the location of the cooling probe within the body part and at some distance from this location. This allows for a reduction in the temperature gradient between iv) They are cryotherapy at a certain temperature or minimum or cooling temperature, but in the absence of nanoparticles. This is larger than when using a cooled probe alone. v) They provide a plateau or temperature maintenance advantage compared to the situation where a freezing system is used alone. This allows for the formation of a retention period or slowing down the warm-up of the body, and the At least one of these, in particular, increases the efficacy and reduces the toxicity of cryotherapy.

[0013] In one embodiment, the internal cooling effect occurs at or within the body part. or body part or device or segment, especially from a penetrating segment 3 , 10 6 or 10 9 It is a cooling action or refrigeration that occurs at a distance of less than 1 nm.

[0014] In another embodiment, the external cooling occurs outside the body part or is performed by a device or is a segment, especially a non-penetrating segment, outside or from a body part, 10 3 , 10 6, or 10 9 It is a cooling action or refrigeration that occurs over distances of more than 1000 nm.

[0015] In one embodiment, cooling or cooling effect, sometimes referred to as freezing, is a reduction in the temperature of a body part. Degrees, especially, may be 0, 1, 5, 10, 50, 100 or 10 3 Over °C, 10 otherwise 10 , 10 3 , or below 100, 5, 2 or 1°C, or It is a reducing action, starting especially at the initial temperature and ending especially at the final temperature.

[0016] In some cases, the cooling probe may include a segment for cooling a body part and a segment for cooling a body part. It can be configured with a cryo-source, in which case the segment communicates with the cryo-source to provide cooling. Diffuses or transports cold air from the source to the segments, especially when the segments are in the same temperature or 10°C higher than the cryosource temperature. 3 , 100, 50, 20, 10, 5, 2, or This results in a temperature that is 1°C below.

[0017] In some cases, when the cooling probe is active or turned on, the temperature of the segment 100, 50, 10, 5, 2, 0, -5, -20, -40, -100, -200 or - The temperature will be below 250°C.

[0018] In some other cases, when the cooling tip is activated or turned on, the segment The values ​​are -200, -150, -100, -50, -40, -20, -10, -5, -1, 0 , temperatures exceeding 2, 5, or 10°C.

[0019] In some other cases, the cooled tip is deactivated or switched off. If so, is the segment at physiological temperature, especially compared to the temperature of the room or environment it is in? and temperatures that are not specifically cooled or reduced by more than 10 or 100°C.

[0020] In some other cases, when the cooling probe is activated or switched on , the segment is deactivated or switched off at least This can be 0, 1, 5, 10, 20, 50, 100 or 200°C lower. The tip is switched on and the cryo source is cool enough to cool the segment. This can occur if time has passed.

[0021] In some cases, the cooling probe may be activated faster than when it is deactivated or turned off. The temperature of the segments when the needle is activated or turned on may be the same. This is because the cryoprobe is switched on and the cryosource is This can happen if there isn't enough time to cool down.

[0022] In some cases, the body part is at the same temperature as the segment or nanoparticle, or the segment or 10 from the temperature of the nanoparticles 5 , 10 3 , 10 2 , 50, 20, 10, 5, 2, 1 or 0. There may be a temperature difference of less than 1°C, which is the temperature difference between the segment or the body part close to the nanoparticle. For 10 minutes, or from a segment or nanoparticle 9 , 10 6 , 10 3 , 10, or This is true for distances of 1 nm or less.

[0023] In some other cases, the body part may have a temperature different from that of the segment or nanoparticle. degrees, or 10 from the temperature of the segment or nanoparticle -5 , 10 -3 , 10 -2 , 0.1 There can be a temperature difference of 0, 1, 10, or even more than 100°C. is for body parts far from the nanoparticle, or 0.1, 1 from the segment or nanoparticle. , 10, 10 3 , 10 6 , or 10 9 This applies when the distance is greater than 100 nm.

[0024] cooled probe

[0025] In one embodiment of the present invention, the cooling probe is adapted to: a) penetrate or non-penetrate a body part; a) a cryogen source; and / or c) a system in which the cryogen source contacts or communicates with the segment. Includes

[0026] In some cases, the segment or cooling probe may be referred to as an instrument, device, apparatus, element, part, section, Divisions, chunks, divisions, portions, slices, fragments, components , wedge, ramp, slab, hunk, parcel, intercept, bundle, subdivision, frac component, element, unit, module, division, compartment, section Cryo-instruments, cryo-equipment, cryo-transport devices ... Equipment, cryo piece, cryo parts, frozen section, frozen chunk, cryogenic division, cryogenic cryogenic section, cryogenic slice, cryogenic fragment, cryogenic component, cryogenic web cryogenic mass, cryogenic slab, cryogenic mass, cryogenic parcel, cryosection, cryobundle, cryo Io subdivision, cryostruction, cryo-component, cryo-element , cryo unit, cryo module, cryo component, cryo department, cryocon compartment, cryo-sector, cryo-branch, and / or cryo-wing and may be so designated.

[0027] In particular, the segment may be, for example, separated from the cooled tip. is not completely or partially decomposed in the body part or in contact with the cooling probe. If it remains the same, it belongs to the cooled probe.

[0028] In some cases, the segment may not belong to the cooling tip, e.g. If the material is separated from the cooling tip, it may be biodegradable and decompose in vivo. For example, when

[0029] In some cases, the nanoparticles are separated from the segment by body parts that do not contain nanoparticles. It has been done.

[0030] In one embodiment of the present invention, the cooling probe is an instrument or device specifically used to apply cold to tissue. or equipment or device or temperature controller or instrument, equipment or device or temperature controller It is in particular a medical or surgical instrument or medical device. It is in particular a personal inserted into or placed on a body part of an individual, but in some cases placed on the outside of that body part This sometimes happens.

[0031] In another embodiment of the invention, the cooling probe is suitable for internal cooling, particularly for cooling of body parts. and particularly including segments and / or cooling sources, the segments being characterized by the cooling sources. The mixture is cooled to 100°C.

[0032] In some cases, the cooling probe includes a segment that penetrates the interior of the body part, and in particular, In particular, the penetrating segment of a cooled probe is the surface or It has at least one of its surfaces, particularly the external surface, in contact with a body part.

[0033] In some other cases, the cooling probe does not penetrate the interior of the body part or It includes segments located outside the part, and specifically refers to the non-penetrating segments of the cooling probe. In particular, the non-penetrating segment of the cooling probe is different from the penetrating segment of the body part and is located on its surface. or does not have at least one part of its surface, especially an external surface, in contact with a body part .

[0034] In some cases, the volume VS or length LS or dimension DS or diameter dS of a segment is calculated based on the The maximum volume of a body part, VBP, or the maximum length of a body part, LBP, or the maximum dimension of a body part, DBP or the maximum diameter of the body part, dBP. VS / VBP or LS / LBP or DS / D BP or dS / dBP ratios are 1, 0.8, 0.5, 0.2, 10 -1 , 10 -3 , 10 - 5 or 10 -10 It can be the following:

[0035] In some cases, the maximum volume, dimension, length, or diameter of a body part is: i) The maximum volume of the cooled or pathological or tumorous or swollen body part , dimensions, length, diameter, or ii) pathological or tumorous or containing at least one pathological cell or unhealthy The volume, dimensions, length, and diameter of the body part.

[0036] In some cases, the maximum volume, dimension, length, or diameter of one body part of an individual relative to another body part The boundary of the tumor is the boundary or edge of the tumor or unhealthy area, and is the boundary between healthy and unhealthy areas of an individual. This is sometimes identified by microscopy, histology, or surgical excision. can be identified.

[0037] In some other cases, the volume VS, length LS, dimension DS, or diameter d of the segment S is the maximum volume of the body part, V BP , or the maximum length of the body part, L BP , or body parts The maximum dimension of the part, D BP , or the maximum diameter of the body part, d BP Greater than. Ratio V S / V BP Ma or L S / L BP or D S / D BP or d S / d BP is 1, 2, 5, 10, 10 3 , or 10 5 It can be bigger.

[0038] In still other cases, the ratio V S / V BP or L S / L BP or D S / D BP or d S / d BP is 10 -10 From 10 10 , 10 -5 From 10 5 , 10 -5 to 1 or 10 -3 It is between 0 and 1.

[0039] In one embodiment of the present invention, the segments are 10 , 10 5 , 10 3 , 200, 10 0, 50, 20, 10, 5, 2, 1, 0.5, 10 -1 , 10 -3 , 10 -5 , 10 -7 or 10 -10 cm or cm 2 or cm 3 At least one of the following: Having a dimension or length or diameter or surface or volume.

[0040] In one aspect, the present invention provides a cooling probe, particularly a segment, most particularly a penetrating segment, comprising nanoparticles. Allows for a smaller size when used in the presence of offspring than in their absence In some cases, such sizes are possible when a cooled tip is used in conjunction with a nanoparticle. When the cooled probe is used, the rf is at least 0.0 compared to when the probe is used without nanoparticles. Smaller by a factor of .5, 1, 1.1, 2, 3, 5, 10 or 100 can be done.

[0041] In one embodiment of the present invention, the cooling probe is a non-porous segment that does not penetrate the interior of the body part. Includes penetration segments.

[0042] In particular, the segments, whether permeated or not, act as a cooling source that specifically cools the segments. I'm in contact.

[0043] In some cases, the segments are kept at sub-physiological temperatures or at 100, 50, 37, 20, 10, 5, 1, 0, -2, -5, -10, -20, -50, -100, -150, -200, or or below -250°C. If ice sphere formation is desired, for example, a lower cooling Temperature may be required.

[0044] In some other cases, the segments are -250, -200, -150, -100, - Above 50, -40, -20, -10, -5, -2, -1, 0, 2, 5, 10 or 20°C Too low a cooling temperature can be avoided, e.g. to prevent the formation of ice balls. do.

[0045] In particular, the through or non-through segments, in particular the non-through segments, are particularly susceptible to gases coming from the cooling source. By discharging, diffusing or transporting gases or liquids, especially cryogenic gases or liquids, Cools the body part and diffuses from segment to body part, especially between the segment and the body Diffuse without contact or direct or close contact between parts.

[0046] In particular, the penetrating or non-penetrating segment, in particular the penetrating segment, may be formed on its surface or on the surface thereof. Cooling a body part, especially by bringing a part into direct or close contact with the body part do.

[0047] In one embodiment of the present invention, the cooled probe, in particular the segment, most particularly the penetrating segment, is than when using a cooled probe without particles, and In particular, those that are large by a factor of at least 0, 0.5, 1, 2, 5, 10, 103, or 105 Cooling a body part or a volume specifically contained in a medium.

[0048] In another embodiment of the invention, the cooled probe, in particular the segment, most particularly the penetrating segment, is The presence of the .OMEGA. particle is greater than the absence of it, especially at least 0.1, 1, 5, 10 , 20, or 50°C greater, cooling or cooling body parts to minimum temperatures, especially body It achieves similar activity as the destruction of part of or tumors.

[0049] In some cases, the minimum temperature for at least one step of the process is designated as T min can be specified as follows.

[0050] In another embodiment of the invention, the cooling probe, in particular the segment, most in particular the penetrating segment, The body part is cooled by a spatial temperature distribution within the body part or a spatial temperature gradient within the body part. Specifically, at least 0.1, 1, 5, 10, 20, or 50 °C higher than in the absence of nanoparticles It exists and specifically reaches similar activities such as the destruction of body parts or tumors.

[0051] In another embodiment of the present invention, the cooled probe is subjected to at least one cooling step and at least It is possible to realize at least one cycle including one heating step, where the cooling step The step is accelerated, generated, or initiated by the cooled probe or by activation of the cooled probe. and the heating step is slowed down by the nanoparticles.

[0052] In another embodiment of the present invention, the body part or tumor is examined using a nanoparticle-free cooling probe. The use of a freezing system containing nanoparticles is more efficient than the use of a freezing system containing nanoparticles. This is due to the low incidence of side effects from selected cryosystems in the group consisting of: At least one characteristic can be responsible, i) A smaller cooled tip size than without the nanoparticles; ii) an increase in the volume of the body part cooled compared to without the nanoparticles; iii) a reduction in temperature gradient compared to without nanoparticles; iv) cooling or an increase in minimum temperature compared to without nanoparticles, and v) A slower warming step than without nanoparticles.

[0053] Binding or binding materials

[0054] In one aspect of the invention, the freezing system includes a second portion, which is an embodiment of the invention is an assembly of at least two nanoparticles, which are bound or bound together by a material. The nanoparticles are characterized by comprising at least two nanoparticles bonded or bound to each other via an interfacial link.

[0055] In one embodiment of the present invention, the binding or tethering material provides a bond or binding between at least two nanoparticles. or a joining material.

[0056] In some cases, the binding or tethering material may bind at least two nanoparticles together. -3 , 10 - 1 , 0, 1, 5, 10, 10 2 or 10 3 Separation of more than nm.

[0057] In some other cases, the binding or tethering material binds at least two nanoparticles together. 5 , 10 3 , 100, 70, 50, 20, 10, 5, 2 or 1 nm or less separation.

[0058] In still other cases, the distance separating at least two nanoparticles is such that the nanoparticles are bonded or or binding substances than in their absence, especially at least 0, 1, 1.1, 2 , 5, 10 or 10 3 It is large by a coefficient of .

[0059] In still other cases, the binding or binding material may form or bind ice or ice balls. or can be converted to it, especially when the temperature is 10, 5, 2, 1, 0, -2, If the temperature drops below -5 or -10 °C, nanoparticles will form or become ice spheres. or cannot be converted into it.

[0060] In some other cases, nanoparticles may distribute particularly well in the presence of binding or tethering materials. It is not clumped, well dispersed, and evenly distributed, but without binding or binding material. , the nanoparticles are particularly agglomerated, interpenetrating, or unevenly distributed.

[0061] In some cases, the binding or binding material binds at least two nanoparticles, particularly At least two nanoparticles are incorporated or surrounded or bonded to each other via a is the surrounding material.

[0062] In some cases, the bonding or binding material may be destroyed during cryotherapy.

[0063] In some other cases, the binding or tethering material can be preserved during cryotherapy.

[0064] In some cases, the binding or tethering material may be a coating on the nanoparticles.

[0065] In some cases, the cooling temperature refers to a temperature selected from the following group: i) at least one temperature between the initial temperature and the minimum temperature; ii) the temperature of at least one of the cooling steps; iii) minimum temperature, and iv) Hold temperature, the temperature of at least one of the hold steps.

[0066] In some cases, the minimum temperature is set for the entire treatment or at least one step of the treatment. This is the lowest temperature.

[0067] In one embodiment, the binding or tethering material is derived specifically from magnetotactic bacteria, e.g., specifically from magnetotactic cells. Non-denatured proteins, such as lipids, endotoxins, and / or non-denatured proteins derived from bacteria Contains no more than 50%, 25%, 10%, or 1% by mass of organic material.

[0068] In one embodiment, the binding or tethering material is a metal ion located within or on the surface of the nanoparticle; Fe 2+ or Fe 3+ ion, hydroxyl OH - , oxide O 2- , crystal defects in nanoparticles or It comprises at least one compound capable of establishing an interaction or bond with an impurity.

[0069] In one embodiment, the binding or tethering material comprises at least one compound, atom, ion, or contains chemical functional groups such as acid, carboxylic acid, phosphoric acid, or sulfonic acid functional groups, where The bonded or bound material is a compound, atom, or ion embedded in the material. Interaction or bonding, chemical functionality of nanoparticles, metal ions, Fe2 + , Fe 3+ , hydroxyl OH - ions of nanoparticles such as oxides or interactions with crystal defects of nanoparticles A connection can be established.

[0070] The atoms, chemical functions, or ions of the nanoparticles may be located within or on the surface of the nanoparticles.

[0071] In one embodiment, the binding or tethering material is a substance that provides better cooling properties for the nanoparticles. Therefore, the bonding or binding material should include a material that is a good thermal conductor. It is preferable to do so.

[0072] In one embodiment, the binding or tethering material creates organization or aggregation properties between the nanoparticles. The compound is selected to enhance the therapeutic or cryotherapy effect on the nanoparticles.

[0073] In some cases, the effects of treatment or cryotherapy may be, among other things, the production of ice and / or the It could be the motion, vibration, rotation or translation of the nanoparticles.

[0074] In one embodiment, the binding or tethering material is less than or equal to the average diameter of the nanoparticles, or less than half that diameter. , a quarter of its diameter, or 10, 5, 2.5 or 1 μm, 500, 400, 300 , 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, The thickness is less than 3, 2, 1, or 0.5 nm. Such thicknesses are particularly effective in limiting toxicity. This may allow for limiting

[0075] In one embodiment, the binding or tethering material is typically larger than the average diameter of the nanoparticles; Greater than one-quarter of half this diameter, 0.1, 0.5, 1, 2, 4, 8, 10, 15 , 20, or 25 nm. Such thicknesses are particularly suitable for nanoparticles. This may allow the particles to bind together or prevent the formation of agglomerates. The presence of a sufficiently thick coating is particularly important for these nanoparticles to interact with each other and As the nanoparticles approach each other, the strength of the magnetic forces increases and the nanoparticles become denser under the influence of the mutually acting magnetic forces. This can prevent the device from wearing off.

[0076] In one embodiment, the binding or tethering material is at least 1, 2, 5, 1 0, 10 2 , 103 , 10 4 , 10 5 or 10 6 2 times lower metal or iron content has a mass percentage.

[0077] In another embodiment, the bonding or tethering material is at least one atom other than iron and oxygen. In the center of the synthesized nanoparticles, 1, 2, 5, 10, 10 2 , 10 3 , 10 4 , 10 5 or 10 6 It has a content or mass percentage that is more than twice as high.

[0078] In one embodiment, the binding or tying material is at least one selected from the group consisting of: Compounds include: chelating agents, amphiphilic molecules, polar or charged polymers, metal or silicon oxides, metal or silicon hydroxides, acids, and the acidic, basic, oxidizing, or reducing properties of these compounds Original, neutral, positively charged, negatively charged derivatives, and some combination of these compounds or derivatives. Combination.

[0079] In one embodiment, the binding or tying material is at least one selected from the group consisting of: Compounds include: polysaccharides, fatty acids, phospholipids, polymers of amino acids, polymeric or non-polymeric - Silica, and aliphatic amine polymers, and the acidity, base, oxidation, and reduction of these compounds , neutral, positively charged, negatively charged derivatives, and some of these compounds or derivatives. A few combinations.

[0080] In one embodiment, the binding or tethering material is a phospholipid or a protein or an RNA or DNA or bacteria, cells or compounds of biological origin or compounds derived from magnetotactic bacteria Does not include.

[0081] In one embodiment, the binding or tying material is at least one selected from the group consisting of: containing functional groups, Phosphoric acid, carboxylic acid, sulfonic acid, ester, amide, ketone, alcohol, phenol , thiols, amines, ethers, sulfides, acid anhydrides, acyl halides, amidines, nitrates Alkyl, hydroperoxides, imines, aldehydes, peroxides, acids and salts of these compounds Basic, oxidized, reduced, neutral, positively charged, negatively charged derivatives, and their compounds or Some combinations of their derivatives.

[0082] In one embodiment, the binding or tying material according to the present invention is suitable for sterilization, particularly autoclave sterilization, biocompatible The materials are selected from sterilizable materials, such as synthetic and / or biodegradable materials, which are particularly metabolically and / or biodegradable. Immunologic, cytotoxic, and / or pharmacological agents that may be administered via intravenous, intraarterial routes and / or Such substances include povidone, PEG 400, poloxamer 188, dextromethorphan, Xystran, phosphatidylcholine, dipalmitoyl-sn-glycero-3-phosphatidylcholine The compound may be a galacolin or a derivative of these substances.

[0083] In some cases, the type of bonding or binding material can be selected according to the following parameters: do. (i) Route of administration of synthetic nanoparticles: For example, in the case of intravenous administration, macrophages react with PEG or Finally, a coating that can prevent the capture of synthetic nanoparticles such as dextran is applied. You can choose to (ii) Cellular internalization: To support this, positively charged molecules such as poly-L-lysine are used. The coating can be selected "finally."

[0084] In one embodiment, the binding or tethering materials and / or nanoparticles according to the present invention are particularly suitable for use in, e.g. It may be used as a drug or diagnostic agent in the context of tumor treatment, for example using cryotherapy. This can be done.

[0085] In one embodiment, the binding or tethering material is selected from the group of compounds that is or includes: Selected: Citric acid, oleic acid, polymethacrylic acid, poly(ethylene oxide)-b-poly(meth) Acrylic acid, polyacrylic acid (PAA), polylactic acid, poly(ethylene oxide)-block Cupric (glutamic) acid, phosphonic acid, albumin, alendronate, alginate , gold, gold atoms, Al2O3, alginate, aluminum hydroxide, arabinogalactan, tonite, carboxymethyl cellulose, cellulose, chitosan, cholesterol, Cetate, dextran, dimercaptosuccinic acid, dopamine, DOPC, DTAP, DVB, ethyl Cellulose, red blood cells, ferrite, folic acid, gelatin, human serum albumin, liposomes , MIPS, MnO, MnO, oleic acid, PEI, PEG, PEO-PGA, PLA, PLGA, polymer, phosph Fatidylcholine, phosphorylcholine, Pluronic, polyacrylamide, polyacrylic PAA acid, polyaniline, polyethylene glycol with terminal carboxyl groups, polypeptide Poly(ethylene oxide), poly(vinyl alcohol), poly(N-isopropyl alcohol) acrylamide), poly(vinylpyrrolidone), poly(oligoethylene oxide), poly(N, N-dimethylethylaminoacrylate), poly(imine), poly(acrylic acid), poly -DL lactide, polyalkyl cyanoacrylate, polymer (PAMAM, PDMAEMA, PPEGMA ), PolyNIPAAM, polyacrylic acid, polydipyrrole / dicarbazole, poly-L-lysine, Polymethyl methacrylate, polymersome, agarose, donopolysaccharide, alginate phosphate, calreginan, chitosan, dextran, haparin, gum arabic, pullulan and and / or polysaccharides such as starch, polystyrene, PVA, PVP, silica, especially amorphous or mesoporous, silane, SiO2, sodium oleate, starch, styrene -Divinylbenzene, TaOx, ZrO2, and derivatives or combinations of these compounds.

[0086] In one embodiment, the binding or tying material comprises at least one of the compounds listed in the previous embodiment. It's not a mixture.

[0087] In one embodiment, the binding or tying material is selected from the following group: i) agarose, alginate, calreginan, chitosan, dextran, heparin, polysaccharides such as gum arabic, pullulan and / or starch, ii) Acids selected from the group consisting of acids such as citric acid, oleic acid, polymethacrylate Poly(ethylene oxide)-b-poly(methacrylic acid), polyacrylic (PAA) acid, Polylactic acid, poly(ethylene oxide)-block poly(glutamic acid), phosphonic acid, Dimercaptosuccinic acid, fatty acids, folic acid, PLA (poly(lactide acid) polyacrylic acid PAA), a compound containing at least one carboxylic acid functional group, iii) dextran, poly(ethylene oxide), poly(vinyl alcohol), poly( N-isopropylacrylamide), poly(vinylpyrrolidone), poly( oligoethylene oxide), poly(N,N-dimethylethylaminoacrylate), poly( imine), poly(acrylic acid), iv) carboxylates, v) Inorganic compounds such as SiO2, Al2O3, ZrO2, ferrite, MnO, Mn3O4, Au, vent carbon such as activated carbon and graphitized carbon; vi) metal compounds; vii) MIP, cellulose, DV8, Ppy, chitosan, polyacrylamide, alginate , PEI, surfactants and other organic compounds, viii) phosphoric acid-containing compounds; ix) silica-containing compounds; x) gold-containing compounds; xi) dextran-containing compounds; xii) compounds containing PEG; xiii) and combinations or derivatives of these compounds.

[0088] nanoparticles

[0089] In one embodiment of the present invention, the at least one nanoparticle is characterized in that it comprises: do: a) iron and at least 1, 2, 3, 5, or 10 other metals or metalloids other than iron These metals or metalloids are present inside or on the surface of nanoparticles, especially nanoparticles. 0, 10 per gram -10 , 10 -5 , 10 -1 , 1, 5, 10, 50, 100, 2 00, 500, 10 3 , or 10 5 It is contained in concentrations of more than μg. and / or b) 0, 1, 5, 10, 20, 50, 70, 90, 99, or by mass of iron or iron oxide If it exceeds 99%, this mass fraction is especially MI / Mallmetals, MIO / Mallmetals, MI / MNano or MIO / Mnano, where MI, MIO, Mallmetals are the metals inside the nanoparticles and are the masses of iron, iron oxide, and all metals contained on the surface of the particle, respectively, and MNano is the mass of the nanoparticle.

[0090] In another embodiment of the invention, the at least one nanoparticle comprises or is known to comprise: Characterized by: a) A first metal or metalloid and 0 other metals or a metalloid, or at least 1, 2, 3, 5 or 10 metals or metalloids, where These metals or metalloids are especially nanoparticles with a concentration of 0, 10 per gram. -10 , 10 -5 , 10 -1 , 1, 5, 10, 50, 100, 200, 500, 10 3 or 10 5 It is contained in high concentrations of more than μg. and / or b) Mass of the first metal or first metalloid: 0, 1, 5, 10, 20, 50, 70, 90 , 99, or more than 99% of the mass, where this percentage of mass is specifically M FM / M a llmetals or M FM / M Nano where MFM and Mallmetals are the metals inside or outside the nanoparticle. are the masses of the initial metal or metalloid and all metals contained on the surface of the nanoparticle, respectively. and MNano is the mass of the nanoparticle.

[0091] In some other cases, the at least one nanoparticle may include: a) iron and Other than 100, 50, 20, 10, 5, 2, or 1 or less other metals or metalloids, The other metals or metalloids are present inside or on the surface of the nanoparticles, especially in the nanoparticle granules. 10 per unit 10 , 10 5 , 10 3 , 100, 50, 20, 10, 5, 2 or is present in concentrations less than 10 μg of metal or metalloid, and / or b) Not more than 100, 90, 70, 50, 20, 5, 2, or 1% by mass of iron or iron oxide , where this mass percentage is specifically MI / Mallmetals, MIO / Mallmetals, MI / MN ano or MIO / MNano, where MI, MIO, and Mallmetals are the metals inside the nanoparticles and in the nanoparticles. are the masses of iron, iron oxide, and all metals contained in the surface of the molecule, respectively, and MNano is the is the mass of the .lamda. particle.

[0092] In some other cases, the at least one nanoparticle may include: a) First metals or first metalloids, and 100 other than first metals or first metalloids , 50, 20, 10, 5, 2, or 1 or less other metals or metalloids, where this metal or or semimetals, especially nanoparticles, 10 , 10 5 , 10 3 , 100, 5 Inside or on the surface of nanoparticles at concentrations of 0, 20, 10, 5, 2, or 10 μg or less Included in and / or b) 100, 90, 70, 50, 20, 5, 2, by mass of the first metal or first metalloid or 1% or less, where this mass percentage is MFM / Mallmetals and MFM / MN Specifically, MFM and Mallmetals are metals contained within or on the surface of nanoparticles, respectively. is the mass of the first metal or metalloid and all metals, and MNano is the mass of the nanoparticle. .

[0093] In some cases, the metal or metalloid may be designated as the first metal or metalloid.

[0094] In some other cases, a metal or metalloid may be designated as another metal or metalloid. .

[0095] In one embodiment of the present invention, the freezing system contains at least one nanoparticle, in particular a magnetic or A second portion is included which is a metal nanoparticle.

[0096] As used herein, the term "nanoparticle" refers to a nanoparticle that is sized to measure the length, width, surface, volume, or thickness of a nanoparticle. At least one dimension, such as the length, is in the size range of 0.1 to 1000 nm, particularly 1-1 00 nm size range.

[0097] As used herein, the term "magnetic nanoparticles" refers to nanoparticles that respond when exposed to a magnetic field. is meant to include any nanoparticle that gives rise to the response can be: i) non-zero magnetization or coercivity; ii) coercivity or magnetization that increases in strength with increasing magnetic field strength; iii) the magnetic moment of the nanoparticles coupled to the magnetic field, and / or iv) Nanoparticle movement, especially induced by spatially inhomogeneous magnetic fields. The term is meant to include ferromagnetic, ferrimagnetic, paramagnetic, superparamagnetic and diamagnetic materials. Suitable non-limiting examples include: i)Fe2O3, Fe3O4, Fe2O4, Fe x Pt y , Co x Pt y , MnFe x O y , CoFe x O y , NiFe x O y , CuFe x O y , ZaFe x O y , and CdFe x O y where x and y are in particular between 1 and 6. and / or ii) Especially predominantly magnetic materials such as Fe, Pt, Au, Ag, Mg, Zn, Ni, or Si Contains nanoparticles. Those composed of iron or iron oxide, without an external magnetic field or below 1 mT Nanoparticles that are magnetic in the presence of a strong magnetic field, such as those made of gold or silver, 0 -5 , 10 -3 , magnetic in the presence of external intensities, especially those higher than 1 or 10 mT. It can be distinguished from certain nanoparticles.

[0098] As used herein, the term "metal nanoparticle" refers to a nanoparticle having a length, width, surface, volume, or has at least one dimension, such as thickness, in the size range of 0.1-1000 nm, especially It is meant to include any nano-sized metal within the size range of 1-100 nm. In some embodiments, the term "metal nanoparticles" refers to any nanoparticle, such as gold or silver nanoparticles. Some metal nanoparticles are excluded. In some embodiments, the term "metal nanoparticles" , containing only iron or iron oxide nanoparticles.

[0099] In one embodiment, the nanoparticles are temperature-sensitive nanoparticles or temperature-sensitive nanocapsules or Temperature capsules or temperature sensitive polymers or temperature sensitive vesicles or temperature sensitive hollow nanoparticles Nanoparticles that are non-particles or release drugs when cooled or heated Or nanocapsules or polymers or hollow nanoparticles or vesicles.

[0100] In some cases, the drug according to the present invention is different from or is present in the nanoparticle core. It may be an active ingredient not included in

[0101] In some cases, the hollow nanoparticles are specifically filled with at least one metal or metal atom. These are nanoparticles that are not yet formed.

[0102] In one aspect, the present invention provides nanoparticles or freezing systems for use according to the present invention, or The method or freezing system according to the present invention, wherein the nanoparticles are selected from the group consisting of: having at least one characteristic selected from i) Size in the range 1~10 3 nm, ii) metallic, magnetic, and / or crystallized structures; iii)10 -5 ~10 5 Thermal conductivity in the range of W / mK, iv) cm of the suspension 3 per mg , or cm of body part 3 mg per 10 -5 From 10 5 Nanoparticle concentrations ranging from Degrees.

[0103] In one embodiment of the invention, the nanoparticles are selected from the group consisting of: Nanospheres, nanocapsules, dendrimers, carbon nanotubes, lipid / solid nanoparticles molecules, lipid or protein or DNA or RNA based nanoparticles, especially stabilizing layers, most especially Nanoparticles with an internal aqueous environment surrounded by a phospholipid layer, multilayer nanoparticles, polymer nanoparticles, nanoparticles, quantum dots, metal nanoparticles, polymeric micelles or nanoparticles, carbon-based nanostructures Manufacturing, nanobubbles, nanosomes, pharmacy, niosomes, nanopores, microorganisms, microorganisms, viruses drugs, especially recombinant, herbal nanoparticles, antibodies, and vesicles.

[0104] In another embodiment of the invention, the nanoparticles are not: Nanospheres, nanocapsules, dendrimers, carbon nanotubes, lipid / solid nanoparticles molecules, lipid or protein or DNA or RNA based nanoparticles, especially stabilizing layers, most especially Nanoparticles with an internal aqueous environment surrounded by a phospholipid layer, multilayer nanoparticles, polymer nanoparticles, nanoparticles, quantum dots, metal nanoparticles, polymeric micelles or nanoparticles, carbon-based nanostructures Manufacturing, nanobubbles, nanosomes, pharmacy, niosomes, nanopores, microorganisms, microorganisms, viruses drugs, especially recombinant, herbal nanoparticles, antibodies, and / or vesicles.

[0105] In some embodiments, the nanoparticles may be present in a particular body part prior to, during, or after administration. , or later contained in a liquid, gas, or solid environment.

[0106] In still other cases, the nanoparticles may be magnetic fluids, chemical or biological magnetic fluids. wherein the chemical and biological ferrofluids are ferrous fluids, In particular, nanoparticles are formed, which are produced by chemical or biological synthesis, respectively.

[0107] In yet some other cases, the ferrofluid or nanoparticle assemblies may be formed by the nanoparticles and excipients. The nanoparticles may include an agent, solvent, matrix, or gel to allow delivery of the nanoparticles to an individual or body part. This makes it particularly possible to administer

[0108] In still other cases, the nanoparticles may be synthetic, biological, or inorganic materials. Contains raw or organic materials.

[0109] In one embodiment of the present invention, the nanoparticle(s) have at least one common It has three characteristics: i) suspensions of nanoparticles; ii) compositions comprising nanoparticles; iii) aggregates of nanoparticles; iv) mineral part of nanoparticles, vi) organic part of nanoparticles, vii) inorganic part of nanoparticles. , viii) a coating on the nanoparticles, ix) a binding or tethering material, or x) a compound.

[0110] In one embodiment of the present invention, the nanoparticles are 3 1, 10, 10 per 2 , 10 3 , 10 5 , 10 10 or 10 50 The above nanoparticles or nanoparticle aggregates be.

[0111] In another embodiment of the present invention, the nanoparticles are 3 10 per 50 , 10 10 , 10 5 , 10 3 , 10 2 , 10, 5 or 2 nanoparticles or clusters of nanoparticles It is a combination.

[0112] In one embodiment of the present invention, the nanoparticles are-100 , 10 -50 , 10 -10 , 1 0 -5 , 10 -1 , 1, 10, 10 2 , 10 3 , 10 5 , 10 10 , 10 20 or 10 50 of nanoparticles, or mg of nanoparticles, or iron or is mg or cm of metal 3 mg of nanoparticles per cm of body part 3 Around mg of nanoparticles, or cm 3 mg of iron contained in nanoparticles per, or body part commercial 3 aggregates or suspensions containing more than mg of iron per nanoparticle Being or representing a liquid or compound.

[0113] In some embodiments, an aggregate comprising at least one nanoparticle or a number of nanoparticles or using the suspension or composition to increase temperature, produce radicals or reactive species, or Dissociation of the compound from the nanoparticles can be induced or produced.

[0114] In another embodiment of the present invention, the nanoparticles are 100 , 10 50 , 10 20 , 10 1 0 , 10 5 , 10 2 , 10, 1, 5, 2, 1, 10 -1 , 10 -5 , 10 -1 0 or 10 -50 The following nanoparticles or mg of nanoparticles or mg of nanoparticles are contained in Iron or metal, or cm 3 mg of nanoparticles per cm of body part 3 a mg of nanoparticles per cm 3 mg of iron contained in nanoparticles per Part cm 3 mg of iron contained in nanoparticles per mg of iron, aggregates, suspensions or compositions In some embodiments, to prevent toxicity, a small number of A nanoparticle aggregate or suspension or composition comprising nanoparticles of the formula (I) can be used.

[0115] The present invention also relates to nanoparticles for use according to the invention, wherein the nanoparticles are crystallized, metallic, or magnetic. The present invention relates to nanoparticles or freezing systems for the purpose of

[0116] In some other cases, the nanoparticles may be amorphous.

[0117] In one embodiment of the present invention, the nanoparticles are crystallized. In this case, they are crystallized, in particular under an electron microscope. Observable in a mirror, 1, 2, 10, 10 2 , 10 3 , 10 6 or 10 9 The conclusion is as follows: Specifically having crystal planes or regular atomic arrangements.

[0118] In one embodiment of the present invention, the nanoparticles are metallic. In this case, they have at least 1, 10, 10 3 , 10 5 or 10 9 or at least 1, 10 metal atoms , 50, 75, or 90% of the metal atoms in the nanoparticles. The number or mass of atoms in a nanoparticle is divided by the total number or mass of all atoms in the nanoparticle. The nanoparticles, particularly metal oxide nanoparticles, are preferably at least 1, 10, 10 3 , 10 5 Ma or 10 9 containing oxygen atoms or at least 1, 10, 50, 75, or 90% The percentage may include oxygen atoms, where the percentage refers to the number or mass of oxygen atoms in the nanoparticle. It is the ratio of the total number or mass of all atoms in a molecule divided by the total number or mass of all atoms in the molecule.

[0119] In some cases, the nanoparticles are composed of iron and at least one metal or metalloid different from iron. containing or consisting of, in some cases, metals other than iron or semi-metals The genera are selected from the following groups: Sodium, magnesium, aluminum, potassium, calcium, scandium, titanium chromium, manganese, zinc, gallium, strontium, yttrium, zirconium , niobium, molybdenum, technetium, indium, cesium, barium, lanthanum, Sodium, praseodymium, neodymium, samarium, europium, gadolinium, terbinium , dysprosium, holmium, erbium, thulium, lutetium, hafnium, tungstate.

[0120] In some cases, at least one nanoparticle is partially, primarily, or entirely composed of iron or The iron oxide comprises or consists of iron oxide, which has at least one of the following properties: It can be done i) containing at least one iron atom and one oxygen atom; ii) forming crystalline or mineral structures; iii) Chemical formula FeO, FeO2, Fe3O4, Fe4O5, Fe5O6, Fe5O7, Fe25O32, Fe1 3O19, α-Fe2O3, β-Fe2O3, γ-Fe2O3, ε-Fe2O3, iv) It may consist of vstatite, iron dioxide, magnetite, hematite, and maghemite; v) it can be epsilon, alpha, beta, gamma phase; vi) it may be at various levels of oxidation; vii) It has the formula Fe α O β D γ where α, β and γ are coefficients, in particular the stoichiometric coefficients In some cases, α, β, and γ are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11. , 12, 13, 14, 15, 16, 18, 19, 20. In some other cases α, β, γ are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, Greater than 14, 15, 16, 18, 19, or 20. In still other cases, α, β, and γ are 0, 1, 2, 3, 4, 5, 6, 7, 8, Less than 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, or 20. In some other cases, D is a doping material for the nanoparticles. The plating material is a metal or semimetal, in particular different from iron, or is selected from the following group: Selected materials include aluminum, antimonite, barium, chromium, copper, gold, manganese, silver, Tin, titanium, and zinc.

[0121] In one embodiment of the present invention, the iron oxide contained in the nanoparticles is the main chemical element of the nanoparticles. In some cases, high purity iron oxide nanoparticles may contain large amounts of iron oxide. In some cases, the proportion of iron oxide in the nanoparticles, especially by mass, is 10 -40 , 10 -2 0 , 10-10 , 10 -5 , 10 -2 , 10 -1 , 1, 5, 10, 25, 50 , 75, 80, 90, 99 or 99.9%. The percentage of iron oxide in the nanoparticles may depend on the number, amount, mass, or is the volume divided by the total number, amount, mass or volume of atoms of all chemical elements contained in the nanoparticle. In some other cases, the ratio of the amount of The concentration of iron oxide contained in the nanoparticles was 10 -100 , 10 -50 , 10 -2 0 , 10 -10 , 10 -5 , 10 -3 , 10 -2 , 10 -1 , 1, 10, 50, 100, 10 3 , 10 5 or 10 10 Larger than μg.

[0122] In one embodiment of the present invention, the nanoparticles are administered in a manner that allows them to be dissolved by the body part, for example. In some cases, they contain small amounts of iron oxide. In some cases, they contain acids inside or on the surface of the nanoparticles. The percentages of iron oxide by mass are 100, 90, 80, 70, 50, 30, 10, 5 In some other cases, the nanoparticles contain less than 1, 0.1, or 0.001%. The concentration of iron oxide contained in the nanoparticles was 10 50 , 10 30 , 10 10 , 1 0 5 , 10 3 , 500, 100, 50, 10, 1, 10 -1 , 10-3 , 10 -5 , 10 -10 or 10 -50 μg 10 -5 , 10 -10 , or 10 -50 μ g of iron oxide or less.

[0123] In another embodiment of the present invention, the percentage, concentration, and atomic number of iron oxide in the nanoparticles , amount, mass, or volume is the percentage, concentration, or number of atoms of impurities contained in the nanoparticles. , amount, mass, or volume, especially 1.00001, 1.001, 1.1, 2, 5 , 10, 50, 10 2 , 10 3 , 10 5 , 10 10 , 10 20 or 10 50 It's double.

[0124] In some cases, at least one nanoparticle is a composition.

[0125] In some cases, the at least one nanoparticle is 0, 1, 5, 10, 25, 50, 70, Containing more than 80, 90, 99 or 99.9% by mass of: i) metals; ii) metalloids; iii) metallic elements, iv) magnetic elements, v) iron, or vi) iron oxide. The mass percentages are may correspond to the mass percentage of the metallic or magnetic portion of the nanoparticle or the core of the nanoparticle, or coating or associated or binding materials may be excluded or not taken into account. The use of nanoparticles having metal compositions allows for the formation of nanoparticles with such compositions. This can be beneficial as it can help maintain a lower temperature.

[0126] In some cases, the at least one nanoparticle is 0, 1, 5, 10, 25, 50, 70, Contains more than 80, 90, 99 or 99.9% of the following: i) Especially M FeN / M MN Iron based on the ratio of M FeN is the iron content in at least one nanoparticle. is the mass, M MN is the mass of iron and non-iron metals or metalloids in at least one nanoparticle That is, ii) iron and at least one metal other than iron selected from Group 1 below; Sodium, magnesium, aluminum, potassium, calcium, scandium, titanium chromium, manganese, zinc, gallium, strontium, yttrium, zirconium , niobium, molybdenum, technetium, indium, cesium, barium, lanthanum, Cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium ium, dysprosium, holmium, erbium, thulium, lutetium, hafnium, Rhenium, tungsten, in particular based on the ratio M1 / M2, where M1 is at least 1 The mass of iron in one nanoparticle and at least one other gold selected in Group 1 above M2 is the mass of all metals in at least one nanoparticle, or 5 or or 10 or more masses of different metals or metalloids; and / or iii) iron and at least one nonmetal selected from Group 2 below; Hydrogen, carbon, nitrogen, phosphorus, sulfur, fluorine, chlorine, bromine, iodine, helium, neon, aluminum gon, krypton, xenon, radon, and oxygen, which is based specifically on the ratio M3 / M4 where M3 is the iron in at least one nanoparticle and the metals selected in Group 2 above. mass of at least one other nonmetallic substance, M4, contained in at least one nanoparticle The mass of all nonmetallic elements or more than five or ten different nonmetallic elements.

[0127] In some cases, the at least one nanoparticle is 100, 99.9, 99, 80, or 75, 60, 50, 30, 20, 10 or 5% or less of i) metals, ii) metalloids, iii ) metallic elements, iv) magnetic elements, v) iron, or vi) iron oxide. The mass percentages are: may correspond to the mass percentage of the metallic or magnetic portion of the nanoparticle or the core of the nanoparticle, and may exclude or not take into account coatings or bonding or binding materials. The use of nanoparticles that do not contain only metals such as iron can reduce toxicity, for example. This may be beneficial for improving the nanoparticles' ability to maintain low temperatures or for improving the nanoparticles' ability to maintain low temperatures.

[0128] In some cases, the at least one nanoparticle is 100, 99.9, 99, 90, or Not more than 80, 70, 50, 25, 10, 5, 2 or 1% of i) metals, ii) metalloids, ii i) metallic elements, iv) magnetic elements, v) iron, or vi) iron oxide. This mass percentage is , corresponding to the mass percentage of the metallic or magnetic portion of the nanoparticle or the core of the nanoparticle and excludes or does not take into account coatings or bonding or binding materials. If nanoparticles that are not entirely metallic or iron are used, the nanoparticles It is useful because it maintains the cold inside the body, prevents toxicity, and improves the effectiveness of cryotherapy. It is beneficial.

[0129] In some cases, at least one nanoparticle is 100, 99, 90, 80, 7 Contains 0, 50, 20, 10, 5, 2, or 1% or less of the following: i) Especially M FeN / M MN Iron based on the ratio of M FeN is the iron content in at least one nanoparticle. is the mass, M MN is the mass of iron and non-iron metals or metalloids in at least one nanoparticle That is, ii) iron and at least one metal other than iron selected from Group 1 below; Sodium, magnesium, aluminum, potassium, calcium, scandium, titanium chromium, manganese, zinc, gallium, strontium, yttrium, zirconium , niobium, molybdenum, technetium, indium, cesium, barium, lanthanum, Cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium ium, dysprosium, holmium, erbium, thulium, lutetium, hafnium, Rhenium, tungsten, based in particular on the ratio M1 / M2, where M1 is at least The mass of iron and at least one other metal selected from group 1 above in one nanoparticle and M2 is all metals in at least one nanoparticle, or 5 or 10 or more masses of various metals or metalloids, and / or iii) Iron and at least one other nonmetal selected from Group 2: hydrogen, carbon, nitrogen Nitrogen, phosphorus, sulfur, fluorine, chlorine, bromine, iodine, helium, neon, argon, crypto ion, xenon, radon, and oxygen, which are based in particular on the ratio M3 / M4, where M 3 is a compound containing iron in at least one nanoparticle and at least one of the compounds selected in group 2 above. is the mass of other nonmetallic elements, and M4 is the mass of all nonmetallic elements contained in at least one nanoparticle. It is the mass of a single element, or five or ten or more different nonmetallic elements.

[0130] In one embodiment of the present invention, at least one nanoparticle according to the present invention is selected from the group consisting of 1, 2, 5, 10, 10 3 , 10 5 , 10 10 , 10 20 , 10 50 or 10 100 Exceeding nanoparticles or cm of body parts 3 The nanoparticles are either individual particles or aggregates thereof.

[0131] In one embodiment of the present invention, at least one nanoparticle comprises, partially or completely: , i) at least one impurity, ii) at least one chemical element, or iii) an acid Iron oxide.

[0132] In some cases, iron oxide is 1, 10, 10 3 , 10 5 , 10 10 , 10 20 , 1 0 50 or 10 100 More than 1, 10, or 10 iron atoms 3 , 10 5 , 10 10 , 10 20 , 10 50 or 10 100 represents a collection of more than 100 oxygen atoms, or It is a collection of these.

[0133] In some other cases, the chemical elements and / or Impurities are 1, 10, 10 3 , 10 5 , 10 10 , 10 20 , 10 50 or 1 0 100 Being or representing the above chemical elements and / or impurities.

[0134] In another embodiment of the present invention, at least one nanoparticle according to the present invention is 100 , 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 100, 50, 10, 5 or 2 or fewer nanoparticles or cm of a body part 3 nanoparticles per It is a collection of them.

[0135] In some cases, iron oxide is 1, 10, 10 3 , 10 5 , 10 10 , 10 20 , 1 0 50 or 10 100 Fe atoms and / or 1, 10, 10 3 , 10 5 , 10 10 , 10 20 , 10 50 or 10 100 The following oxygen atoms or aggregates: is.

[0136] In still other cases, the chemical elements and / or Or impurities are 10 100 , 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , Chemical elements contained in nanoparticles of less than 100, 50, 10, 5 or 2, and / or is or represents an impurity.

[0137] In one embodiment, the at least one nanoparticle is a nanoparticle that is capable of acting as a barrier to cryotherapy. In some cases, the nanoparticles contain at least one impurity. Not enough or 10 50 , 10 20 , 10 10 , 10 5 , 10 2 , 10, 5, 2, 5, 1, 10 -2 , 10 -10 , 10 -20 or 10 -50 The following impurities or impurities per gram of nanoparticles, or gram of impurities per gram of nanoparticles In some other cases, the percentage of impurities contained within or on the surface of the nanoparticles In particular, mass is 100, 90, 80, 70, 60, 50, 30, 20, 10, 5, 1 In accordance with the present invention, this percentage of impurities is in some cases less than 0.01%, 0.1%, or 0.001%. In some cases, the amount of impurities contained in the nanoparticles can be determined by the total number of atoms contained in the nanoparticles, the quantity, and the quality of the atoms. It can be defined as the ratio of the total amount of nanoparticles divided by the total volume. All chemical elements are the sum of iron oxide, doping materials, and impurities contained in the nanoparticles. In still other cases, impurities contained within or on the surface of nanoparticles may The concentration of the substance was 10 per gram of nanoparticles. 50 , 10 30 , 10 10 , 10 5 , 10 3 , 500, 100, 50, 10, 1, 10 -1 , 10 -3 , 10 -5 , 10 -10 or 10 -50 Lower than μg of impurities.

[0138] In another embodiment of the present invention, the highly pure iron oxide nanoparticles are useful, for example, for cryotherapy, because they are free of impurities. If it is a large or significant amount, e.g., if it renders an impurity non-toxic or improves its effect, In some cases, the nanoparticles contain 10 -50 , 10 -20 , 10 -1 0 , 10 -5 , 10 -2 , 1, 2, 5, 10, 10 3 , 10 5 , 10 10 , 1 0 20 or 10 50 or more impurities or nanoparticles per gram of impurities or nanoparticles Contains grams of impurities per gram of particle. In some cases, nanoparticles contain large amounts of impurities. In some cases, the amount of impurities contained within or on the surface of the nanoparticles, especially in the hundreds by mass, The fraction is 10 -40 , 10 -20 , 10 -10 , 10 -5 , 10 -2 , 10 -1 , 1 , 5, 10, 25, 50, 75, 80 or 90% or more. In other cases, the concentration of impurities contained within or on the surface of the nanoparticles is Impurities per unit area are 10 -100 , 10 -50 , 10 -20 , 10 -10 , 10 -5 , 10 -3 , 10 -2 , 10 -1 , 1, 10, 50, 100, 10 3 , 10 5 or 10 10Larger than μg.

[0139] In some cases, the impurities may be the same impurities, i.e., impurities containing the same chemical element. do.

[0140] In some other cases, the impurities are different impurities, i.e., in particular at least one different The impurities may include chemical elements that

[0141] In one embodiment of the present invention, the chemical element is selected from the group consisting of: Actinides, actinium, aluminum, americium, antimony, argon, arsenic , astatine, barium, berkelium, beryllium, bismuth, boron, boron element, cesium, calcium, californium, carbon, cerium, chlorine, chromium, cobalt Copper, Copernicium, Cadmium, Curium, Darmstadium, Dubnium, Di Sprosium, Einstein, Erbium, Europium, Fermium, Flerovium fluorine, francium, gadolinium, gallium, gold, hafnium, Sium, Hassium, Holmium, Hydrogen, Indium, Iodine, Iridium, Iron, Crypto Lanthanides, lanthanum, lawrencium, lead, lithium, livermorium, lutetium , magnesium, manganese, meitnerium, mendelevium, mercury, molybdenum, neodymium Gymnemium, Neon, Neptunium, Nickel, Niobium, Nitrogen, Nobelium, Osmium, Acid element, palladium, phosphorus, platinum, plutonium, polonium, potassium, praseodymium , protactinium, promethium, radium, radon, rhenium, rhodium, roentgen Selenium, selenium, silicon, silver, selenium, ruthenium, rubidium, ruthenium, rutherfordium, samarium, selenium, silicon, silver, selenium Thorium, strontium, sulfur, scandium, seaborgium, tellurium, terbium , thorium, thulium, tin, tantalum, technetium, thallium, titanium, tungste Ununoctium, Ununpentium, Ununseptium, Ununtrium, Ununoctium vanadium, vanadium xenon, ytterbium, yttrium, zinc, di Ruthenium, and combinations of several of these chemical elements.

[0142] The present invention also relates to a freezing system according to the invention, in which the impurities contained in the nanoparticles are It is at least one chemical element different from iron, oxygen, and / or iron oxide.

[0143] In some cases, the impurity may be carbon or a carbonaceous material.

[0144] In one embodiment of the present invention, the carbonaceous material comprises at least one carbon atom, and in particular necessarily It does not need to be mixed or compounded with any other chemical element other than carbon.

[0145] In yet another embodiment of the present invention, the carbon or carbonaceous material is a nanoparticle-producing cell. Originating from or produced by cells that produce at least one nanoparticle that is or derived from it.

[0146] In one embodiment of the present invention, iron and / or iron oxides and / or impurities and / or Doping materials and / or chemical elements are included or inserted in: i) inside the nanoparticles, ii) on the surface of the nanoparticles, iii) outside the nanoparticles, and iv) crystalline or amorphous structure of the nanoparticles, v) defects in the nanoparticles, and / or vi) nanoparticles. No particle vacancy.

[0147] In one embodiment of the present invention, iron and / or iron oxides and / or impurities and / or Doping materials and / or chemical elements can interact with nanoparticles in a variety of ways, including electrostatic, strong, weak, nuclear, metallic, and phasic ways. interactions such as von der Waals, Debye, London, or hydrogen bonding interactions.

[0148] In one embodiment of the present invention, iron and / or iron oxides and / or impurities and / or The doping materials and / or chemical elements are removed from the nanoparticles, especially from the center or surface. 50 , 10 20 , 10 10 , 10 5 , 10 3 , 100, 10, 5 or 1 nm In some cases, the center of the nanoparticle is located at a distance of 1 / 2 of the diameter of the spherical nanoparticle. The maximum length of the nanoparticles, such as half or half of the maximum, minimum, and / or average length of the nanoparticles The area or volume or location of a chemical element that is at the center of its largest, smallest, and / or average dimensions Or it is a collection.

[0149] In some other cases, the surface of the nanoparticle is in contact with the center of the nanoparticle while remaining within the nanoparticle. It is the area, location, or collection of chemical elements that is at the greatest distance from

[0150] In yet another embodiment of the present invention, iron and / or iron oxides and / or impurities and and / or doping materials and / or chemical elements from the nanoparticles, especially from the center or the surface From 0.001, 0.01, 0.1, 1, 10, 100, 10 3 , 10 5 , 1 0 10 , 10 20 or 10 50 are spaced apart by more than nm.

[0151] In another embodiment of the present invention, the metal or metal atom is selected from the group consisting of: can be, Lithium, beryllium, sodium, magnesium, aluminum, potassium, calcium Aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, Copper, zinc, gallium, rubidium, strontium, yttrium, zirconium, niobium , molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, Indium, tin, cesium, barium, lanthanum, cerium, praseodymium, neodymium , promethium, samarium, europium, gadolinium, terbium, dysprosium , holmium, erbium, thulium, ytterbium, lutetium, hafnium, tungsten Thallium, tungsten, rhenium, osmium, iridium, platinum, gold, mercury, thallium Zn, lead, bismuth, polonium, francium, radium, radium, thorium , protactinium, uranium, neptunium, plutonium, americium, curium , Berkelium, Californium, Einstein, Fermium, Mendelevium , nobelium, lawrencium, rutherfordium, dubnium, seaborgium, bo Nitrium, Hassium, Meitnerium, Darmstadium, Nitrium, Oscovium, and livermorium or livermorium atoms.

[0152] In another embodiment of the present invention, the nanoparticles are 3 , 10 5 or 1 0 9 Contains the following metal atoms or contains 1, 10, 50, 75 or 90% or less of metals: This ratio is calculated by dividing the number or mass of metal atoms in the nanoparticle by the total number of atoms in the nanoparticle. It is the ratio of the total number or mass of atoms in an atom to the total number or mass of atoms in an atom. 3 , 10 5 or 10 9 Contains the following oxygen atoms or contains 1, 10, 50, 75 or 90% or less of oxygen atoms: This percentage is determined by the number or mass of oxygen atoms in the nanoparticle. , divided by the total number or mass of all atoms in the nanoparticle.

[0153] In one embodiment of the present invention, a nanoparticle is magnetic if it has magnetic behavior or properties; Magnetic behavior or properties can be diamagnetic, superparamagnetic, paramagnetic, ferromagnetic, and ferrimagnetic behavior or properties. is specifically selected from the group consisting of properties.

[0154] In some embodiments, the magnetic behavior or property is present at a temperature below: i) 10 5 , 10 3 , 500, 350, 200, 100, 50, 20, 10, 1, 0.5 or 1 K (Kelvin), ii) Curie temperature, or iii) Block ng temperature.

[0155] In some other embodiments, the magnetic behavior or property is selected from the group consisting of: also exists at high temperatures: i)0.5, 1, 10, 20, 50, 100, 200, 350, 500, 10 3 or 10 5 K, ii) Curie temperature, or iii) blocking temperature, i.e. , the temperature at which there is a transition between superparamagnetic behavior and ferromagnetic or ferrimagnetic behavior.

[0156] In still other embodiments, the magnetic behavior or properties are -20 and 10 20 K, or exists at temperatures between 0.1 and 1000 K.

[0157] In one embodiment of the present invention, the nanoparticles have at least one of the following properties: It is characterized by that. i) The presence of a core, especially magnetic, especially minerals, especially metal oxides such as iron oxide, most especially magma ite or magnetite, or intermediate composition between maghemite and magnetite, ii) the presence of a coating, which surrounds and specifically prevents the aggregation of the cores and nanoparticles; , which specifically allow the administration of nanoparticles in an organism or body part or which allow the core of the nanoparticles to be The coating thickness is stabilized between 0.1 nm and 10 mm. between 0.1 nm and 100 nm, between 0.1 nm and 10 nm, and is between 1 nm and 5 nm, iii) Magnetic properties leading to diamagnetic, paramagnetic, superparamagnetic, ferromagnetic, or ferrimagnetic behavior temperament, iv)0.01, 0.1, 1, 10, 100, 10 3 , 10 4 , 10 5 , 10 9 or 10 20 Coercivity greater than Oe, v) 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 0.9 or a ratio of remanence to saturation magnetization greater than 0.99 vi) a saturation current of 0.1, 1, 5, 10 or saturation magnetization greater than 50 emu / g; vii) Magnetic properties such as coercivity, remanence, and saturation magnetization, which are measured at 0.1 K, 1 K, and 10 K, 20 K, 50 K, 100 K, 200 K, 300 K, 350 K or 3000 Specifically measured or observed at temperatures above K, viii) crystalline, i.e., in particular at least 1, 2, 5, 10, or 100 crystal faces nanoparticles possessing a ix) the existence of a single domain; x)0.1, 0.5, 1.5, 10, 15, 20, 25, 30, 50, 60, Sizes larger than 70, 80, 100, 120, 150 or 200 nm, xi) Between 0.1 nm and 10 μm, between 0.1 nm and 1 μm, between 0.1 nm and 100 nm m, between 1 nm and 100 nm, or between 5 nm and 80 nm, xii) non-pyrogenic or non-pyrogenic, which means that the nanoparticles are, in particular, 10 per mg of nanoparticles or per mg of iron contained in nanoparticles 20 , 100 00, 1000, 100, 50, 10, 5, 2 or 1 EU (endotoxin unit) (unit) or less, or to an organism or body part After administration of nanoparticles, fever or a temperature exceeding 100, 50, 6.6, 5, 3, 2, or 1 °C may occur. This means that it will not cause a significant rise in whole-body temperature. xiii) biosynthesis, especially by bacteria; xiv) chemical synthesis; xv) Not more than 50, 25, 15, 10, 5, 2, or 1% of the active ingredient is derived from a synthetic organism the presence of inorganic or carbonaceous materials, xvi) 1, 10, 1000, or 10 per gram of nanoparticles 4 Watts greater ratio Spectral Absorption Rate (SAR), especially at intensities greater than 0.1, 1, 10, or 100 mT and / or Measurements are particularly taken under the application of alternating magnetic fields with frequencies greater than 1, 10, 100 or 1000 KHz. or alternatively under the application of sound waves, or electromagnetic, acoustic, or optical radiation. It is measured specifically under which radiation is applied.

[0158] In another embodiment of the invention, the nanoparticles have at least one of the following properties: is characterized by: i) 0.01, 0.1, 1, 10, 100, 10 3 , 10 4 , 10 5 , 10 9 or 10 20 Coercivity lower than Oe, ii) 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 0.9, or is the ratio of remanence to saturation magnetization of 0.99 or less, iii) 0.1, 1, 5, 10, 50, 200, 1000, or 5000 emu / g or less saturation magnetization of iv)0.1K, 1K, 10K, 20K, 50K, 100K, 200K, 300K, 35 Magnetic properties specifically measured or observed at temperatures below 0 K or 3000 K, v)0.1, 0.5, 1.5, 10, 15, 20, 25, 30, 50, 60, 70, 80 , sizes of 100, 120, 150 or 200 nm or less, vi) presence of more than 50, 25, 15, 10, 5, 2 or 1% of size, organic or derived from synthetic biology of carbon or carbonaceous materials; vii) 99, 95, 80, 70, 60, 50, or 25% or less of synthetic biological origin the presence of mineral substances, or xi) A specific absorption rate (SAR) of less than 1.10, which is 1.10 per gram of nanoparticles. 000 or 10 4 Lower than W, especially 0.1, 1, 10, 100, 200, 500, 1 0 3 , or 10 5 Intensities below 1 mT and / or above 1, 10, 100, 10 3 , 10 5 or 10 9 Measurements or sounds, especially under the application of low frequency alternating magnetic fields of kHz Measurements have been made in particular under the application of acoustic waves or under the application of radiation such as electromagnetic acoustic or optical radiation.

[0159] In some cases, the synthesizing organism is a cell that produces the nanoparticles.

[0160] In some embodiments, the mineral may be part of a nanoparticle or a magnetosome, which does not contain organic material or contains a low percentage by mass of organic material, in particular Mass of the material: 100, 99, 50, 20, 10, 5, 1, 10 -1 or 10 -2 Par The mineral is particularly the core of the nanoparticle.

[0161] In some other embodiments, the mineral is present in an amount of 0, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 10 ... -50 , 10 -10 , 10 -2 , 10 -1 or containing a mass percentage of organic material greater than 1% This can occur if the purification step fails to remove the organic material or if the purification step This is the case when organic material is added to the mineral after it has been spun.

[0162] In some embodiments, the nanoparticles may be surrounded by a coating. The term "material" refers to a synthetic, organic, or inorganic material or substance selected from the group consisting of: Contains functional groups, Carboxylic acids, phosphoric acids, sulfonic acids, esters, amides, ketones, alcohols, phenols , thiols, amines, ethers, sulfides, acid anhydrides, acyl halides, amidines, amides, nitriles, hydroperoxides, imines, aldehydes, and peroxides. The coating is made of carboxymethyl dextran, citric acid, phosphatidylcholine, In some cases, the coating may be made of phosphate (DOPC), or oleic acid. Dispersion of nanoparticles into a base or solvent such as water, without any aggregation or sedimentation of the nanoparticles. In some cases, the coating may allow for the internalization of the nanoparticles into cells. Migration becomes possible.

[0163] In some other cases, the coating may: i) bind two or more nanoparticles together ii) to prevent aggregation of nanoparticles; and / or iii) to form uniform nanoparticles. The distribution of children can be obtained.

[0164] In some cases, the coating may be a bonding or tethering material.

[0165] In one embodiment of the present invention, the nanoparticles are non-pyrogenic. Non-pyrogenic nanoparticles are in particular: i)10 100 , 10 50 , 10 20 , 10 8 , 10 5 , 10 3 , or 10 EU (endotoxin units) or EU per cm3 of body part, or mg of nanoparticles per EU, or per cm3 of body part containing 1 mg of nanoparticles per EU, or ii) the individual or body part, with or without the application of sound waves or radiation to the nanoparticles; Especially above physiological temperature 10 5 , 10 3 , 10 2 , 50, 10, 5, 4, 3, 2 or induces a temperature rise of only 1°C or less.

[0166] In one embodiment of the present invention, the nanoparticles are made of metals (alkali metals, alkaline earth metals, transition metals, metalloids, nonmetals (halogens, noble gases), chalcogens, lanthanides, actinomycetes Consisting of or comprising chemical elements of the group selected from the group consisting of: Nidos

[0167] In another embodiment of the present invention, the nanoparticles are selected from the group consisting of: consisting of or including, Hydrogen, lithium, sodium, potassium, rubidium, cesium, francium, beryllium sulphur, magnesium, calcium, strontium, barium, radium, scandium , yttrium, lanthanides, actinides, titanium, zirconium, hafnium, razaho Sodium, vanadium, niobium, tantalum, tungsten, chromium, molybdenum, and tungsten Tennium, seaborgium, manganese, technetium, rhenium, boron, iron, ruthenium , Cobalt, Osmium, Hasmium, Rhodium, Iridium, Meitnerium, Nickel , palladium, platinum, darmstadium, copper, silver, gold, roentgen, zinc, cadmium , mercury, copernicium, boron, aluminum, gallium, indium, thallium, Ammonium, carbon, silicon, germanium, tin, lead, flerovium, nitrogen, lithium Arsenic, antimony, bismuth, unpentium, oxygen, sulfur, selenium, tellurium, Polonium, liver tissue, fluorine, chlorine, bromine, iodine, astatine, ununseptium, helium Neon, Argon, Krypton, Xenon, Radon, Ion, Lanthanum, Sium, praseodymium, neodymium, promethium, samarium, europium, gadolinium ium, terbium, dysprosium, holmium, erbium, thulium, ytterbiu lum, lutetium, actinium, uranium, uranium, uranium, uranium, uranium, uranium, uranium Ran, Uranium, Uranium Californium, Einstein, Fermium, Mendelevi Um, nobelium, lawrencium.

[0168] In some embodiments, the nanoparticles may also be alloys, mixtures, or mixtures of these chemical elements. may consist of or contain these oxides.

[0169] In some embodiments, the nanoparticles are 10 -50 , 10 -20 , 10 -10 , 10 - 5 , 10 -2 , 1, 5, 10, 50, 75, 80, 90, 95 or 99% or more The nanoparticles may contain one or several of the above elements, and the proportion of these elements contained in the nanoparticles may be determined by the following formula: Divide the mass or number of chemical elements by the total number or mass of all chemical elements contained in the nanoparticle. It can represent a number.

[0170] In some other cases, the nanoparticles are -50 , 10 -20 , 10 -10 , 10 -5 , 10 -2 , 1, 5, 10, 50, 75, 80, 90, 95 or 99% may consist of or contain one or several of these chemical elements do.

[0171] In yet some other embodiments, these chemical elements are present within the nanoparticles or compounds. or the surface of a nanoparticle or compound, or the mineral or central part of a nanoparticle or compound contained in the coating of the particles or nanoparticles or compounds.

[0172] In one embodiment of the present invention, the nanoparticles are 10 -1 , 1, 2, 5, 10, 2 having a size greater than 0, 50, 70, 100, 200 or 500 nm. Larger sized nanoparticles have higher coercivity and / or remanence than smaller sized nanoparticles. The energy or power of the sound waves or radiation becomes stronger and / or In some cases, the size of the nanoparticles can be reduced to 1.001 , 1.01, 1.1, 1.2, 1.5, 2, 5, 10, 10 3 , 10 5 or 10 7 By increasing the factor by The amounts are 1.001, 1.01, 1.1, 1.2, 1.5, 2, 5, 10, 10 3 , 10 5 or 10 7 It increases by a factor of 1 or more.

[0173] In another embodiment of the present invention, the nanoparticles are 4 , 10 3 , 10 2 , 10, 1 and is 10 -1 It is defined as a particle with a size in one dimension of less than 1 nm. Nanoparticles can be administered more easily, for example intravenously, or may reduce some of the risk of embolism. This may allow some toxic effects to be avoided.

[0174] In yet another embodiment of the present invention, the size of the nanoparticles is 10 -2 and 10 20 nm Between 10 -2 and 10 4 nm, 10 -1 and 10 3 nm or between 1 and 1 0 2 This means that nanoparticles or nanoparticle aggregates are well-defined, particularly This is true when the particles have a fairly narrow size distribution.

[0175] In yet another embodiment of the present invention, the nanoparticle size distribution is 1000, 100, 75, The narrow nanoparticle size distribution is less than 50, 25, 10, 5, 2, or 1 nm. , which may be desirable to prevent aggregation or to promote nanoparticle chain organization. there is.

[0176] In yet another embodiment of the present invention, the nanoparticle size distribution is 1000, 100, 75, Larger than 50, 25, 10, 5, 2 or 1 nm. Large size distribution of nanoparticles. This may allow for more rapid removal of nanoparticles.

[0177] In another embodiment of the invention, the nanoparticles have a surface charge, which is in particular −200, − 100, -50, -10, -5, 0.1, 1, 2, 5, 10, 50 or 1 00 mV, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, In particular, the nanoparticles can be electrochemically depleted without being destroyed. The surface is surrounded by a coating that allows the cargo to reach the high pH It can have an electric charge.

[0178] In another embodiment of the present invention, the surface charge of the nanoparticles is not destroyed but is instead transferred to such charge. When surrounded by a coating that allows it to reach -200, -100, - is less than or equal to 50, -10, -5, 0.1, 1, 2, 5, 10, 50, or 100 mV; Specifically, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or The pH will be greater than 14.

[0179] In yet another embodiment of the present invention, the nanoparticles are polarized at +200 and -200 mV, +100 and -100 mV, +50 and -50 mV, +40 and -40mV, +20 and -20, +10 and -10 mV, or +5 and -5 mV, and , at a pH of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 or higher.

[0180] In yet another embodiment of the present invention, the nanoparticles are polarized at +200 and -200 mV, +100 and -100 mV, +50 and -50 mV, +40 et-40mV, +20 and -20, +10 and -10 mV, or +5 and -5 mV, especially 0.1, 1, 2, At a pH greater than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 .

[0181] In another embodiment of the present invention, the nanoparticles are mass-produced in grams (g) or kilograms (kg ), or milligrams (mg), or having a weight or mass that is specifically expressed in units such as nanograms (N). A gram of particle can be a gram of metal, such as iron, contained in the nanoparticle. or weight is the mass or weight of a single nanoparticle, or the mass or weight of an aggregate of nanoparticles It can correspond to the weight.

[0182] In one embodiment, the mass of the or at least one nanoparticle is 10 -20 , 10 - 10 , 10 -5 , 10 -2 , 1, 10, 10 3 , 10 9 or 10 20 grams Larger, potentially increasing the amount of acoustic energy absorbed by the nanoparticles Therefore, a large nanoparticle mass may be desirable.

[0183] In one embodiment, the mass of the or at least one nanoparticle is 10 -20 , 10 - 10 , 10 -5 , 10 -2 , 1, 10, 10 3 , 10 9 or 10 20 grams In some cases, nanoparticles may be used to prevent or minimize their toxicity. It may be desirable for the particle to have a low mass.

[0184] In one embodiment of the present invention, the nanoparticles, suspensions, compositions or aggregates of nanoparticles are, in particular Over time, especially in the 10 -10 , 5, 10, 10 50 or 10 100 Greater than minutes In some cases, nanoparticles, suspensions of nanoparticles, compositions The object, or aggregate, is a nanoparticle that is present within 1 m of the solvent, substrate, or body part surrounding or containing the nanoparticle. 1, 5, 10, 50, 100, 200, 500, or 1000 mg or more per liter In some cases, nanoparticles, suspensions of nanoparticles, compositions The composition, or aggregate, may be stable: i) the nanoparticles have not deteriorated or lost some or all of their coating; It can be administered to any part of the body. ii) The optical density, suspension, composition, or aggregates of nanoparticles are particularly m or another fixed wavelength, and particularly homogenization, mixing of this suspension or nanoparticle composition or after optical density or absorbance measurements at 1, 5, 10, 10 3 , 10 7 or 10 2 0 Within seconds, especially 1, 5, 10, 50, 75, 90% or more, or especially 10 -10 , 1 0 -3 , 10 -1 , 0.5 or 0.7 or more. This percentage is (OD B -OD A ) / OD B or OD A / OD B can be equal to OD B nanoparticles, suspension, composition The measurement was performed immediately after the aggregation of nanoparticles or nanoparticles, or within 1 second or less. Homogenization or mixing of suspensions, compositions, or aggregates, or optical density or absorption measurements1 is the optical density measured after 1 minute, OD A of nanoparticles, suspensions, compositions, or aggregates Optical density, which is the homogenization, mixing of nanoparticles and nanoparticle suspensions, compositions, or aggregates. , optical density measurement, absorbance measurement, absorption measurement after a certain time, or after 1 second or more or 1 minute or more This has been determined.

[0185] In some cases, the nanoparticles are suspended in a liquid or dispersed in a substrate or body part to provide a uniform distribution. A uniform nanoparticle dispersion or a highly stable nanoparticle composition or suspension can be obtained. do.

[0186] In one embodiment of the present invention, the nanoparticles are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 Arranged in chains containing 5, 20, 25, 30, 35 or 40 or more.

[0187] In another embodiment of the invention, the nanoparticles are arranged to have chains, which have i) 2.10 10 , 2.10 5 , 2.10 3 or 2.10 2 Length shorter than nm or ii) 2, 5, 10, 10 2 or 10 3 The number of nanoparticles in each chain is smaller than In some cases, short chains of nanoparticles may be desired or obtainable. For example, to favor the internalization of nanoparticles within cells or after partial or complete disruption of long chains is.

[0188] In another embodiment of the invention, the nanoparticles are arranged in a chain, which has: i)10 -1 , 1, 5, 10, 2.10 2 , 2.10 3 or 2.10 5 nm a longer length, or ii) 2, 5, 10, 10 2 or 10 3 The number of nanoparticles in each chain is greater than In some cases, the amount of heat or compound dissociated from the nanoparticles under the application of sound waves or radiation is To increase the particle size, to prevent aggregation of nanoparticles, or to allow uniform nanoparticle distribution, Therefore, long chains of nanoparticles may be desirable or obtainable.

[0189] In yet another embodiment of the present invention, the nanoparticles are arranged in a chain, which has: i) 10 -1 and 10 10 nm, or 1 and 10 5 nm, or ii) 2 and 10 5 , 2 and 10 3 , 2 and 10 2 , or between 2 and 50 for each strand The number of nanoparticles in

[0190] In yet another embodiment of the present invention, the nanoparticles are bonded or tethered to one another. A chain-like arrangement occurs when the crystallographic directions of two adjacent nanoparticles in a chain are aligned. Such alignment is due to the crystallographic orientation of two adjacent nanoparticles in the chain. Depending on the angle between 90, 80, 70, 60, 50, 20, 10, 3, or 2° or less Particularly characterized.

[0191] In particular, when nanoparticles are biologically synthesized, they may be arranged in chains of: i) within the organism that synthesizes them, also designated as the synthesizing organism, or ii) Outside this organism. In particular, the nanoparticles are arranged in chains after or before extraction or isolation from the organism.

[0192] In one embodiment of the present invention, the nanoparticles are not arranged in chains.

[0193] In another embodiment of the present invention, the nanoparticles are used for the crystallization of iron oxides, stabilization of iron oxide minerals, nanoparticles Organisms can be generated in 1, 2, 5, 10, or even 100 steps. If related to or derived from a living organism, they are chemically synthesized or synthesized by living organisms. In some cases, chemical synthesis is performed in the majority of steps, or in one or two steps. , 5, 10, or more than 1, 2, 5, 25, 50, 75, or 90% steps This can be defined as the synthesis of living organisms, or DNA, RNA, proteins, enzymes, lipids, etc. It may involve chemical reactions that occur without the participation of any part of an organism.

[0194] In another embodiment of the invention, chemical synthesis is carried out in a compartment, organelle, or other biological It is used to create chemicals that mimic, copy, or reproduce bodily substances, and these chemical compounds The compound or chemical may be used in or result in the production of nanoparticles. In some cases, compartments, organelles, or other biological material may be separated into lysosomal Iron in spheres, endosomes, vesicles, and especially in vesicles, is dissolved or converted to free iron or The iron can be a biological material with the ability or function to convert it into crystallized iron. In some cases, this transformation is partial, especially with partially crystallized iron atoms or ions. This results in the destruction or formation of aggregates of iron, in particular a mixture of crystallized and amorphous iron. In some cases, crystallized iron is composed of clusters of iron atoms or ions, which leads to the presence of crystal faces. and can be characterized using techniques such as transmission or scanning electron microscopy. In particular, free iron is a small number of iron atoms or iron atoms that do not lead to the presence of crystal faces. can be defined as one of the characterization methods, e.g., transmission or scanning electron microscopy. This is particularly evident in the absence of a diffraction pattern when used as a diffraction method.

[0195] In one embodiment of the present invention, the nanoparticles are biologically or synthetically produced biological or nanoparticles. It is synthesized by living organisms designated as cells, which in particular contain at least 1, 2, 5, 1 0, 10 3 , 10 6 or 10 9 eukaryotic cells, prokaryotic cells, or parts of these cells , in some cases, parts of eukaryotic or prokaryotic cells contain RNA, DNA, organelles, nucleoli, Nucleus, ribosome, vesicle, rough endoplasmic reticulum, Golgi apparatus, cytoskeleton, smooth endoplasmic reticulum, mitochondria , vacuoles, cytosol, lysosomes, centrosomes, plasma membranes, etc., originate or are generated by these cells. In some cases, biological synthesis may be the most stabilizing factor. Steps of 1, 2, 5, 10, or 1, 2, 5, 25, 50, 75, or can be defined as a synthesis containing more than 90% of steps, which means that at least 1, 2, 1 0, 10 3 , 10 6 or 10 9 Individual organisms, or DNA, RNA, proteins, enzymes, lipids It involves chemical reactions that occur with the participation of parts of living organisms, such as substances.

[0196] In some embodiments, the synthesized organisms include magnetotactic bacteria, bacteria of a type other than magnetotactic bacteria, or enzymes from certain bacteria, e.g., Mycobacterium paratuberculosis, Schwab Nera oni densi, Diosthrix fermentans, ants, fungi, or various plants , and in particular synthesizes nanoparticles extracellularly.

[0197] In yet another embodiment of the present invention, the nanoparticles are compartments, organelles, or synthesized or by other biological materials such as proteins, lipids, enzymes, DNA, or RNA produced or crystallized or assembled or transformed, especially in eukaryotic or prokaryotic cells Produced by or derived from

[0198] In another embodiment of the invention, the nanoparticles comprise at least one eukaryotic cell, prokaryotic cell, or It is synthesized by or within a portion of this cell.

[0199] In another embodiment of the present invention, the nanoparticles are i) a group located outside at least one eukaryotic or prokaryotic cell or part of such a cell quality or medium or environment, or ii) synthesized by or within the extracellular matrix;

[0200] In one embodiment of the present invention, the crystallization of iron oxides, the stabilization of iron oxide minerals, e.g., chains or aggregates, At least 1, 2, 5, 10 or 100 steps in their generation, such as organization within When biologically related or derived, nanoparticles are synthesized by living organisms. do.

[0201] In another embodiment of the invention, the nanoparticles according to the invention have a core or cores of the nanoparticles. In particular, the surrounding coating.

[0202] In another embodiment of the present invention, the nanoparticles according to the present invention comprise metal atoms and a carbonaceous material. The carbonaceous material surrounds, is mixed with, or is attached to the metal atoms. It is inserted.

[0203] In one embodiment of the present invention, the core or coating of the nanoparticles is iron or iron oxide or At least one impurity or doping material or chemical element concentration common to the nanoparticles It has two characteristics.

[0204] In one embodiment of the present invention, the nanoparticles, nanoparticle cores or coatings have the following properties: (a) to (p) (a) Magnetic, diamagnetic, superparamagnetic, ferromagnetic, ferrimagnetic, and / or paramagnetic behavior or is a characteristic, this is especially 10 , 10 5 , 10 3 , 10 2 At temperatures below 10 or 1 K Observed or measured in degrees, especially 10 -50 , 10 -40 , 10 -20 , 10 -10 , 10 -5 , 10 -2 or 10 -1 Observation under application of a magnetic field with a strength greater than T or In some cases the core has different magnetic properties than the coating. The coating can be diamagnetic or paramagnetic, while the core is ferromagnetic or superparamagnetic. It can be sexual. (b) in particular at least 1, 2, 5, 10, 50, 100, 10 3 , 10 5 , 10 7 , 10 9 , 10 20 or 10 50 Crystal planes or crystalline parts containing ordered crystalline structures This can be observed or measured under an electron microscope. In some cases, the core is The core can have a different crystal structure from the ring. For example, the core can be 1, 5, 10, 10 3 or 10 5 The coating has more than 10 crystal planes or crystal-ordered structures. 5 , 10 3 , 10, 5, or 2 or fewer crystal planes or crystal ordering structures. (c) metals or metal oxides, especially iron oxides, most especially maghemite and / or magnetite In some cases, the core comprises a different composition than the coating. For example, the core may be 1, 5, 10, 25, 50, 75, 90, 95 or 99 parts by mass of iron oxide. Contains 100% or more of the coating, 99, 95, 90, 75, 50, 10, 5 or 1 percent, or less by mass of iron oxide. This percentage is based on the core and / or the amount, volume, number of atoms, and mass of iron oxide contained in the coating and the core and / or or the total amount, total volume, total number of atoms, and total mass of all chemical elements contained in the coating It is a ratio. (d) Single domain, or magnetically single domain. (e) Preferred directions such as the easy axis of magnetization or crystallographic directions such as the

[0111] of the nanoparticle core. Magnetic fine particles that can be characterized by the presence of magnetic field lines that can be oriented in a preferred direction Such magnetic microstructures can be observed under certain conditions, especially by electron holography. It is possible to infer this. (f) Between 1 nm and 105 nm, 1 nm and 103 nm, or 1 nm and 100 nm Size. (g) 0.1, 1, 2, 5, 10, 15, 20, 25, 30, 35 or is a size larger than 40 nm. (h) In other cases, 10 10, 10 5 , 10 4 , 2000, 1000, 50 0, 400, 300, 200, 150, 120, 100, 95, 90, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 2 Sizes of 0, 15, 10 or 5 nm or less. (i) Zeta potential, charge, or surface charge, which is -10 10 mV and 10 10 mV, -10 5 mV and 10 5 mV, -10 4 mV and 10 4 mV, -10 2 mV and 10 2 mV, -10 and 10 mV, and specifically pH 0 to 14, 1 to 13, and 2 to 12 , between 3 and 11, 4 and 10, 5 and 9, or 6 and 8. (j) Zeta potential, charge, or surface charge, sometimes referred to as -10 50 , -10 2 0 , -10 10 , -10 5 , -10 3 , -10, -5, -1, 0, 5, 10, Above 20, 50, or 100 mV, especially at 0, 1, 2, 3, 4, 5, 6, 7, 8, At a pH greater than 9, 10, 11, 12, or 13. (k) Zeta potential, charge, or surface charge. In other cases it is -10 50 , -10 20 , -10 10 , -10 5 , -10 3 , -10, -5, -1, 0, 5, 10, 20 , 50, or 100 mV or more, especially 14, 13, 12, 11, 10, 9, 8, 7, at a pH of 6, 5, 4, 3, 2, 1, or 0 or less. (l) Zeta potential, charge, or surface charge. In other cases, it is 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 10, 5, 1, 0, -5, -10, -20, -50 or -100 mV or less, especially 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, At a pH of 10, 11, 12, or 13 or higher. (m) Zeta potential, charge, or surface charge. In other cases, it is 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 10, 5, 1, 0, -5, -10, -20, - Below 50 or -100 mV, especially 14, 13, 12, 11, 10, 9, 8, 7 , at a pH below 6, 5, 4, 3, 2, 1, or 0. (n) 0 and 14, 1 and 13, 2 and 12, 3 and 11, 4 and 10, 5 and 9, or an isoelectric point between 6 and 8. (o) In some cases, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or or an isoelectric point of 13 or higher. and / or (p) In some other cases, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 , 4, 3, 2, 1, or an isoelectric point of 0 or less.

[0205] In one embodiment of the present invention, the core or coating is synthesized by nanoparticle-producing cells. can be.

[0206] In another embodiment of the invention, the core or coating is synthesized by nanoparticle-producing cells. It will not be done.

[0207] In one embodiment of the present invention, the nanoparticle-producing cells are eukaryotic or prokaryotic cells.

[0208] In one embodiment of the present invention, the nanoparticle-producing cells are whole cells.

[0209] In yet another embodiment of the present invention, the nanoparticle-producing cells are composed of cell membranes, vesicles, enzymes, proteins, Cellular components such as proteins, lipids, DNA, RNA, organelles, compartments, cytoplasm, and viruses It is a part that is contained in, originates from, replicates in, or is produced by nanoparticle-producing cells.

[0210] In one embodiment of the present invention, the nanoparticle-producing cells are cells that synthesize nanoparticles.

[0211] In one embodiment of the present invention, the nanoparticle-producing cells synthesize nanoparticles intracellularly. When partially or fully synthesized, assembled, and crystallized, they are particularly expressed intracellularly as follows: Synthesized: i) organelles, Golgi vesicles or apparatus, endosomes, exosomes, ribosomes; Endoplasmic reticulum, actin filaments, nucleus, peroxisomes, microtubules, lysosomes, mitochondria by or on cells such as diatribes, filaments, centrosomes, flagella, or cell membranes Within or near or within a part of a cell ii) within a region that is intracellular; or iii) 10 from a portion of the cell 5 , 10 3 , 100, 10 or 1 nm or less In the area that is.

[0212] In another embodiment of the invention, the nanoparticle-producing cells synthesize nanoparticles extracellularly. The particles are synthesized, assembled, crystallized, partially or completely intracellularly, and Specifically synthesized: i) in a region outside the cell, or ii) at a distance greater than 1, 10, 100, 103, or 105 nm from any part of the cell In a certain area.

[0213] In some cases, the cells are 1, 10, 10 3 , 10 5 , 10 10 , 10 20 , 10 50 or 10 100 In some other cases, cells is 10 100 , 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 100, 50 , 10, 5, or aggregates of less than 2 cells.

[0214] In one embodiment of the present invention, the nanoparticle-producing cells are eukaryotic cells, in particular human, animal, or plant cells. , trees, powder, branches, mushrooms, fungi, archaea, birds, fish, pigeons, trout, mammals, ants, honeybees Chi, or insects. In one embodiment of the present invention, the nanoparticle-producing cells are prokaryotic cells or bacteria.

[0215] In some cases, the nanoparticle-producing cells are Mycobacteria, particularly Mycobacterium patens. tuberculosis, Shewanella, especially Shewanella onidensis, Diosthrix, especially Diosthrix These bacteria may be osmotic fermenters. These bacteria specifically synthesize nanoparticles extracellularly.

[0216] In some other cases, the nanoparticle-producing cells are Magnetospirillum magnetica strain AMB-1, magnetotactic coccus strain MC-1, three facultative anaerobic Vibrio strains MV-1, MV-2 and and MV-4, Magnetospirillum magnetosticum strain MS-1, Magnetospirillum magnetosticum Griffithswaldens strain MSR-1, facultative aerobic Magnetotactic Spirirum, Mag Netospirillum magneticum strain MGT-1, an obligate anaerobe, and Desulfovibrio These bacteria can be magnetotactic bacteria, such as Bacillus magneticus RS-1. These bacteria are particularly intracellular. Nanoparticles are synthesized using

[0217] body parts

[0218] In some cases, the body part may be designated as a personal body part or a personal juvenile part.

[0219] In particular, an individual is an organism, most in particular a metazoan, most in particular an animal, even more in particular a mammal, most in particular a mammal. In particular a human, especially an adult, adolescent, or child.

[0220] In one embodiment of the invention, the individual is a mammal, a bird, a fish, a human, a plant, a fungus, or an archaea. is.

[0221] In some cases, the body part is a body part that contains nanoparticles or a particular amount of nanoparticles. , especially 1, 2, 5, 10, 10 3 , 10 5 , 10 10 , 10 50 or 10 100 after administration of the nanoparticles to the body part.

[0222] In some other cases, the body part is cooled by a cooling probe or a certain amount of cooling probes, particularly 1, 2, 5, 10, 10 3 , 10 5 , 10 10 , 10 50 or 10 100 More than cold It may be a body part including a cryoprobe, for example after insertion of the cryoprobe into the body part.

[0223] In still other cases, the body part is exposed to a freezing system or a specific amount of freezing system. Especially, 1, 2, 5, 10, 10 3 , 10 5 , 10 10 , 10 50 or 10 100 The body part may include more than one freezing system, for example, a freezing system This was after administration / insertion of the drug.

[0224] In some cases, the body part does not contain nanoparticles or a certain amount of nanoparticles, particularly 10 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2 or 1 or less The body part includes nanoparticles, eg, prior to administration of the nanoparticles to the body part.

[0225] In some other cases, the body part does not contain a cooling probe or a certain amount of cooling probes. Yes, especially 10 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2 or is a body part containing one or less cooling probes, e.g., prior to administration of the cooling probe to the body part. It is possible.

[0226] In yet some other cases, the body part is subjected to a freezing system or a specific amount of freezing system. Stem, especially, 10 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2 or less, not containing 1 or less cryosystems, especially body parts prior to administration of the cryosystems It could be.

[0227] In some cases, the amount of nanoparticles, cooling probes, and freezing systems can be measured in cm of a body part. 3 Such as Specifically measured or estimated per unit volume.

[0228] In another embodiment of the invention, the body part is in particular 3 Measured per 1 and 10 100 , 1 and 10 10 , or 1 and 10 3 Nanoparticles between the frozen tip and the frozen A biological system, cell, device, tissue, organ, biomolecule, molecule, atom, entity, or organism It contains or is an aggregate of bodily substances.

[0229] In some embodiments, the device, nanoparticle, cooling probe, freezing system, tissue, organ, living body The molecules, molecules, atoms, entities, and / or biological materials are the same or The same nanoparticles, cooled probes, freezing systems, tissues, organs, biomolecules, molecules, atoms, Belonging to an entity or collection that includes biological material.

[0230] In some other embodiments, the device, nanoparticle, cooling probe, freezing system, tissue, organ, Biomolecules, molecules, atoms, entities, or biological materials that are different or different nanoparticles , cooling probe, freezing system, tissue, organ biomolecule, molecule, atom, entity, or bio It belongs to an aggregate that includes bodily matter.

[0231] In yet some other embodiments, nanoparticles, cooling probes, freezing systems, devices, tissues, Organs, biomolecules, molecules, atoms, entities, and / or biological materials do not belong to living organisms , not derived from them and not produced by living organisms.

[0232] In yet some other embodiments, the body part is a whole or part of an organism.

[0233] In one embodiment of the present invention, the body part is a eukaryotic or prokaryotic cell, DNA, RNA, protein , lipids, biological materials, organelles, cell nucleus, cell nucleus, ribosomes, endoplasmic reticulum, Golgi apparatus, chloroplast body, or mitochondria, or at least 1, 10, 10 3 , 10 5 , 10 10 or 10 100 Includes pieces of them.

[0234] In some embodiments, the body part is a head, neck, shoulder, arm, leg, knee, foot, hand, ankle, elbow, trunk. In some other cases, the area of ​​the body may be all or part of the lower or upper limbs. The portion is or belongs to: Organs, musculoskeletal, muscle, digestive, respiratory, urinary, female reproductive, male reproductive, circulatory, cardiac Vascular, endocrine, circulatory, lymphatic, nervous (peripheral or non-peripheral), ventricular, enteric, sensory, or external Skin system, reproductive organs (internal or external), sense organs, endocrine glands. Organs or body parts are skeleton, joints, ligaments, tendons, mouth, teeth, tongue, salivary glands, parotid glands, submandibular glands, sublingual glands, pharynx, esophagus, Stomach, small intestine, duodenum, jejunum, ileum, large intestine, liver, gallbladder, mesentery, pancreas, nasal cavity, pharynx, larynx , trachea, bronchi, lungs, diaphragm, kidneys, ureters, bladder, urethra, ovaries, fallopian tubes, uterus, vagina, vulva, Clitoris, placenta, testes, epididymis, vas deferens, seminal vesicles, prostate, bulbourethral glands, penis, scrotum, lower Pituitary gland, pineal gland, thyroid gland, parathyroid gland, adrenal gland, pancreas, heart, arteries, veins, capillaries, lymphatic vessels , lymph nodes, bone marrow, thymus, spleen, gut-associated lymphoid tissue, tonsils, brain, cerebrum, cerebral hemispheres, diencephalon , brainstem, midbrain, pons, medulla oblongata, cerebellum, spinal cord, choroid plexus, nerves, cranial nerves, spinal nerves, ganglion eyes , eye, iris, ciliary body, lens, retina, ear, outer ear, earlobe, eardrum, middle ear, ossicles, inner ear, cochlear In cattle, the vestibule of the ear, the semicircular canal, the olfactory epithelium, the tongue, the taste buds, the mammary gland, or the skin. It may belong to the fluid circulation or circulatory system.

[0235] In some embodiments, the body part comprises at least one tumor, cancer, virus, bacteria, or or cells, particularly living cells, particularly diseased cells. The body part may contain healthy cells. In some other cases, the body part may contain healthy cells. Does not include.

[0236] In one embodiment of the present invention, the body part is a liquid that is a mixture of water, an excipient, a solution, a suspension, at least one chemical In some embodiments, the body part is synthetic. obtained, i.e., produced using chemicals that mimic the body parts of living organisms. In some other embodiments, the body part may be produced by a living organism.

[0237] In one embodiment of the present invention, the body part may be a pathological site, a healthy site, and / or a nano-site. Includes particle regions.

[0238] In one embodiment of the present invention, the body part is a pathological site or a pathological cell or virus. Is or contains

[0239] In some embodiments, a pathological site is an unhealthy site, or a site that is different from a site in a healthy individual. It is the site of a different condition or an unhealthy individual. It can be tumor cells, bacteria, or bacteria. may contain pathological cells such as karyotic or prokaryotic cells, as well as viruses or other pathological material Pathological cells may be: i) not positioned or functioning as they normally do in healthy individuals; ii) dividing faster than healthy cells, iii) transformed or modified healthy cells; iv) Living organisms that are dead due to the presence of a virus or other life form; or v) Contact with or interaction with foreign substances that do not belong to an individual, such as viruses, The virus can invade, colonize, and replicate in these cells. In some cases, the pathological cells colonize or destroy the target cells. or use cells or participate in interactions with cells, especially their own reproduction the same as a virus or other organism or entity that allows it to survive, multiply, survive, or die In some cases, the pathological site may contain or produce or amplify healthy cells. They may contain, but are particularly less numerous, less active or proliferating than pathological cells.

[0240] In one embodiment, the virus is a virus of at least one selected from the group consisting of: Belongs to the family: Avisoviridae, Ackermannviridae, Adenoviridae, Alloherpesvirus Family, Alphaflexiviridae, Alphasatellitidae, Alphatetraviridae, Albanaviridae, Amargaviridae, Amnoviridae, Ampuloviridae, Anelloviridae, Arenaviridae, Arteriviridae, Artoviridae, Ascoviridae Viridae, Asphaviridae, Aspiviridae, Astroviridae, Absinthe Iroidae, Bacilladonaviridae, Baculoviridae, Barnaviridae, Belpao Viridae, Beniviridae, Betaflexviridae, Bicudaviridae, Bidna Viridae, Birnaviridae, Bornaviridae, Botryllaviridae, Bromow viruses, caliciviruses, Calmotetraviridae, Caulimoviridae, chrysoviruses Scutella, Chewviridae, Circovirus, Clavaviridae, Closteroviridae, Coronaviridae, Corticoviridae, Cururiviridae, Cystoviridae, Delta Flexiviridae, Dicistroviridae, Endornaviridae, Euronivirus Family, Filoviridae, Fimoviridae, Flaviviridae, Fuselloviridae, Cancer Mafleviviridae, Globiviridae, Genomoviridae, Genomoviridae, Glo Broviridae, Gattaviridae, Hantaviridae, Hepadnaviridae, Hepewi Rusidae, Herpesviridae, Herpesvirus, Hypoviridae, Hydrosavirus Family: Ifraviridae, Inoviridae, Iridoviridae, Kitaviridae, Rabida Viridae, Reishubiridae, Levivirus, Liposthrixviridae, Lispiviridae Viridae, Luteoviridae, Malacoherpesviridae, Marnaviridae, Marse Iyuviridae, Matonaviridae, Medioniviridae, Magavirnaviridae, Me Zoniviridae, Metaviridae, Microviridae, Mimiviridae, Momonivirus Mymonaviridae, Myovirus, Mypoviridae, Neiroviridae, Nanou Iridaceae, Narnaviridae, Nimaviridae, Nodaviridae, Nudiviridae, Niviridae Mycaviridae, Orthomyxoviridae, Obaliviridae, Papillomavirus, Paramyxoviridae Viridae, Partitiviridae, Parvoviridae, Peribunyaviridae, Periviridae Mutetviridae, Phasmaviridae, Fenuiviridae, Phycodnavirus Family, Picobirnaviridae, Picornaviridae, Plasmaviridae, Pleurolipoidea Rusidae, Pneumoviridae, Podoviridae, Polycypiviridae, Polydnavirus Family: Polyomaviridae, Portoglobiviridae, Fungales, Potyviridae, Potyviridae Cesviridae, Pseudoviridae, Chinviridae, Quadriviridae, Leuviridae Russidae, Retroviridae, Roniviridae, Rudiviridae, Saltoroviridae, Secoviridae, Siphoviridae, Sumacoviridae, Solemoviridae, Sorinviridae Irusidae, Sphaerolipoviridae, Spiraviridae, Sanviridae, Tectiviridae Viridae, Tobaniviridae, Togaviridae, Trexatellidae, Tombasui Rusidae, Tospoviridae, Totiviridae, Tristromaviridae, and Turrivirus Family: Tymoviridae, Birgaviridae, Bupedeviridae, Synmoviridae, and Te Yueviridae.

[0241] In one embodiment of the present invention, the body part is or is a healthy site or healthy cell. In some cases, a healthy area is defined as an area or region that contains healthy cells. A healthy cell can be a cell belonging to a healthy individual or part of the body of a healthy individual, a diseased cell can be a cell belonging to a diseased ... cells that are not pathological cells, or that grow at a normal rate or speed, or at a rate or speed lower than pathological cells can be defined as cells that divide at a rate that is too fast or that do not form tumors or metastases do.

[0242] In some embodiments, the healthy site is 1, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 100, 100, 100, 200, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 ...100, 100, 200, 35, 40, 45, 50, 55, 60, 65, 70, 85, 90, 100, 100, 200, 35, 40, 45, 50, 55, 60, 65, 70, 100, 200, 35, 40, 45, 50, 55, 60, 65, 70, 100, 200, 35, 40, 45, 50, 55, 60, 65, 70, 100, 200, 35, 40, 45, 50 -1 , 10 -3 , 10 -6 or 10 -9 It particularly surrounds the pathological site when located at a distance of less than m.

[0243] In some embodiments, the present invention provides a method for treating a body part or volume exposed to a treatment as defined herein. The number of pathological or healthy cells included is 10 100 , 10 50 , 10 20 , 10 10 , 10 5 , 10, 5, 2 or 1 cell cm of body part 3 less than one cell per

[0244] In some other embodiments, the body part or volume exposed to the treatment defined in the present invention Specifically, the number of pathological or healthy cells involved is 1, 10, 10 3 , 10 5 , 10 7 , 1 0 9 , 10 20 , 10 50 or 10 100 cm of a cell or especially a body part 3 Fine details can be more numerous than the cells.

[0245] In still other embodiments, the body part or volume exposed to treatment according to the present invention In particular, the ratio of the number of diseased cells to the number of healthy cells is 10 100 , 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 10 2 , 10, 5, 2 or 1 or less.

[0246] In still other embodiments, the body part or volume exposed to treatment according to the present invention In particular, the ratio of the number of diseased cells to the number of healthy cells is 1, 2, 5, 10, 10 3 , 10 5 , 10 20 or 10 100 Greater than.

[0247] In another embodiment of the present invention, the body part, healthy or pathological site, or nanoparticle region is , 10 -50 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 10 or 10 3 m( (in length), mm 2 (on the surface) or m 3 Larger (by volume).

[0248] In another embodiment of the present invention, the body part, healthy or pathological site, or nanoparticle region is , 10 50 , 10 10 , 10 3 , 1, 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 or 10 -9 m (in length), mm 2 (on the surface) or m 3 (by volume) is less than or equal to:

[0249] In one embodiment of the present invention, cytotoxicity is induced by the method or freezing system according to the present invention. The amount of nanoparticles that can be used is 100 μg of nanoparticles per 250,000 cells. (0.5 ng of nanoparticles per cell or 0.01 ng per μm of body part). In some embodiments, preferably at least 2, 5, 10, 10 3 or 10 5 Coefficient of A smaller amount of nanoparticles may be obtained, for example, when the temperature is reduced to below 0°C by the method. and / or if the method involves a significant number of cycles, is efficient in disrupting cells. In some other embodiments, it may be at least 2, 5, 10, 10 3 ,or 10 5 A larger amount of nanoparticles is required to destroy cells by this method, by a factor of approximately and / or the method may be efficient if it involves a limited number of cycles.

[0250] In another embodiment of the invention, the nanoparticles are preferably administered in a 1, 2, 5, 6 or 7-well dose during the treatment according to the invention. , 10, 20, 50, 100, 10 3 or 10 4 for more than one step or cycle , especially 1, 2, 5, 10, 50, 100 or 10 3 Seconds, hours, days, months, or years It remains on the body part for a period of time.

[0251] In some other embodiments, the nanoparticles are delivered to the body part during treatment according to the present invention. The child's size decreased by 10 between before and after administration. -4 , 10 -1 , 1, 10, 20, 50, 70, 9 9, 100, 500, 10 3 or 104 % and remains in the body part without decreasing This percentage depends on the size of the nanoparticles after administration to the body part and the amount of nanoparticles in the body. The ratio between the size of the nanoparticles before administration to the area.

[0252] In some other embodiments, the at least one nanoparticle is administered to the body during treatment according to the present invention. Being a part or remaining in a body part.

[0253] In some cases, the size of the nanoparticles may vary by 1 or 2 times before and after administration of the nanoparticles to the body part. 0 -4 , 10 -1 , 1, 10, 20, 50, 100, 500, 10 3 or 10 4 % or more In particular, it decreases.

[0254] In some other embodiments, the body part is -10 , 10 -5 , 10 -1 , 1, 5, 10 , 10 3 , 10 6 or 10 10 More than 100 nanoparticles or cm of body part 3 or mg When nanoparticles are present in a body part, the amount of nanoparticles in the body part is 1,5,1 0, 50, 90, or 99% or more are destroyed or cured by treatment according to the present invention. will be done.

[0255] In still other embodiments, 10 10 , 10 6 , 10 3 , 10, 5, 1, 10 - 1 or 10 -3 of nanoparticles or mg or cm of body part 3 nanoparticles per mg When included in a body part, especially in terms of mass or volume, 100, 99, 90, 50 of the body part , 10, 5 or less than 1% is destroyed.

[0256] treatment

[0257] In one embodiment of the invention, the treatment is selected from the group consisting of: i) cryotherapy after at least one step of the method according to the invention or the treatment of a disease such as cancer therapy, ii) diagnosis, in particular cryodiagnosis according to at least one step of the method according to the invention or Diagnosis of diseases such as cancer, iii) The present invention is directed to the treatment of symptoms such as cosmetic procedures, skin disorders, deformities, aging, riddles, or conditions. In particular cryocosmetic or cosmetic treatments with at least one step of the method according to iv) at least one of the methods according to the invention with or onto a medium or body part Mixing or administering nanoparticles by steps.

[0258] In one embodiment of the present invention, a cryotherapy treatment, a method, or a step of a method according to the present invention The nanoparticles or frozen system may contain drugs or doxorubicin or chemotherapy drugs or does not cause or induce the presence or release or activation of the pharmaceutical agent It is not related to the nanoparticles or the freezing system according to the present invention. are different entities.

[0259] In another embodiment of the present invention, a cryotherapy treatment, method, or step of the method according to the present invention is , nanoparticles, or frozen systems, drugs or doxorubicin or chemotherapy drugs or It is the presence or release or activation of a pharmaceutical agent or is the result or consequence thereof. It is a particularly distinct or different entity from the nanoparticles or freezing system according to the present invention. .

[0260] In yet some other embodiments, the treatment, preferably the warming step, is performed by adjusting the temperature of the body part. Induce at least one heating step, also designated as a ramp or heating temperature. The temperature is determined by determining whether the body part is absorbing at least one nanoparticle. At least 1 if the body part contains at least one nanoparticle than if it does not. 001, 1.1, 1.2, 1.5, 2, 5, 10 or 10 3 higher by a factor of .

[0261] In some cases, at least one of the treatments or body parts includes at least one nanoparticle. The properties of the nanoparticles are similar or the same or as close as possible to each other except for the presence or absence of nanoparticles. Specifically, the nanoparticles are compared to at least one characteristic of a treatment or body part that does not contain nanoparticles under measurement. can be.

[0262] Optionally, the treatment or at least one step of the method is performed in the presence of radiation. can be.

[0263] In some other cases, the treatment or at least one step of the method does not involve radiation. It will be carried out under the supervision of the

[0264] In some other cases, the process or at least one step of the method comprises multiple frequency Magnetic field or magnetic field oscillating at multiple frequencies or patent EP336 incorporated by reference 3496 / PCT-IB2018000218 / WO2018150266 The method is not performed in the presence of a magnetic field that has at least one characteristic in common with the magnetic field being used.

[0265] In some other cases, the process or at least one step of the method comprises radio frequency and and not be carried out in the presence of magnetic fields oscillating at medium and / or low frequencies, where high frequencies The waves are up to 1MHz, and in most cases, the mid-frequency is lower than the high frequency, and the low frequency is lower than high frequencies and, if present, lower than mid frequencies, where, optionally, high frequency f h and low frequency f l The ratio f between h / f l is greater than 1.01 Low and / or medium frequencies f m and low frequency f l The ratio f between m / f l is greater than 1.01 , where, optionally, the maximum magnetic field H max and the mean magnetic field H av The ratio is greater than 1.00001 Listen, H max is the maximum magnetic field amplitude estimated between the values ​​of the local maximum magnetic field amplitude of each high-frequency oscillation. , H max_i It is designated as H av is H max_i is defined as the average of various values ​​of can be, wherein the magnetic field, optionally oscillating at high, medium and low frequencies, is configured as follows: Also in one sequence, during which the magnetic field strength or amplitude, or the maximum or average magnetic field, is first It remains constant at value A7 for time t7, or increases to value A7 for time t7 and then At least one other sequence during which the magnetic field strength or amplitude, or the maximum or average magnetic field remains constant at another value A8 during time t8 or decreases to A8 during time t8, where time A8 is smaller than A7, where, optionally, these at least two different sequences are repeated one or more times. can be, Here, the magnetic field oscillating at optional high and low frequencies is configured as follows: At least one sequence during which the magnetic field strength or amplitude, or the maximum or average magnetic field , which is initially constant at value A9 for time t9, or which increases to value A9 for time t9. and at least in another sequence between which the magnetic field strength or amplitude or maximum or The average magnetic field is time t 10 Between different values ​​A 10 is constant at time t 10 Between A 10 where A 10 is smaller than the A9, where, optionally, these at least two different sequences are repeated one or more times. It will be returned.

[0266] In some cases, the radiation is intentionally produced by humans, such as radiation from the Earth's magnetic field. It is particularly different from any other natural radiation and particularly different from radiation whose intensity or power is greater than: i) 1 μT or 1 mT or ii) 10 -9 , 10 -6 , 10 -3 Wat or body cm or cm of body part 2 or cm 3 per watt.

[0267] In still other embodiments, the treatment, preferably the warming step, Induce at least one temperature rise or heating step, even if the temperature is increased or heated. The temperature is such that the body part does not contain at least one nanoparticle. If the body part contains at least one nanoparticle, then it is particularly preferred that the body part contains at least 1.00 nanoparticles. 1, 1.1, 1.2, 1.5, 2, 5, 10 or 10 3 It is small by a factor of .

[0268] In still other embodiments, the invention relates to a method for controlling the temperature of a subject, particularly a cooling probe, particularly a temperature regulator or a cooling probe. The treatment in the step induces a temperature decrease or a cooling temperature or minimum temperature in the body part, If the body part contains nanoparticles, the temperature is than without particles, especially at least 1.001, 1.1, 1.2, 1.5, 2, 5, 10, or 10 3 It is large by a coefficient of .

[0269] In some cases, the temperature regulator is a cooled probe.

[0270] In still other embodiments, the treatment, particularly with a temperature regulator, particularly a cooling step, comprises: In particular, the body part may be at least as sensitive when it contains nanoparticles as when it does not contain nanoparticles. Also 1.001, 1.1, 1.2, 1.5, 2, 5, 10 or 10 3 Small body with a coefficient of Inducing or characterized by a decrease in temperature of a body part.

[0271] In one embodiment of the present invention, the treatment is to remove radicals or reactive oxygen species (ROS) or radicals. It is characterized by the generation of radicals or reactive species such as nitrogen or reactive nitrogen species (RNS). In some embodiments, the ROS are peroxides, superoxides, hydroxyl radicals, , singlet oxygen, and alpha oxygen, or derived from them. In some other embodiments, the RNS may be nitric oxide, superoxide, Peroxynitrite, peroxynitrite, nitrogen dioxide, hydroxyl radical, diacid Carbon dioxide, nitrosoperoxycarbonate, nitrogen dioxide, carbonate radical, trioxide Being or derived from dinitrogen or producing them.

[0272] In another embodiment of the invention, the treatment is characterized by the absence of generation of radical or reactive species. do.

[0273] In some cases, the label produced in the process or method or at least one step of the process The concentration of radical or reactive species is determined by measuring the concentration of radical or reactive species, particularly in the body part. Especially 1cm of the body 3 10 per 50 , 10 10 , 10 5 , 10 3 , 10 2 , 10, 5, 2 , 1, 10 -1 , 10 -5 or 10 -10 The following μM:

[0274] In yet another embodiment of the present invention, the radical or reactive species is Generated during the process or at least one step of the process.

[0275] In some other embodiments, the radicals or reactive species are specifically targeted to the body part or nanoparticle. cm per second or minute, especially of a body part 3 Especially 10 per -10 , 10 -5 , 10 -1 , 1, 5, 10 or 10 3 Temperature changes, temperature rises, or temperature drops greater than °C Under the below, produced by nanoparticles or body parts.

[0276] In some other embodiments, the radicals or reactive species are reacted with the nanoparticles or bodies in the following manner: Generated by body parts: i) No increase or decrease in temperature, particularly of body parts or nanoparticles, or ii) In particular, in body parts or nanoparticles, 10 , 10 5 , 10 3 , 10 2 , 50 , 10, 5, 2, 1, 10 -1 or 10 -5 Temperature changes, temperature rises, or temperatures below °C Decline.

[0277] In some other embodiments, during at least one step of the treatment or method or procedure The concentration of radical or reactive species generated in the body is particularly 1 cm 3 10 per -10 , 10 -5 , 10 -1 , 1, 5, 10, 10 3 , 10 5 , 10 1 0 or 10 50 μM radical or reactive species.

[0278] In yet another embodiment of the present invention, the generation of radical or reactive species, the increase in temperature, and / or or a temperature decrease determines the effectiveness of the treatment according to the present invention, which is at least one cell , especially effective against the partial or complete destruction or damage of pathological cells or body parts It is sex.

[0279] In one embodiment of the present invention, treatment according to the present invention results in or is associated with: R: i) At least some 1, 0, 10 3 , 10 10 or 1050 Individual pathological cells, body parts Destruction or damage to any part of the body, or any part of the body; ii) Treating or curing a body part.

[0280] In some embodiments, a treatment or method according to the present invention is a thermal therapy, such as hyperthermia or thermal ablation. Whether it is heat therapy or another treatment such as radiation therapy, chemotherapy, surgery, or immunotherapy; or combined with them.

[0281] In some cases, the treatment or method may optionally include cooling temperatures of 0, -10, -20, -4 below 0, -50, -100, or -200°C and / or with treatment or The method results in the formation of at least one ice ball and / or ablation of a body part or or related thereto.

[0282] In some other cases, the cooling temperatures are optionally -250, -200, -150, - 100, -50, -40, -30, -20, -10, -5, -2, -1 or below 0°C If so, the treatment or method is not cryoablation and / or the treatment and / or method is , does not cause the formation of at least one ice ball and / or the ablation of a body part, and is not associated with it.

[0283] In some embodiments, treatment according to the present invention is a method for treating atherosclerosis, such as cryoablation, hyperthermia, or thermal ablation. Not another treatment such as heat therapy, radiation therapy, chemotherapy, surgery, or immunotherapy or not combined.

[0284] In one embodiment of the present invention, the destruction or damage to the body part is or relates to: i) a change in size, thickness, or shape of a body part; ii) structural changes, such as a change from a three-dimensional or two-dimensional form to a two-dimensional or one-dimensional form; or changes in the geometry, or proteins, lipids, DNA, RNA, contained in body parts; or degeneration of biological materials.

[0285] In some embodiments, the destruction or damage or healing or detection of a body part is partial. do.

[0286] In some cases, destruction or damage or healing or detection of a body part may result in the mass or or less than 99, 90, 80, 70, 50, 20, 10, or 5% of the total volume, or a range thereof It can occur within

[0287] In some other embodiments, the destruction or damage or healing or detection is systemic.

[0288] In some other cases, the destruction, damage, healing, or detection of body parts is 10 by part or by mass or volume -10 , 10 -5 , 10 -1 , 1, 5, 10, 5 This could be 0, 70, 90 or even 99% or more.

[0289] In one embodiment of the present invention, the treatment, also specifically designated as treatment of a body part, is the repair of a body part, Destruction of a body part, preferably a pathological site or pathological cells such as tumor cells contained in a body part. Destruction or detection or cure or treatment.

[0290] In one embodiment of the present invention, the treatment according to the invention is carried out by cryotherapy, which comprises , in particular by cooling a body part, the cooling being carried out during cryotherapy or cryotherapy treatment. In some cases, cryotherapy can be a reduction in the temperature of a body part between the start and end of the treatment. A gradual reduction in the temperature of the body part can be employed, i.e., preferably at least Although temperatures may exceed -100, -40, or -20°C in some cases, unlike cryoablation, or direct destruction or selective cooling application / surface treatment of one or two body parts It does so by not inducing destruction within the cells. Destroy the tumor in at least one body part with two cooling cycles at temperatures below -100°C. This differs from the current tumor cryoablation method.

[0291] In one embodiment of the present invention, the treatment according to the present invention is carried out by cryosurgery, wherein the cryo Surgery is especially the step of introducing a substance or instrument into a body part or applying a substance or instrument to a body part. a cryotherapy treatment including the step of removing the device or substance therefrom, The first and second parts of the freezing system.

[0292] In one embodiment of the present invention, the cryosurgical treatment is carried out in accordance with steps a) to a) of the method according to the present invention. d) before, during or after, in particular, the introduction / administration to or into any body part of: The removal from a body part of: i) nanoparticles, ii) a cooled probe, iii) a nanoparticle as defined in the present invention. iv) a temperature regulator; v) a device preferably used to warm the body during the warming step. and vi) any instrument or substance used to treat the body part.

[0293] In some cases, to heat sensors, thermoregulators, and / or body parts The tool or material used may be included in the cooling probe.

[0294] In one embodiment of the present invention, cryosurgery is performed using catheters, syringes, instruments, materials, cryoprobes ( It is performed with the help of an instrument or substance or nanoparticles or is the insertion / introduction / administration of a cooling probe, device, substance or nanoparticle into or within a body part. or probe, or instrument, substance, nanoparticle, or cryogenic probe from a body part Allows removal.

[0295] In some embodiments, the cryosurgical instrument is placed on or in contact with the body part. Contact or 10 3 , 10 2 , 10, 1, 10 -1 , 10 -3 , 10 -6 or 10 -9 m from the body part. This is because the cryosurgical instrument This may be the case when it is directly introduced.

[0296] In some other embodiments, the cryosurgical device is positioned outside the body part or is positioned within the body part. No contact with or from body parts for 10 minutes -50 , 10 -10 , 10 -9 , 10 -5 , 10 -3 , 10 -1 or located at a distance of more than 1 m. This is because the cryosurgical instrument is This may be the case if the device is an electromagnetic radiation device located at a distance from the device or body part. do.

[0297] In another embodiment of the invention, the cryosurgery or cryotherapy is nanocryosurgery or nanocryotherapy. Nano-cryosurgery and nano-cryotherapy are methods in which or between nanoparticles Cryosurgery and cryotherapy, types of cryotherapy administered to or within body parts It is a type.

[0298] In some embodiments, nanocryosurgery or nanocryotherapy is freezing without the use of nanoparticles. Efficient with higher minimum temperatures and fewer side effects compared to cryosurgery or cryotherapy This allows for the attainment of appropriate treatment.

[0299] In one embodiment of the present invention, the treatment according to the present invention is cryotherapy, cryosurgery, nanocryotherapy or or nano-cryosurgical procedure or corresponds thereto.

[0300] In yet another embodiment of the present invention, the process according to the present invention comprises or involves: i) the duration of the treatment or at least one step of the treatment, ii) the initial temperature, ii) Cooling temperature, iv) Maintaining temperature, v) Minimum temperature, vi) Warming temperature, vii) Maximum temperature degrees, viii) final temperature, ix) initial, cooling, minimum, maximum, warming, and / or final Rate at which temperatures are reached, x) Initial, Cooling, Minimum, Maximum, Warming, and Final temperatures are reached xi) the rates for reaching the initial, cooling, minimum, maximum, warming, and final temperatures; xii) the use of instruments or substances for the treatment of body parts or nanoparticles during the procedure; or any equipment or object for measuring the temperature or ROS or NOS generated thereby Quality use.

[0301] In some cases, the final temperature is preferably the final temperature of a warming step of the treatment.

[0302] In some cases, the maximum temperature is the maximum temperature of the treatment or of at least one step of the treatment. The maximum temperature, especially Tmax is specified.

[0303] In some cases, the maximum temperature may be the maximum temperature of the warming step, but may also be the temperature of the final stage. Sometimes it corresponds to the degree.

[0304] In some other cases, the maximum temperature may be the maximum temperature of the cooling step, or In some cases it corresponds to the initial temperature.

[0305] In another embodiment of the invention, cryotherapy is carried out in particular on a body part, cm 3 At least 1, 10, 10 per 3 , 10 5 , 10 10 , 10 50 or 10 10 0 occurs or takes place in the presence of nanoparticles or mg of nanoparticles.

[0306] In another embodiment of the invention, the treatment according to the invention is particularly comprised in a body part, particularly a body part commercial 3 10 per 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2 or It occurs or is carried out in the presence of no more than one nanoparticle or mg of nanoparticles.

[0307] In one embodiment of the present invention, the maximum volume of a body part is related to the largest dimension, diameter, of the body part. In some cases, the maximum volume of a body part is estimated by calculating the volume that the body part will contain. Unhealthy areas, such as tumors, bacteria, viruses, and / or tumor cells, and healthy areas. For example, healthy tissue or non-tumor tissue or tissue containing bacteria, viruses and / or tumor cells. No boundary between tissue and healthy tissue is defined by the surface or external surface of the volume. is the volume of the represented body part.

[0308] Insertion of nanoparticles and / or cooled probes

[0309] Cryotherapy treatment according to the present invention involves administering nanoparticles and / or cooling probes to a body part. administration or treatment comprising at least one step or step of administering during or between The administration of nanoparticles and / or cooling probes to / into the body part is the first step in the treatment. This can correspond to the step or administration step of

[0310] In some cases, administering or administering step refers to administering to or into a body part, especially This involves administering a segment belonging to a cooling probe or a penetrating segment.

[0311] In some other cases, the administration or administration step involves non-penetrating segments, particularly those belonging to a cooled probe. of low-cooling gases, liquids, or solids, especially those expelled or diffused from the ment, to a body part. or administration into or towards.

[0312] In one embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled gas The drug, liquid, or solid is administered to the body part only once.

[0313] In one embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled gas Gas, liquid, or solid may be applied to or in body parts in amounts of 2, 5, 10 or 10 3 more than once It is administered.

[0314] In some embodiments, the nanoparticles leave the body part during treatment or are separated in the body part. When dissolved, and / or the nanoparticles in the body part destroy the body part or cause the desired treatment. to / on body parts if the device is not efficient enough to reach the desired medical, therapeutic or diagnostic activity The administration of nanoparticles in the body part is repeated several times.

[0315] In some embodiments, the nanoparticles, cooled tips, penetrating segments, and / or cooled gas The use of oral, liquid, or solid drugs is particularly problematic when a single administration is not sufficient to achieve a therapeutic effect or Or administered more than once to / into a body part if treatment is not completely effective.

[0316] In one embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled gas Gas, liquid, or solid may be present on or in body parts for 10 minutes. 10 , 10 5 , 10 3 , 10, 5 or It is given in two or fewer doses.

[0317] In some embodiments, administration of nanoparticles to a body part results in the nanoparticles remaining in the body part. or repeated a limited number of times if not broken down by the body part during the procedure.

[0318] In embodiments of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled gas The substance, liquid, or solid is such that such limited administration is sufficient to destroy or treat a body part. is sufficiently efficient to achieve the desired medical, therapeutic or diagnostic activity of the The dose is administered to the body part at the specified times.

[0319] In one embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled gas When a substance, liquid, or solid is administered directly to or near a body part, Body parts 1, 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 or 10 - 9 administered to or within a body part when administered at a distance of 1 m or less In this case, the nanoparticle, the cooled tip, the penetrating segment, and / or the cooled gas, liquid, or The solids or particles may be released from the area or site where they are administered to the body part, e.g., in the blood circulation. Therefore, there may be no need to transport or distribute it.

[0320] In another embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled Gases, liquids, or solids are released into the body indirectly or from the body. away from the body, especially from parts of the body. -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 - 6 or 10 -9 m or more apart, administered to or into a body part In this case, the nanoparticle, the cooled tip, the penetrating segment, and / or the cooled gas, liquid, or The solids may be transported or diffused from the area or site of administration to the body part. do.

[0321] In yet another embodiment of the present invention, the nanoparticles, cooled tips, penetration segments, and / or Administering a cooling gas, liquid, or solid to a body part is a dip in the next step. At least one of: i) localizing or cooling probes, penetrating segments, and nanoparticles within the body part; and / or cooling gases, liquids, or solids, ii) nanoparticles, cooled tips, penetrating segments, and / or cooled gases, liquids, or solids; Diffuse or transport the body to body parts, iii) nanoparticles, cooled tips, penetrating segments, and / or cooled gases, liquids, or Transporting solids to body parts, or iv) nanoparticles, cooled tips, penetrating segments, and / or cooled gas, liquid, or solid imaging the body, in particular using nanoparticles, cooled probes, penetrating segments, and / or cooled gases; The presence of a liquid or solid reaching or within a body part, or directed towards a body part transported or diffused by, or distributed or localized to, body parts Make sure you have.

[0322] In another embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or cooled Gases, liquids, or solids are those that, especially by mass or volume, occupy 10% of a body part. -9 , 10 - 7 , 10 -5 , 10 -3 , if it occupies more than 1, 10, 25, 50 or 75 % This percentage is administered to or within the body part. Nanoparticles in the nanoparticle region, cooled tip, penetrating segment, and / or cooled gas, liquid, or is the area occupied by the solid and the nanoparticle, the cooled tip, the penetrating segment, and / or the cooled gas. This occupancy can be the ratio between the volume of gas, liquid, or solid. 10 after the penetration segment and / or administration of cryogenic gas, liquid, or solid -5 , 10 -3 , 10 -1 , 1, 10, 103 or 10 5 This may correspond to measurements taken in minutes.

[0323] In another embodiment of the present invention, the nanoparticles, cooled tips, penetrating segments, and / or The cooling gas, liquid, or solid is administered to a body part by at least one of the following routes of administration: or into a body part: topically, enterally, gastrointestinal, parenterally, locally, orally, by inhalation, intramuscularly, Subcutaneous, intratumoral, intraorgan, intravenous, intraarterial, intrablood, or intratissue.

[0324] In some cases, the freezing gas, liquid, or solid may be the same as the cooling gas, liquid, or solid. It is possible.

[0325] In another embodiment of the invention, the nanoparticles are in suspension or in an aggregate, and the nanoparticle suspension The concentration of the liquid is 1 ml or cm of the suspension or aggregate. 3 10 per 10 , 10 5 , 10 3 , 500, 200, 100, 50, 20, 10, 5, 2, 1, 10 -1 , 10 -3 or 10 -5 mg of nanoparticles, or at least one chemical compound contained in nanoparticles, especially metal nanoparticles. In some embodiments, the concentration of the nanoparticle suspension or aggregate is The threshold above which nanoparticles cannot be dissolved or dispersed in the suspension or suspension medium. In some embodiments, the nanoparticle concentration is sufficient to avoid side effects. Very low.

[0326] In some cases, the nanoparticles, optionally in aggregate, are preferably delivered to the body part. Before, during, or after particle administration, preferably inside or outside the body part or Nanoparticles in powder, dry, soluble, or dispersed form without body parts.

[0327] In another embodiment of the present invention, the concentration of the nanoparticle suspension, preferably the concentration of the administered nanoparticle suspension The concentration of the liquid, especially metals, suspension 1 ml or cm 3 10 per -50 , 10 -30 , 10 - 20 , 10 -10 , 10 -5 , 10 -1 , 1, 5, 10, 100, 250, 500, 10 3 or 10 5 mg of nanoparticles, or in particular metal nanoparticles, In some embodiments, the nanoparticle concentration is sufficient to be effective. It's quite expensive.

[0328] In another embodiment of the present invention, the concentration of the nanoparticle suspension, in particular the concentration of the administered nanoparticle suspension, Degrees are used to measure the volume of a suspension or aggregate in 1 ml or cm 3 10 per -50 and 10 50 , 10 -1 0 and 10 10 , 10 -5 and 10 5 , 10 -3 and 10 3 , or 10 -1 and 10 3 Between mg of nanoparticles, or preferably metal nanoparticles, containing at least one chemical It is a scientific element.

[0329] In another embodiment of the invention, the nanoparticles are delivered to the body part in a manner that allows them to be ... 10 per second -100 , 10 -50 , 10-20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 10, 50, 100 or 10 3 mg of nanoparticles, or especially metal nanoparticles. The rate or velocity of at least one chemical element contained in the nanoparticles is administered. In some embodiments, for example, administration must be performed under anesthesia, particularly local or general anesthesia. It is necessary to administer it quickly if the duration of anesthesia needs to be short.

[0330] In some cases, the nanoparticles may be administered before, simultaneously with, or after the cooled tip.

[0331] In some cases, administering a cooling probe to a body part has similarities to administering nanoparticles to a body part. This is realized by at least one characteristic.

[0332] In another embodiment of the invention, the nanoparticles are administered to or into a body part every second, particularly 10 per second of the given time 100 , 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 1 0, 5, 1, 10 -3 or 10 -5 mg of nanoparticles, or especially metal nanoparticles, In some embodiments, the at least one chemical element is administered at a lower rate or speed. For example, after administration, the pressure in the body part is large, pushing the nanoparticles to the outside of the body part. If this occurs, slow administration is necessary.

[0333] In some cases, the nanoparticles may enter or penetrate the body part at a slower rate than the cooled probe. It is administered during

[0334] In another embodiment of the invention, the nanoparticles are delivered to or into a body part, particularly at a rate of: Especially 10 per second of administration time -100 and 10 100 , 10 -50 and 10 50 , 10 -20 and 10 20 , 10 -10 and 10 10 , 10 -5 and 10 5 , 10 -5 and 10 3 , or 10 -3 and 10 2 At least 1 mg of nanoparticles, or in particular metal nanoparticles, It is administered at a rate or speed of one chemical element.

[0335] In one embodiment of the present invention, the syringe or catheter or the medium in which the nanoparticles are suspended is Any device or material used to administer nanoparticles may be used to ensure that the method or treatment according to the invention is effective. This allows for sufficient nanoparticle concentrations to be reached in the targeted body area.

[0336] cryotherapy

[0337] In some cases, cryotherapy is a method or treatment according to the present invention or a method or treatment according to the present invention. may be or specify as a specified method or treatment,

[0338] In one embodiment, cryotherapy is not or is different from cryoablation or induces ablation of a body part. or not to generate or to increase the temperature of a body part, especially to 10% of the mass or volume of the body part. -3 , 10 -1 , 1, 5, 10, 50, 70, 80 or 90% or more, especially 1, 10 or 10 3Seconds or more, 0, -5, -10, -20, -40, -50, -100, -150, - Do not allow temperatures to drop below 200 or -250 °C.

[0339] In one embodiment of the present invention, cryotherapy is preferably performed by or with a freezing system. Use to cool or maintain the temperature of a body part, preferably from an initial temperature to a minimum or maintenance temperature. A therapy or medical procedure that includes at least one step of reducing the temperature of a body part. The reduction, preferably from the initial temperature to a cooling or minimum or maintenance temperature, is the second stage of the treatment. This may correspond to a heating step or a cooling step.

[0340] In one embodiment of the present invention, the method or treatment according to the present invention, also referred to as cryotherapy, involves the treatment or to produce any medical, cosmetic, therapeutic, or diagnostic effect or activity by Related, such effects or activities may be destructive and occur specifically in the body part or region of the nanoparticle. Destruction, healing, treatment, disappearance, attraction, movement, change in color or appearance, compound, substance, or nanoparticle It can be the creation of a child.

[0341] In one embodiment, the freezing system preferably cools the body part during the cooling step.

[0342] The step of cooling the body part containing the nanoparticles is specifically designated as step b) and The temperature of a body part is calculated by dividing the initial or maximum temperature of that body part by the temperature of the body part that is lower than the initial temperature. The cooling step is performed by cooling or maintaining or lowering the temperature to a minimum temperature.

[0343] In one embodiment of the present invention, the cooling step specifically involves cooling the body part containing the nanoparticles. In some embodiments, it means, relates to, or is can consist of: i) Cooling or maintaining the temperature of a body part from an initial temperature or cooling or reducing the temperature to a minimum temperature to cause, or ii) Cooling or maintaining or reducing the temperature of a body part to a minimum temperature. In some embodiments, the temperature of the body part is cooled from an initial temperature or maintained or at a minimum temperature. Cooling or lowering the temperature of a body part more simply means cooling it. Or it expresses a decrease.

[0344] In one embodiment of the present invention, at least one of the steps of the method, preferably the cooling step, , the step at which a medical, cosmetic, diagnostic, or therapeutic effect or activity occurs.

[0345] In one embodiment of the present invention, the cooling temperature achieved during the procedure is suitable for medical, cosmetic, diagnostic, or therapeutic purposes. is the temperature at which the effect or activity of

[0346] In one embodiment of the present invention, the temperature gradients that occur during the cooling and / or warming steps The distribution is expressed as a function of time or as a function of space or unit surface or volume of a body part. In particular, the estimated temperature interval by which a medical, cosmetic, diagnostic, or therapeutic effect or Activity occurs.

[0347] In some cases, a temperature gradient can be a change in temperature over time and / or in the temperature of a body part. It can be the change in temperature between two different locations.

[0348] In one embodiment of the present invention, the medical, cosmetic, diagnostic, or therapeutic effect or activity is , a change in the color or appearance of a body part, or destruction or damage to pathological cells or tissues of a body part Partial or complete healing.

[0349] In one embodiment of the present invention, the medical, cosmetic, diagnostic or therapeutic effect or activity is most Preferably, mainly at cooling or heating or at the minimum or maximum temperature, or at the cooling or heating stage. During or at the end of a cooling and / or warming step, or during a temperature gradient occurs in.

[0350] In one embodiment of the present invention, the medical, cosmetic, diagnostic, or therapeutic effect or activity is Preferably, the temperature rise occurs primarily at the maintenance temperature or at the beginning, during or end of the maintenance step. Optionally, the maintaining step comprises maintaining at least one nanoparticle, preferably Preferably at least one other atom other than iron, preferably at least one other metal atom Occurring in or due to the presence of nanoparticles containing

[0351] In some cases, the maintaining step may be performed until the temperature of the body part is maintained or -20 , 10 -3 , 1, 5, 10, 90, 99, 100 or 10 20 There can be steps that do not change by more than % This percentage is then calculated as [T maxm -T minm ] / T avm where , T maxm , T minm , and T avm are the maximum, minimum, and and average temperature.

[0352] In some cases, the cooling step is performed after the temperature of the body part has dropped by 10 -20 , 10 -3 ,1, The steps can be 5, 10, 90, 99 or 100% or more of change or decrease. Here, this percentage is [T maxm -T minm ] / T avc , where T max m , T minm and T avc are the maximum temperature, minimum temperature, and average temperature of the cooling step, respectively. degrees.

[0353] In some cases, the warming step is performed during which the temperature of the body part rises by 10 -20 , 10 -3 ,1, It can be a change or increase step of 5, 10, 90, 99 or more than 100%. , where this percentage is [T maxm -T minm ] / T avc , where T m axm , T minm and T avc are the maximum temperature, minimum temperature, and average temperature of the heating step, respectively. It is the uniform temperature.

[0354] In one embodiment of the present invention, the medical, cosmetic, diagnostic, or therapeutic effect or activity is does not occur primarily at the maximum, initial and / or final temperatures.

[0355] In one embodiment of the present invention, when the temperature is maintained at the maintenance or cooling temperature during the maintenance step, During the cooling step, the temperature is cooled from the initial or maximum temperature to the maintained or minimum temperature. and / or during the warming step, from the minimum or maintenance temperature to the maximum. When the temperature rises to its final or maximum value, it produces a medical, cosmetic, diagnostic, or therapeutic effect or More activity appears.

[0356] In one embodiment of the present invention, the medical, cosmetic, diagnostic, or therapeutic effect or activity is: It is more pronounced at the cooling or minimum temperature than at the initial or final or maximum temperature.

[0357] In one embodiment of the invention, the initial temperature of the body part or nanoparticles occurs when: i) before, during, or at the end of the administration step; or ii) during the cooling step. At the start of the step. Situations i) and ii) are 100, 75, 50, 25, 10, 5, 2, or corresponds to a temperature T of the body part or nanoparticle lowered by less than 1%, where this percentage is T / T i or after at least one step of the method according to the invention, 5 , 10 3 , 100, 10, 5, 2, 1 or 10 -1 The decrease is less than °C.

[0358] In another embodiment of the invention, the initial temperature of the body part or nanoparticles in particular is: i) the maximum temperature reached during the treatment or method according to the invention ii) No device or substance or cryogenic device is used to regulate the temperature of a body part. Sometimes, devices, substances, or cooling probes are used to regulate the temperature of a body part. the temperature reached before iii) Preferably, a device or substance used to regulate the temperature of a body part or The body part is free of a cooling probe and is in contact with the surrounding environment or with the living organism or individual that contains the body part. The temperature reached when thermal equilibrium is established.

[0359] In some embodiments, thermal equilibrium of the body part with the surrounding environment occurs when the temperature of the body part is below 10 -5 , 10-3 , 10 -1 , 1, 5, 10, 10 2 or 10 3 °C, especially ° per second C, or cm of body part 3 This occurs when the temperature does not change by more than 100°C.

[0360] In one embodiment, the present invention provides a method for treating a pulmonary artery disease in which the initial temperature and / or the final temperature is a physiological temperature, The present invention relates to a nanoparticle or freezing system for use according to the disclosure.

[0361] As used herein, physiological temperature refers to normal body temperature, or the body temperature of a healthy individual. In some cases, physiological temperature is measured in a body part of an individual or in the whole organism, or in an individual. The normal or optimum body temperature of a part of a person.

[0362] In some embodiments, the physiological temperature is measured in a healthy individual, or in an individual with a fever, or The temperature of an individual with a maximum body temperature of 43°C.

[0363] In some embodiments, physiological temperature may be 37±6°C.

[0364] In some embodiments, the physiological temperature is 37, 40, 45, 50, 60, 70, 80 , 90 or 100 °C, which may be the case if the individual is undergoing hyperthermia or thermal ablation. When the individual is treated by a method of removal, or when the individual is different from humans, for example, especially This is the case when an extremophile can live in an environment with temperatures exceeding 50°C.

[0365] In some embodiments, physiological temperatures are 37, 30, 20, 10, 5, 0, -10, - Temperatures can be significantly lower than 20, -50, or -100 °C, e.g., individuals may suffer from hypothermia. When the individual is different from humans, for example, in low temperature conditions, preferably below 0°C. This is the case when the organism is an extremophile that can survive in extreme environments.

[0366] In one embodiment, the initial temperature is the body temperature or trunk temperature of a healthy individual, most preferably In some embodiments, the initial temperature is between 36°C and 37.8°C. When in a hyperthermic state, temperatures below 36°C, especially below 30, 20 or 10°C In some other embodiments, the initial temperature is 37.8°C if the individual has a fever. It can be higher, especially above 38, 39, 40, and 41 °C. In embodiments, for example, when an individual is treated with thermotherapy, such as whole body hyperthermia, The initial temperature may be greater than 38, 40, 43, 45, 50, or 55°C. In some other embodiments, for example, the individual is treated with thermal ablation or high intensity focused ultrasound. If placed in a coolant bath, the initial temperature must not exceed 55, 60, 65, 70, 80, 90 or 100°C. do.

[0367] In some other embodiments, T c The cooling temperature can be specified as In some embodiments, the temperature of a body part or individual at the beginning, during, or end of a test. is the temperature at the end of the cooling step, T ECS is at least 10 -1 , 1, 5, 10, 2 5, 50, 75, 80, 90, 95 or 99%, or at least 10 -50 , 10 - 10 , 10 -1 , decreased by 1, 5 or 10 °C. The temperature at the start of the cooling step, T BC Sat least 10 compared to -1 , 1, 5, 10, 25, 50, 75, 80, 90, 95 or 99% or at least 10 -50 , 10 -10 , 10 -1 , 1, 5 or 10 °C, and this rate is |T ECS / T BCS | or |T ECS -T B CS | / |T BCS is equivalent to |, where the symbol || specifies the absolute value.

[0368] In some embodiments of the present invention, T BCS after the administration step or by the temperature regulator or At least 10 minutes after using or switching on the cooling probe -50 , 10 -3 , 10 -1 , 1, 5, 10, 10 2 or 10 3 This is the temperature that occurs after 1 second.

[0369] In some embodiments of the present invention, T ECS before starting a heating step or The cooling probe should be cooled for at least 10 minutes before use or before switching it off. -50 , 10 -3 , 10 -1 , 1, 5, 10, 10 2 or 10 3 is the temperature generated in seconds.

[0370] In some embodiments of the present invention, T ECS is at least 10 -50 , 10 -3 , 10 -1 , 1, 5, 10, 10 2 or 10 3 T by the passage of time in seconds BCS is separated from

[0371] In another embodiment of the present invention, the cooling temperature is maintained during the treatment or at least one step of the treatment. This is the lowest temperature reached inside.

[0372] Optionally, the minimum temperature is the minimum temperature reached during at least one step of the method. It could be.

[0373] In another embodiment of the present invention, the cooling temperature is adjusted to the initial temperature by the amount or variation of the temperature of the second step. The temperature is lower than the DT 2S = |T C -T i | which is 1, 2, 5, 1 Greater than 0, 20, 50, 100 or 200 °C.

[0374] In another embodiment of the present invention, the cooling temperature is determined by an amount, factor, or percentage |T C -T i | / |T i | or |T C | / |T i is a temperature lower than the initial temperature, which is 1 0 -5 , 10 -3 , 10 -1 ,0,1,5,10,25,50,75,80,90,95, 99, 100, 10 3 or 10 5 Greater than.

[0375] In some embodiments of the present invention, if it is desired to form ice balls or to perform the method according to the present invention, If it is desired to limit the number of cycles, a lower cooling temperature is desirable.

[0376] In another embodiment of the present invention, the cooling temperature is lower than the initial temperature by DT=|T C -T i | temperature, which is 103 , 100, 50, 20, 10, 5, 2 or 1 °C lower stomach.

[0377] In another embodiment of the present invention, the cooling temperature is increased by an amount, factor, or percentage from the initial temperature. Page |T C -T i | / |T i |or |T C | / |T i | is a lower temperature, which 10 5 , 10 3 , 100, 99, 90, 75, 50, 20, 10, 0, 10 -1 , 10 -3 or 10 -5 Lower.

[0378] In some embodiments of the present invention, the effects of excessively low cooling temperatures, such as those associated with the formation of ice balls, If side effects are to be avoided, high cooling temperatures, especially above 0°C, are desirable.

[0379] In another embodiment of the present invention, the cooling temperature is determined by the amount or change in temperature of the second step, DT2 S =|T C -T i The temperature is lower than the initial temperature by |, and this change is 10 -10 and 1 0 10 , 10 -5 and 10 5 , 10 -3 and 10 3 , or 10 -1 Between and 10 °C be.

[0380] In another embodiment of the present invention, the cooling temperature is determined by an amount, factor, or percentage DT 2S =| T C -T i | / |T i |or |T C / Ti is lower than the initial temperature by | is 10 -50 and 10 50 , 10 -10 and 10 10 , 10 -5 and 10 5 , 10 -3 and 10 3 ,Ma or 10 -1 It is between 10 and 11.

[0381] In one embodiment of the present invention, the initial temperature, the cooling temperature, the maintaining temperature, the warming temperature, the minimum temperature, the maximum temperature Degrees, and / or final temperatures are -273, -150, -100, -50, -20, -10, -5 , -2, -1, 0, 1, 5, 10, 20, 50, 70 or higher than 100 °C.

[0382] In another embodiment of the present invention, the initial temperature, cooling temperature, maintaining temperature, warming temperature, minimum temperature, maximum temperature Temperature, and / or final temperature, 10 3 , 10 2 , 70, 50, 20, 10, 5, 2 or less than 1 °C.

[0383] In yet another embodiment of the present invention, the initial temperature, cooling temperature, maintaining temperature, warming temperature, minimum temperature , maximum temperature, and / or final temperature are -273 and 10 3 , -50 and 100, -20 and 20, -20 and 10, -10 and 10, -5 and 5, -2 and 5, -1 and 5, or Between 0 and 5 °C.

[0384] In yet another embodiment of the present invention, the cooling or maintaining or minimum temperature and the initial or final or The difference between the maximum temperature at which an organism can survive or produce enzymes, proteins, or DNA The strands are not denatured or broken, and the temperature is between 100°C and 0°C. is the temperature difference.

[0385] In one embodiment of the present invention, cryotherapy is performed by maintaining or cooling the temperature of a body part, preferably at a or at least one step during or within the freezing system A therapy or medical procedure in which a body part is maintained at a constant or cooled temperature for a period of time. The step may correspond to the third or maintenance step of the treatment according to the invention.

[0386] In some cases, the maintenance step may occur within the cooling step. In this case, the temperature of the body part may first drop, remain constant, and then drop again. In such a situation, the cooling step is split into two parts separated by a maintaining step. can.

[0387] In some cases, a maintenance step may occur within a warming step. In this case, the temperature of the body part may first rise, remain constant, and then rise again. In such a situation, the warming step is divided into two parts separated by a maintenance step. can.

[0388] In one embodiment of the present invention, during the method, preferably during the maintenance step, There is no break, and the maintenance step is especially -50 , 10 -20 , 10 -10 , 10 -5 , 10 - 3 , 10 -1 , 1, 5, 10, 10 3 or 10 5 seconds, during which the temperature change is 10 10 , 10 5 , 10 3 , 100, 75, 50, 25, 10, 5, 2, 1 or 10 -1 °C or less, or 100, 75, 50, 25, 10, 5, 2, 1 or 10 -1 % and this percentage is |DT / T min |or |DT / T max Equal to | Here, DT, T min and T max is the temperature reached during this time or period. Degree fluctuation, minimum and maximum temperature.

[0389] In one embodiment of the present invention, the duration of the maintenance step is 10 50 , 10 30 , 10 20 , 10 10 , 10 5 , 10 3 , 100, 75, 50, 25, 10, 5, 2, 1, 10 -1 or 10 -3 Less than a second.

[0390] In one embodiment of the present invention, the temperature of the body part is maintained or cooled or cooled to a minimum temperature of 100°C or less. 90, 80, 70, 60, 50, 20, 10, 5, 1 or 10 -1 There is a difference of less than % When the temperature of a body part is maintained or reduced to a minimum or cooling temperature, especially by a freezing system This percentage is maintained at (T BP -T CT ) / T CT , T CT / T BP or T BP / T CT , (T BP -T MT ) / T M , T MT / T BPor T BP / T MT , (T BP -T minT ) / T minT , T minT / T BP or T BP / T m inT where T BP , T CT , T MT , and T minT Yes, respectively These are the body part temperature, cooling temperature, maintenance temperature, and minimum temperature.

[0391] In some cases, the maintained temperature may be cooling or warming, a minimum or maximum temperature.

[0392] In one embodiment of the invention, a person or refrigeration system may provide cooling or maintenance by: Maintaining or warming or preventing the temperature of a body part from being maintained at a minimum or maximum temperature You can: i) When or before cooling or maintaining or warming or reaching a minimum or maximum temperature specifically stopping or turning off the temperature regulator or cooling probe, or ii) blood or tissue, surrounding air, or cooling or maintaining or warming or or maximum temperature, or cooling, or maintaining, or warming, or minimum, or maximum temperature, or cooling, or or exposed to media not maintained or heated or maintained below minimum or maximum temperatures. This warms the body part.

[0393] In one embodiment of the present invention, a person or a freezing system cools or maintains body temperature by: Or can be heated or maintained at a minimum or maximum temperature: i) Use or turn on a temperature regulator or cooling probe. Cooling or maintaining or warming or before the minimum or maximum temperature is reached, or ii) Having the nanoparticles maintain the temperature of the body part at a predetermined value.

[0394] In one embodiment of the present invention, cryotherapy is performed by a freezing system during which the body part is The temperature is increased, especially by cooling or maintaining or raising a body part from a minimum temperature to a final or maximum temperature. It is a therapy or medical procedure that includes at least one step of raising or lowering the temperature. or maintenance or raising the temperature of the body part from the minimum temperature to the final temperature is the fourth step of the treatment. This may correspond to a step of heating or quenching.

[0395] In some cases, cryotherapy is also designated as step d), preferably cryotherapy. Optionally, step d) includes heating the body part with the heating system. , cooling or maintaining the temperature of a body part from a minimum temperature, By raising the final or maximum temperature of the body part above the minimum temperature, Such steps may be designated as warming steps. and at least one of the temperatures is a warming temperature.

[0396] In one embodiment of the present invention, the warming step is performed by cooling or maintaining or minimizing the temperature of the body part. Heating the body part containing the nanoparticles by increasing the temperature to a final or maximum temperature. It consists of doing.

[0397] In one embodiment of the present invention, the final temperature of the body part is determined at the end of the cryotherapy treatment or is the temperature measured or occurring at the end of the method or at the end of the warming step In some cases, it may be the entire treatment or at least one step of the treatment. The temperature may be the maximum temperature of the heating step.

[0398] In one embodiment of the present invention, the medical, cosmetic, diagnostic, or therapeutic effect or activity is: Most preferably, it occurs primarily at the beginning, during or end of the warming step.

[0399] In some embodiments, T f The final temperature, designated as the temperature of the body part or individual at the end of the procedure. In some embodiments, the end of treatment is reached when: i) the temperature of the body is increased; ii) the end of the heating process, ii) the start of the treatment or the switching on of the temperature regulator or cooling probe At least 10 -50 , 10 -20 , 10 -10 , 10 -5 , 10 -1 , 1, 5, 10 and is 10 3 seconds later, and / or iii) when or thereafter the temperature of the body part has stabilized.

[0400] In one embodiment of the present invention, the change in temperature DT of a body part is measured over time, in particular over 10 -50 , 10 -20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 10, 10 3 or 10 5 Within Dt longer than 10 seconds 10 , 10 5 , 10 3 , 100, 75, 50, 25, 10, 5 , 2, 1 or 10 -1 °C or less, or the temperature of the cooling and / or warming steps Degree fluctuations of at least 0, 0.5, 1, 1.1, 1.5, 2, 5, 10, 10 3 Also is 10 5If the temperature of the body part is small by a factor of .gamma., the temperature of the body part is stabilized.

[0401] In some cases, the temperature of the body part stabilizes during the maintenance step.

[0402] In one embodiment, the final temperature T f is the initial temperature T i has the same value as the initial temperature differ by less than the following temperature: i)10 -50 , 10 -10 , 10 -1 , 0, 1, 5, 10, 10 3 , 10 5 , 10 10 , 10 20 or 10 50 °C, and / or ii) 10 -50 , 10 -10 , 10 -1 , 1, 5, 10, 25, 50, 75, 90, 99 or 100%, this percentage is |T f / T i |, |T i / T f |, |T f -T i | / |T i |or |T f -T i | / |T f |It can be.

[0403] In another embodiment of the present invention, T f The final temperature specifically designated as the temperature of the fourth step Degree amount or variation DT 4S =|T f -T c |or |T f -T M | (This is 10 -10 , 10 -1 , 1, 2, 5, 10, 20, 50, 100 or greater than 200 °C The temperature is higher than the minimum temperature.

[0404] In another embodiment of the present invention, the final temperature may be cooled, maintained, or adjusted to a temperature higher than the minimum temperature by an amount, factor, or ratio. or T as a percentage f / T c , D.T. 4S / T c , |T f / T c |, T f / T M , D.T. 4S / T M , |T f / T M |, T f / T min , D.T. 4S / T min , and / or | T f / T min |(This is 10 -5 , 10 -3 , 10 -1 , 0, 1, 5, 10, 25, 50 , 75, 80, 90, 95, 99, 100, 10 3 or 10 5 (greater than stomach.

[0405] In one embodiment of the present invention, the final temperature is cooled, maintained, or increased above the minimum temperature by becomes: i) having a large temperature gradient during the warming step; ii) have a low cooling or minimum temperature; and / or iii) have a high final temperature; where the values ​​of i) to iii) correspond to the desired medical or cosmetic or therapeutic or diagnostic effect of the treatment. This makes it possible to achieve particularly discontinuous activities.

[0406] In another embodiment of the invention, the final temperature may be adjusted by a quantity or amount greater than the cooling or maintenance or minimum temperature. is the temperature change DT 4S=|T f -T c |or |T f -T M | or |T f -T m in |(This is 10 3 , 100, 50, 20, 10, 5, 2 or 1 °C or less ) higher temperature.

[0407] In another embodiment of the present invention, the final temperature may be cooled, maintained, or adjusted to a temperature higher than the minimum temperature by an amount, factor, or ratio. or percentage DT 4S / T c , |T f / T c |,DT 4S / T M , |T f / T M | , D.T. 4S / T min , and / or |T f / T min |(This is 10 5 , 10 3 , 100, 99, 90, 75, 50, 20, 10, 0, 10 -1 , 10 -3 or 10 -5 (less than or equal to) higher temperature.

[0408] In one embodiment of the present invention, the temperature between the final or maximum temperature and the cooling or holding or minimum temperature is The temperature difference is small when: i) the warming step is characterized by a small temperature gradient; ii) A large number of cycles, especially within a short period of time; iii) Small temperature gradients are compensated for by multiple cycles; Here, points i) to iii) are particularly relevant to the desired medical or cosmetic or therapeutic effect of the treatment. or diagnostic activities.

[0409] In another embodiment of the present invention, the final temperature is T 4S =|T f -T c | or |T f / T M |or |T f / T min |(This is 10 -10 and 10 10 , 10 -5 and 10 5 , 10 -3 and 10 3 , or 10 -1 Between and 0°C The temperature is higher by a factor of 10.

[0410] In another embodiment of the present invention, the final temperature may be cooled, maintained, or adjusted to a temperature higher than the minimum temperature by an amount, factor, or ratio. or percentage |T f / T c | / |T c |, |T f / T c ||, |T f / T M | / |T M |, |T f / T M |, |T f / T min | / |T min | and / or |T f / T min |(This is 10 -50 and 10 50 , 10 -10 and 10 10 , 10 -5 and 10 5 , 10 -3 and 10 3 , or 10 -1 and 10).

[0411] In one embodiment of the present invention, the initial temperature is maintained at least for one step of the process, in particular for the cooling step. The temperature is measured at the start of the loop. In one embodiment of the present invention, the cooling temperature is measured at the beginning, during or end of the cooling step. This is the temperature.

[0412] In one embodiment of the present invention, the initial temperature is maintained at least for one step of the process, in particular for the cooling step. The temperature is measured at the start of the loop.

[0413] In one embodiment of the present invention, the maintain temperature is measured at the beginning, during, or end of the maintain step. This is the temperature.

[0414] In one embodiment of the present invention, the warming temperature is measured at the beginning, during, or end of the warming step. This is the temperature at which the temperature is determined.

[0415] In another embodiment of the invention, the final temperature is adjusted for at least one step of the treatment, preferably This is the temperature measured at the end of the warming step.

[0416] In some cases, the temperature does not change during the administration step or is changed during the cooling or warming step. There is less change than during the preview.

[0417] In one embodiment of the present invention, at least two nanoparticles or at least one nanoparticle The assembly is cooled by the cold probe or by switching on the cold probe. Such mechanisms are particularly relevant to cold transitions or the initiation of such transitions or the cooling of the tip. Activation of such transfer to nanoparticles or positioning of a cooled tip at the nanoparticle position do.

[0418] In one embodiment of the present invention, at least two nanoparticles or at least one nanoparticle The ensemble can be cooled by not using the cryoprobe or by turning the cryoprobe off. Such a mechanism is particularly useful for the positioning of a cold tip or nanoparticle on a nanoparticle. The cooling probe is positioned in the position shown in FIG. This means that the movement of cold air is less important after stopping the movement that has started than before.

[0419] temperature

[0420] In one embodiment, the temperature is selected from the group consisting of: i) Initial temperature, ii) Final temperature, iii) Minimum temperature, iv) Maximum temperature, v) Cooling temperature degree, vi) maintaining temperature, vii) warming temperature, viii) physiological temperature, viii) nanoparticles temperature of the ice ball, ix) the temperature of the body part, x) the temperature of the ice ball, especially the nanoparticle-ice ball, xi) the shape of the ice ball xii) the temperature of the process or at least the temperature of the process, especially the formation of nanoparticles-ice spheres; Also one step temperature.

[0421] In some cases, the temperature may be -273, -50, -200, -100, -50, -40, -20, - 10, -5, 0, 5, 10, 15, 20, 50, 100, 10 3 , 10 5 or 10 1 0 It can exceed °C.

[0422] In some other cases, the temperature is 10 20 , 10 10 , 10 5 , 10 3 , 10 2 , 10 , 5, 2, 1, 0, -5, -10, -20, -50, -100, -150, -200 or -2 below 50 °C.

[0423] In still other cases, the temperatures were between -273 and 10 20 , -273 and 10 3 ,- 273 and 100, -273 and 25, -200 and 25, -100 and 25, -50 and 2 5, -40 and 25, -20 and 20, -10 and 0, -273 and 0, or -5 and 0 The temperature may be between 100°C and 200°F.

[0424] In some cases, the initial temperature and / or the final temperature is the maximum temperature.

[0425] In some cases, the warming and / or cooling temperatures are preferably adjusted so that they are consistent with the cooling stage. The minimum temperature is measured at the end of the tap or the beginning of the warming step.

[0426] In some cases, the minimum temperature is lower than the maximum temperature, especially at least 0.0100.0 ... 5, 1, 1.1, 1.5, 2, 5, 10, 10 3 or 10 5 By a factor of or less Tomo10 -10 , 10 -1 , 0, 1, 5, 10, 20, 50 or 100 °C lower .

[0427] radiation

[0428] In one embodiment of the present invention, a cryotherapy, treatment, method, or cryosystem related to any of the present inventions is provided. Systems, nanoparticles, and cooled probes may be used with or without the application of radiation or with or without the application of radiation. or radiation, specifically from the following groups: Selected are: i) magnetic fields such as alternating magnetic fields or magnetic fields oscillating at one or more frequencies; ii) lasers; iii) sonic or ultrasonic waves or sequentially applied ultrasonic and sonic waves.

[0429] In one embodiment of the present invention, a cryotherapy, treatment, method, or freezing system according to any of the present inventions is provided. , nanoparticles, cooled probes may or may not include: i) lasers or Application of patent EP19020331.5 / US16412933 (EP / US Pat. Appl. N umb.) lasers as defined in ii) medical or biological applications of continuous laser radiation or magnetosomes or cryosystems for use in therapeutic or cosmetic treatments - Patents.com , wherein the nanoparticles or magnetosomes are administered to a body part of an individual as needed; Optionally: - In the first step, magnetosomes are irradiated by laser radiation with a first power, In the second step, the magnetosomes are irradiated with a laser beam of lower power than in the first step. The second step involves cooling and / or laser irradiation of the magnetosomes. includes non-dissociation of at least one compound from the magnetosome, and Optionally, the sequence including the first step and the second step is repeated at least once. It is repeated.

[0430] In one embodiment of the present invention, the cryotherapy, treatment, method, freezing system, nanoparticles, The cooling probe by either method does not involve or include: i) ultrasound or sonic waves; or patents IB2018001460 and WO2019106428 incorporated by reference Ultrasonic or sonic waves as defined in / EP18827221.5 / US16486574 or ii) nanoparticles for use in sonomedical treatment of a body part of an individual, The nanoparticles are optionally administered to the individual's body part, and acoustic waves are optionally applied to the body part. The frequency is arbitrarily set to 0.01 to 100 MHz and can be set as follows: Used: i) 10 as needed 3 Sub-watt intensity, power, or power density of a body part W per cm, or cm of body part 2 W per, or cm of body part 3 Around W, or W per cm of transducer, or cm of transducer 2 Atata Watts per second, or cm of transducer 3 per W; or ii) 10 in energy or energy density 5 W.se per cm of body part below c, or cm of body part 2 per W.sec, or cm of body part 3 Per W.se c, or W.sec per cm of transducer, or c of transducer m 2 per W.sec, or cm of transducer 3 W.sec per wherein, optionally, the treatment includes a heating step, and the temperature increase in the heating step is optionally and wherein the maximum temperature reached during said heating step remains below 50°C; or wherein optionally, a temperature increase in the body part or nanoparticles exposed to the acoustic waves is , which is between 0.1 and 30°C higher than the temperature of the body part before the application of the sound waves.

[0431] In one embodiment of the present invention, radiation is applied to a body part or nanoparticles or to a body The moieties or nanoparticles are preferably frozen in at least one step of the method, in particular by a freezing system. During the warming step, the cells are exposed to radiation.

[0432] In one embodiment of the present invention, radiation is not applied to the body part or nanoparticles, or the body The moieties or nanoparticles are preferably frozen by a freezing system, preferably at least one of the steps of the method. During one step, there is no exposure to radiation during the warming step of the method.

[0433] In some embodiments, the radiation is electromagnetic radiation, light, monochromatic or polychromatic, laser, magnetic field , especially alternating magnetic fields, sound waves, especially low-frequency sound waves, ultrasound, high-frequency sound waves, or radio-frequency sound waves could be.

[0434] In some embodiments, the radiation may be heat radiation, and may be directed to a body part or nanoparticles. Temperature rise, especially in cm per second or minute, especially in body parts 3 Preferably 10 per - 10 , 10 -5 , 10 -1 , 1, 2, 5, 10, 10 3 , 10 5 or 10 10 °C It can be triggered beyond that.

[0435] In some other embodiments, the radiation may be non-thermal, specifically not inducing a temperature rise or or especially cm per second or minute, especially of a body part 3 10 per 10 , 10 5 , 10 3 , 10, 5, 2, 1, 10 -1 or 10 -5 Induces a temperature rise of less than °C.

[0436] In one embodiment of the present invention, the freezing system does not include the application of a magnetic field, particularly an alternating magnetic field.

[0437] In another embodiment of the invention, the freezing system comprises the application of a magnetic field, in particular an alternating magnetic field.

[0438] In another embodiment of the present invention, the freezing system may be configured to break ice or have the potential to break ice. This does not include the application of ice-destroying or radioactive sources.

[0439] In another embodiment of the present invention, the freezing system may be configured to break ice or have the potential to break ice. This includes the application of ice-destructive or radioactive sources.

[0440] In another embodiment of the present invention, the freezing system does not include the application of radiation.

[0441] In another embodiment of the present invention, the freezing system includes the application of radiation.

[0442] According to the present invention, radiation can be electromagnetic waves, waves such as sound or acoustic waves, or particle waves. A particle can have: i) weight or mass in some cases, and ii) gravity in other cases. having no quantity or mass, iii) motion in some cases, or iv) motion in other cases There is no.

[0443] According to the invention, the radiation may be electromagnetic radiation, acoustic radiation force, radiation force, or radiation pressure, preferably body radiation. It can be a body part radiation.

[0444] Preferably, the radiation is selected from the group consisting of: i) a magnetic field or an electric field; i) laser light, iii) light produced by a lamp, iv) light emitted at a single wavelength v) light emitted at multiple wavelengths; vi) ionizing radiation; vii) microwaves; vi ii) Radio frequencies, and ix) Sound waves.

[0445] In some cases, the radiation is selected from the following group: alpha, beta, gamma, X particles of rays, neutrons, protons, electrons, ions, neutrinos, muons, mesons, and photons Child or radiation.

[0446] Preferably, the radiation is optionally selected from the group consisting of: sonic, ultra-low Frequency sound, sound, ultrasound, and high frequency sound waves.

[0447] The invention relates to a freezing system for use according to the invention, the second part of which comprises: and has at least one property selected from the group consisting of: i) the mass or volume of the binding or binding material is greater than the mass or volume of at least one nanoparticle; less than the product, ii) the bonding or binding material is not an ice nucleation site; iii) At least one nanoparticle is an ice nucleation site.

[0448] In some cases, the binding or tethering material comprises nanoparticles and at least one selected from the group consisting of: They also differ in one characteristic: i) amorphous or non-crystallized; ii) partially, primarily, or entirely organic or carbonaceous; and iii) Does not contain metal or iron or iron oxide in large part or in excess of 50% by mass.

[0449] In some cases, the binding or tethering material may function to prevent aggregation of the nanoparticles, and and / or to allow for a uniform distribution of nanoparticles and / or to form nanoparticles into chains. Placing and / or coating nanoparticles and / or The crystal orientation of the two nanoparticles must be aligned in the same direction, and / or the nanoparticles must be aligned in a line. The material is a collection of geometric shapes that can be circles, spheres, rectangles, or squares. is.

[0450] In some cases, the volume or mass of the binding or tethering material is greater than the volume or mass of the nanoparticles. At least 10 10 , 10 5 , 10 3 , 100, 50, 20, 10, 5, 2 or This is because the freezing system works by promoting ice formation, binding or is useful when the binding material is not a nucleation site for ice.

[0451] In some cases, ice nucleation sites are sites or materials on which ice can grow. It is a material that is particularly conducive to the formation of ice balls, especially in the absence of ice formation sites or materials. The ice balls formed are larger than the ice balls that are generated.

[0452] In some cases, the binding or tying material may be at least partially formed in the presence of such material. No other ice ball is larger, or at least 2, 5, or 10 times larger, than that At least one ice ball of a size equal to or smaller than the size of the ice ball that would form in the absence of such material. If it is, it is not an ice formation site.

[0453] In some cases, the nanoparticles and the binding or tethering material are anti-freeze agents.

[0454] In some other cases, the nanoparticles and / or binding or associating materials may be used to provide anti-freeze properties. It is not a drug.

[0455] The present invention also relates to a freezing system for use in accordance with the present invention, wherein the freezing system comprises: At least two elements bound or joined together through a bonding material The nanoparticle aggregate has an outer surface, which is formed by bonding or bonding the outer surfaces of at least two nanoparticles. is the outer surface of the associative material, wherein the outer surface is at least one selected from the group consisting of: It has the characteristics of: i) the outer surface of at least two nanoparticles is greater than the outer surface of the binding or tethering material; ii) the outer surfaces of at least two nanoparticles are suitable for ice nucleation or serve as ice nucleation sites; It is a thread iii) The outer surface of the binding or binding material is not suitable for ice nucleation or does not have sufficient ice nucleation surface area. Not to, iv) the outer surface of one nanoparticle is separated from the outer surface of another nanoparticle by more than 1 nm; v) not on the outer surface of at least one nanoparticle contained in a nanoparticle assembly or aggregate vi) the outer surface of a chain, ring or segment, in particular straight or curved; comprising at least two nanoparticles, vii) Exposed to or in contact with any body part.

[0456] In one embodiment of the present invention, the nanoparticles and / or binding or tethering material are located on the interior surface or has an internal volume and / or an external surface. In some cases, nanoparticles and / or The interior surface or volume of the binding or binding material is free from nanoparticles and and / or bond or bind the surface or volume of the material. The outer surface of the nanoparticles and / or binding or association material in contact with the body part. and / or the surface of the binding or association material.

[0457] The present invention also relates to a freezing system for use according to the invention, wherein the nanoparticles are and has at least one property selected from the group consisting of: i) ferromagnetic or ferrimagnetic, ii) crystalline, not amorphous, or containing multiple crystal faces; iii) filled or non-hollow nanoparticles; iv) Absence of: a) ice inside the nanoparticles or b) possible formation inside the nanoparticles or c ) Ice inside the nanoparticles when the nanoparticle temperature is below 10°C, v) the presence of: a) ice on the outside of the nanoparticles, or ii) the possibility of forming ice on the outside of the nanoparticles; or c) ice on the outside of the nanoparticles if the temperature of the nanoparticles is below 10°C; vi) ice nucleation sites, especially intracellular ice nucleation sites; vii) Solid nanoparticles or more than 50% of their chemical elements or atoms are in the solid state solid nanoparticles, viii) magnetosomes, and ix) Chemical analogues of magnetosomes.

[0458] In one embodiment of the present invention, the ferromagnetic or ferrimagnetic behavior of the nanoparticles and / or the nanoparticles The crystallinity of the nanoparticles and / or the presence of at least one crystal face in the nanoparticles or nanoparticles are filled, not hollow, or have surfaces that promote ice nucleation. are.

[0459] In one embodiment of the present invention, the filled or non-hollow nanoparticles preferably have a mass or is at least 1, 10, 50, 70, 80, 90, 95 or 99% by volume in solid state The nanoparticles include:

[0460] In one embodiment, for example, at least one crystal face of the nanoparticle is in the crystal structure of the nanoparticle. Nanoparticles can prevent ice from forming inside, for example, by preventing the insertion of ice atoms into the nanoparticles. If it cannot form, it is characterized or has the characteristic of having no ice inside. The absence of ice in the nanoparticles is 100, 90, 80, 50, 20 by mass or volume. , 10, 5, 2, 1% or less can be made of ice, where nanoparticles are particularly This corresponds to the metal or core part of the nanoparticle. The absence of ice on the surface of the nanoparticle is at least The ice or ice ball in one nanoparticle is 10 -40 , 10 -20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 10, 10 3 , or 10 5 nm, nm 2 or nm 3 below This corresponds to the fact that

[0461] In one embodiment, the nanoparticles exhibit an absence of ice within them under one of the following conditions: Having or characterized by at least one property such as: i) The temperature of the nanoparticles is measured or observed, especially under a microscope, and it is 10, 5, 2, is below 1, 0, -5, -10, -20, -40 or -100°C, and ii) After or during treatment according to the present invention.

[0462] In one embodiment, the nanoparticles have a structure in their interior or their core. The crystallized core of the nanoparticles is preferably free of ice or less than its nanoparticle size. Large size, preferably below 10, 5, 0 or -5°C, without ice, The presence / absence of ice can be particularly observed, for example, by microscopy.

[0463] In one embodiment, ice may form or be formed on the exterior of, e.g., nanoparticles. The surface or outer surface is favorable for the formation of ice or ice morphology, or the top or outer surface of the nanoparticles When located thereon, the nanoparticles have or are characterized by the presence of ice on their exterior. The presence of ice on the surface of a nanoparticle means that there is ice or ice on the surface of at least one nanoparticle. 10 balls -40 , 10 -20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 10, 10 3 or 10 5 nm, nm 2 or nm 3 This is equivalent to the above.

[0464] In one embodiment, the nanoparticles are characterized by the presence of ice within them under one of the following conditions: Having or characterized by at least one property such as: i) The temperature of the nanoparticles is measured or observed, especially under a microscope, and it is 10, 5, 2, is below 1, 0, -5, -10, -20, -40 or -100°C, and ii) After or during treatment according to the present invention.

[0465] In one embodiment of the present invention, the binding or tying material is a binding material or a binding material inside or The ice or ice balls are preferably arranged on the outside of the container, and are preferably of a size, diameter, length, surface area, etc. The surface or volume is preferably nm, nm of the bonded or bound material. 2 or nm 3 or Nano 10 per gram -40 , 10 -20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1 , 10, 10 3 or 10 5 nm, nm 2 or nm 3 is greater than.

[0466] In one embodiment of the present invention, the nanoparticles are preferably free of binding or tethering materials, and are suitable for ice nucleation. A nucleation site is a site where ice or ice balls form, especially in a volume or size larger than i) in the absence of such sites or nanoparticles, particularly at least 0, 1, 5, 10 or 10 3 The volume or size of the ice or ice ball formed by the coefficient of and / or ii) 10 -40 , 10 -20 , 10 -10 , 10 -5 , 10 -1 , 1, 5 , 10, 10 3 , 10 5 or 10 10 nm 3 .

[0467] In some cases, the ice or ice balls are 50, 37, 20, 10, 5, 2, 1, 9, -5, -1 Formed or observed at temperatures below 0, -40 or -100°C.

[0468] In some other cases, the ice or ice ball is -200, -100, -50, -20, -1 Formed or observed at temperatures above 0, -5, -2, -1, 0, 2, 5, or 10°C can be.

[0469] In some cases, the ice or ice balls are intracellular or form intracellularly.

[0470] In some other cases, the ice or ice balls are extracellular or form outside the cell.

[0471] In some other cases, the nanoparticles are solid nanoparticles, where solid nanoparticles refers to one, two, five, ten or more chemical elements or atoms, 1, 10, 50, 70, or 90% or more of the product is in a solid state, or 1, 1 by mass or volume 0, 50, 70 or more than 90% in solid state, this property is especially -200, -100, - This is particularly observed at temperatures above 50, -20, -10, 0, 5, 10, 50 or 100°C. This is especially common.

[0472] In one aspect, the present invention relates to nanoparticles or freezing systems for use in accordance with the present invention. and where the nanoparticles are magnetosomes.

[0473] In one embodiment of the present invention, the magnetosomes are synthesized by magnetotactic bacteria. The nanoparticles are contained in, originate from, extracted from, or isolated from the nanoparticles.

[0474] In one embodiment of the present invention, the magnetotactic bacteria are selected from the group consisting of: Netospirillum magnetimum strain AMB-1, magnetotactic cocci strain MC-1, and three The facultative anaerobic Vibrio strains MV-1, MV-2 and MV-4, Magnetospirillum magne Totakutim strain MS-1, Magnetospirillum gryphiswaldense strain MSR-1, facultative Anaerobic Magnetotactic Spirirum, Magnetospirillum magnetum strain MGT- 1. Obligate anaerobe, Desulfovibrio magneticus RS-1, Nitrospira, Nitros Pyra moscoviensis, Magnetobacterium babaricum, Desulfovibrio magneticum Body, Desulfovibrio desulfuricans, Geobacter metallireducens, Pro Magnetotactic bacteria, MMP5, MMP2, where MM is magnetotactic multicellular prokaryote, Magnetococcus , MC-1, CS103, NKMC5, a-Protobacteria, Rhodospirillum sp. , Agrobacterium vitis, Magnetospirillum magneticum MS-1, Magnetospirillum magneticum AMB-1, Magnetospirillum magneticum Neticum MGT-1, Magnetospirillum Griffithswaldens MSR-1, Marine Magnetism Vibrio MV-1, Magnetospirillum Griffithswardens MSR-1, Magnetos Pyrillum magneticum AMB-1, Magnetospirillum magneticum MS-1, Magnetospirillum magneticum strain MGT-1, galvanotactic coccus strain MC-1, Sulfovibrio magneticus RS-1, anaerobic Vibrio strains MV-1, MV-2, and MV- 4.

[0475] In one embodiment of the present invention, the magnetotactic bacteria belong to a class of bacteria selected from the group consisting of: Zetaproteobacteria, Betaproteobacteria, Gammaproteobacteria A, Deltaproteobacteria, Epsilonproteobacteria, Nitrospira, OP3 , and Alphaproteobacteria.

[0476] In one embodiment of the present invention, the magnetotactic bacteria synthesize or synthesize magnetosomes. These magnetosomes have at least the following characteristics: They are particularly characterized by one of the following: i) they are produced intracellularly; ii) they are magnetic, iii) they contain minerals, iv) their cores are made of metal acids, especially iron oxides v) their cores are composed of biological compounds such as lipids, proteins, and endotoxins; vi) they are surrounded by target material and are particularly removable; vi) they are arranged in chains; i) Application of an alternating magnetic field with a typical frequency of 20 to 200 kHz and a typical strength of 1 to 50 mT. Heat can be generated under application.

[0477] In one embodiment of the present invention, the magnetosomes are characterized by at least one of magnetic, size, composition, chain One common to nanoparticles, such as configuration, charge, core, mineral, coating, or crystallinity Or have some properties.

[0478] In one embodiment of the present invention, magnetosomes are mineral moieties synthesized by magnetotactic bacteria. In this case, the iron oxide produced by these bacteria is called magma. The mineral portion of the netosome or magnetosome is responsible for the transport of proteins, lipids, and endotoxins. , or specifically free of carbon-containing biological material or 0.1, 1, 10, 30, 50 or 7 Contains 0% or more or less than 0% by weight of carbon, and the carbon is present in these bacteria. Produced by Lear.

[0479] The present invention also provides a method for treating a cancer cell comprising administering to a subject therapies ... Regarding the use of nanoparticles or freezing systems.

[0480] In some cases, chemical analogs of magnetosomes can be chemically synthesized, and and / or not synthesized by magnetotactic bacteria.

[0481] In some cases, chemical analogs of magnetosomes have at least one or two similar properties to magnetosomes. , 3, 4, 5, 6, 7, 8, 9, or 10 common properties. A common property is ferrimagnetic behavior, especially at 0, 5, 10, 50, 100, 10 at temperatures above 200, 300, 500, or 1000 K -50 , 10 -10 , 10 -2 , coercivity exceeding 1, 5, 10, or 100 Oe, large size, preferably a size and / or chain arrangement greater than 1, 5, 10, 20, 50 or 70 nm; Preferably, the arrangement is of chains of 1, 2, 5 or more than 10 nanoparticles.

[0482] In one embodiment of the present invention, the nanoparticles or magnetosomes are purified to remove endotoxins and and / or other biological organisms, such as proteins or lipids derived from synthetic or magnetotactic bacteria. Removes 10, 50, or 90 percent or more by mass of chemical substances. In some cases, the nanoparticles or magnetosomes may be used to treat endotoxins and / or or 100, 99.9, 99, 95 or 90 percent or quality of other biological material The purified nanoparticles are purified to remove less than 100% of the total amount of NADH. In some cases, this percentage is (Q BP -Q AP ) / Q BP or Q AP / Q BP QBP and Q APs are endotoxins, biological materials, proteins, or is the amount of lipid.

[0483] In some cases, the purification step involves the use of methods or detergents such as NaOH and / or KOH. This can be achieved by using synthetic organisms or magnetotactic bacteria or bacterial debris, among others. from inorganic materials, especially those mixed with organic substances or contained in nanoparticles or magnetosomes Separating organic materials, especially nanoparticles or magnetosomes It can specifically harvest tosome minerals.

[0484] In some cases, the purified nanoparticles or magnetosomes are It is a granular mineral.

[0485] The present invention also relates to a freezing system for use according to the invention, wherein the nanoparticles are and has at least one property selected from the group consisting of: i) more than one metal atom or more than 1% by mass, atomic number, or volume of metal atoms; ii) it is composed partially, predominantly, or entirely of a metal oxide; iii) contains at least one iron atom iv) It is particularly selected from the group consisting of barium, zinc, and manganese, other than iron. containing at least one other metal, v) It is necessary to add at least one metal other than iron to the nanoparticles by mass of all metals present. 10 for -20 % and 50% by weight, vi) It has a volumetric mass and / or density greater than that of water. stomach, vii) Surface to volume ratio is 10 -10 nm, viii) A specific heat capacity less than the specific heat capacity of the body part or substrate or medium in which it is contained Have a quantity, ix) a thermal conductivity greater than that of the body part or substrate or medium in which it is contained I have x) melting greater than the enthalpy of fusion of the body part or substrate or medium in which it is contained It has enthalpy, xi) has a viscosity greater than that of the body part or substrate or medium in which it is contained; Ru, xii) the heat capacity, thermal conductivity, and / or enthalpy of fusion are lower at the surface than at the center; and Call xiii) The size is between 1 and 1000 nm.

[0486] In one embodiment of the present invention, at least one nanoparticle is 0, 1, 5, 10, 10 3 , 1 0 5 or 10 10 metal atoms, or mass, number of atoms, or volume of metal atoms greater than 0, Contains more than 1, 5, 10, 25, 50, 70, 80, 90, 95 or 99% metal atoms nothing.

[0487] In one embodiment of the present invention, at least one nanoparticle is 10 20 , 10 10 , 10 5 , 10 3 , 10, 5, 2, 1 or 0 or less metal atoms, or mass or atomic number or gold The volume of group atoms is 100, 99, 90, 85, 80, 70, 50, 30, 20, 10, 5, Contains less than 2, 1 or 0% metal atoms.

[0488] In one embodiment of the present invention, the nanoparticles have a metallic composition. The compound maintains a cooling sensation especially locally, especially within the body part.

[0489] In one embodiment of the present invention, the nanoparticles comprise at least 1, 2, 5, 10 or 20 other than iron. In some cases, the presence of such other metals may have one of the following properties: Two: i) The ability of nanoparticles to enhance the capacity to maintain coldness locally, especially within a body part. Increase. ii) reduce toxicity and / or increase the efficacy of cryotherapy;

[0490] In one embodiment of the present invention, the nanoparticles contain at least one metal other than iron in the nanoparticles. 0, 10 for all metal masses ―20 , 10 ―10 , 10 -5 , 10 -1 , 1, 5 , 10, 20, or greater than 50% by mass.

[0491] In one embodiment of the present invention, the nanoparticles contain at least one metal other than iron in the nanoparticles. Mass percentages of all metals are 100, 70, 50, 30, 20, 10, 5, Contains less than 2 or 1%.

[0492] In one embodiment of the present invention, the nanoparticles contain at least one metal other than iron in the nanoparticles. 10 mass percent of the mass of all metals ―20 Between 10% and 50% -1 and 20% Between or 10 -1 and 5% inclusive.

[0493] In one embodiment of the present invention, the at least one nanoparticle has a volumetric mass and / or density of Greater than the volumetric mass and / or density of water.

[0494] In one embodiment of the present invention, the at least one nanoparticle is a nanoparticle or nanoparticle aggregate. commercial 3 10 per -20 , 10 ―10 , 10 ―5 , 10 ―3 , 10 ―1 , 0, 1, 5, or has a volumetric mass or density greater than 10 grams.

[0495] In some cases, the large volume or density of nanoparticles may encourage ice formation on the nanoparticle surface. For example, it prevents ice from breaking down, coalescing, and turning into liquid water. and provide coordination sites specifically at the atomic or molecular level at the interface between the nanoparticle surface and ice. It does so by:

[0496] In another embodiment of the invention, the at least one nanoparticle is a nanoparticle or nanoparticle assembly. Body cm 3 10 per 20 , 10 10 , 10 5 , 10 3 , 10, 5, 2, 1 or 10 - 1 Having a volumetric mass or density less than a gram.

[0497] In some cases, when the volumetric mass or density of the nanoparticles is low, ice may form between the nanoparticles. This may happen.

[0498] In one embodiment, at least one nanoparticle has a surface, preferably an outer surface, and a The ratio of the volume to -50 , 10 ―10 , 10 ―5 , 10 ―1 , 0, 1, 5 or 10 nm. In some cases, a large surface / volume ratio can lead to ice formation on the nanoparticle surface. is promoted.

[0499] In one embodiment, at least one nanoparticle has a surface, preferably an outer surface, and a The ratio between the volume of 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2, 1, 0, 10 -1 or 10-3 nm. In some cases, low The surface / volume ratio can prevent the collapse of nanoparticles from a three-dimensional structure to a two-dimensional structure, for example. do.

[0500] In one embodiment of the present invention, at least one nanoparticle has a specific specific heat capacity or per gram of nanoparticles or per mole of nanoparticles commercial 3 Per K per 10 -10 , 10 -5 , 10 -1 , 1, 5 or 10J It has a large specific heat capacity or heating capacity.

[0501] In another embodiment of the present invention, the at least one nanoparticle has a particular specific heat capacity or K per gram of nanoparticles or K per mole of nanoparticles or nanoparticles Child's commercial 3 Per K per 10 10 , 10 5 , 10, 5 or 1 J It has a quantity or heating capacity.

[0502] In some cases, heat capacity is called isobaric mass heat capacity, isobaric molar heat capacity, isovolumetric molar heat capacity, isochoric The heat capacity may be the volumetric heat capacity, and / or the equivalent atomic molar heat capacity.

[0503] In one embodiment of the present invention, at least one nanoparticle is 10 ―20 , 10 ―10 , 10 ―5 , 10 ―1 , 0, 1, 5, 10, 10 2 , 10 3 , 10 5 or 10 10 Wm -1 .K -1In some cases, nanoparticles have a higher thermal conductivity than their They have high thermal conductivity due to their metallic composition, crystallinity and / or nanometer size. are.

[0504] In another embodiment of the present invention, at least one nanoparticle is 50 , 10 10 , 10 5 , 10 3 , 10, 5, 1, 10 -1 or 10 -3 Wm -1 .K -1 Lower heat conduction In some cases, the nanoparticles may have a rate of, for example, 100% when they are degraded. It has a moderate thermal conductivity.

[0505] In one embodiment of the present invention, at least one nanoparticle is administered to the body part or Enthalpy of fusion or latent heat of fusion greater than the enthalpy or latent heat of fusion of the substrate or medium Pee or has latent heat of fusion or latent heat.

[0506] In another embodiment of the present invention, the at least one nanoparticle is 10 per -50 , 10 -10 , 10 -5 , 10 -1 , 0, 1, 2, 5, 10, 10 3 Ma or 10 5 If the enthalpy or latent heat of fusion is greater than KJ, In some cases, the large enthalpy of fusion of nanoparticles is due to the metal composition of the nanoparticles. This may be advantageous in some cases, particularly in preventing ice formation or ice melting on the nanoparticle surface. obtain.

[0507] In another embodiment of the present invention, the at least one nanoparticle is 10 per 50 , 10 10 , 10 5 , 10, 5, 2, 1, 10 -1 or 10 -5 KJ In some cases, nanoparticles have a lower enthalpy of fusion or latent heat of fusion than nanoparticles. The small enthalpy of fusion of the particles may be due to the decomposition of the nanoparticles.

[0508] In one embodiment of the present invention, at least one nanoparticle is 10 ―50 , 10 ―10 , 10 ―5 , 10 ―3 , 10 ―1 , 0, 1, 5, 10, 10 2 , 10 3 , 10 5 or 10 10 In some cases, the nanoparticles have a viscosity greater than 1 Pa.sec. If it moves or diffuses slowly over minutes, it may have a high viscosity.

[0509] In another embodiment of the present invention, at least one nanoparticle is 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2, 1, 10 -1 , 10 -3 or 10 -5 Pa.sec. than seconds In some cases, nanoparticles move or move rapidly in water or in the body. or diffusion can result in a lower viscosity.

[0510] In another embodiment of the present invention, the nanoparticles have a greater heat capacity at their surface than at their center. Has.

[0511] In another embodiment of the present invention, the nanoparticles have a greater thermal conductivity at their center than at their surface. It has.

[0512] In one aspect, the present invention relates to nanoparticles or freezing systems for use in accordance with the present invention. The nanoparticles have at least one property selected from the group consisting of: Having: i) Heating capacity is 10 per mg of nanoparticles per second -20 , 10 -10 , 10 -5 , 10 -1 , 0, 1 or 10 and 0, 1, 5, 10, 10 5 or 10 10 Configured in °C will be done. ii) Heating capacity is the rate at which the body part containing nanoparticles heats up compared to the body part without nanoparticles. This is the difference between the heating rate. iii) The heating capacity is measured during the heating step. iv) Applying radiation or external forces such as sound or ultrasonic waves, lasers, magnetic fields to body parts or nanoparticles By applying an external radiation source, the heating capacity can be increased. v) nanoparticles, where the heating capacity is reduced by the presence of nanoparticles, especially in the absence of radiation application; destroys cells more efficiently than in the absence of nanoparticles and in the absence of applied radiation. and vi) As the heating capacity increases, nanoparticles that are particularly exposed to radiation will lose their heat energy compared to those that are not exposed to radiation. They are particularly effective at destroying cells compared to non-metallic nanoparticles.

[0513] In one aspect, the present invention relates to nanoparticles or freezing systems for use in accordance with the present invention. The nanoparticles have at least one cooling ability selected from the group consisting of: It has. i) The cooling capacity is 10 per second per mg of nanoparticles. -20 , 10 -10 , 10 -5 , 10 -1 , 0, 1, 5, 10, 10 5 or 10 10 It consists of °C. ii) Cooling capacity is the ratio of the cooling rate of the body part containing nanoparticles to that of the body part without nanoparticles. This is the difference between the cooling rate. iii) The cooling capacity is measured during the cooling step. iv) The cooling capacity can be increased by switching on or activating the cooling probe. can. v) Especially when the cooled tip is activated, the presence of nanoparticles is greater than the absence of them. In this case, the cooling capacity is greater. vi) The cooling capacity is increased by the presence of nanoparticles, especially due to the activation of the cooling tip. , nanoparticles destroy cells more efficiently than: a) without nanoparticles and with a cooled tip; b) lack of application of nanoparticles and cooled probes. and vii) As the cooling power increases, nanoparticles that are particularly exposed to the cold tip tend to be more sensitive to the They are particularly effective at destroying cells compared to non-nanoparticles.

[0514] In one aspect, the present invention relates to a nanoparticle or a freezing system for use according to the present invention, Nanoparticles have the ability to maintain the temperature of a body part at a temperature called the maintenance temperature, and are classified into the following groups: having at least one characteristic selected from: i) The temperature to be maintained is -200 to -100°C, -200 to 0, -100 to 10, -100 to Between 0, -40 to 10, -40 to 0, -20 to 0, or -10 to -5°C, and Beauty ii) The change in the maintenance temperature is 10 5, 10 3 , 1, 10 -1 , or 10 -3 Sub-minute time Especially 10 -3 , 1, 10, 50, 90, 99, or 100% or less. The percentage of |(T min -T max ) / T av Specifically, equal to |, T min , T m ax , T av are the minimum, maximum and average temperatures measured during this time period.

[0515] In one embodiment of the present invention, the nanoparticle heating capability is preferably achieved by reducing the heating step or other steps in the process. During at least one step, preferably per second, preferably per mg of nanoparticles This is the temperature in degrees Celsius obtained by the nanoparticles.

[0516] In some embodiments, the nanoparticles are exposed to a radiation source, preferably a heat-generating radiation source. Without this, the nanoparticle heating capacity is estimated.

[0517] In some embodiments, the heating ability of the nanoparticles can be achieved by exposing the nanoparticles to radiation or a radiation source, preferably Preferably, the condition is estimated by exposure to a heat-producing radiation source. The value of the heating capacity may be increased compared to the heating capacity measured without application of the radiation source.

[0518] In another embodiment of the present invention, the heating capacity is measured by a body part containing nanoparticles. The difference between the temperature value and the temperature obtained by a body part that does not contain nanoparticles. The degree values ​​are estimated specifically per second and specifically per mg of nanoparticles during the heating step.

[0519] In one embodiment of the present invention, the heating capacity of the nanoparticles is in particular per second, in particular mg of nanoparticles Per. 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 10, 1, 10 -1 , 10 - 3 or 10 -5 °C or lower.

[0520] In another embodiment of the invention, the heating capacity of the nanoparticles is in particular per second, in particular per mg of nanoparticles. 10 ―50 , 10 ―10 , 10 ―5 , 10 ―1 , 1, 5, 10, or 10 3 °C expensive.

[0521] In yet another embodiment of the present invention, the heating capacity of the nanoparticles is in particular m of nanoparticles per second. 10 per g ―50 ~10 50 , 10 ―10 ~10 20 , 10 ―10 ~10 10 ,or 10 ―5 ~10 5 The temperature is between °C.

[0522] In yet another embodiment of the present invention, the nanoparticle heating capacity is determined by the amount of the nanoparticles, particularly during the warming step. is the particle heating rate.

[0523] In another embodiment of the invention, the nanoparticle cooling capacity is in particular per second, in particular per mg of nanoparticles. Specifically, the number of degrees Celsius lost by the nanoparticles during the cooling step.

[0524] In some embodiments, the cooling capacity may be used to keep the nanoparticles in a stable state, particularly during the cooling or maintaining step. Allows for temperature adjustment during probing without exposure to substances or equipment or cooled probes It is determined.

[0525] In some embodiments, the cooling capacity may be sufficient to keep the nanoparticles at a temperature, particularly during the cooling or maintaining step. Such conditions are estimated by exposing the temperature to a temperature controller or a cold probe. or the nanoparticle cooling capacity compared to that measured in the absence of a cooled tip. This may increase the value of

[0526] In one embodiment of the present invention, the efficacy of treating and / or destroying a disease is determined by heating and and / or cooling capacity.

[0527] In another embodiment of the present invention, the cooling capacity is determined by the number of degrees lost by the body part containing the nanoparticles. is the absolute difference in priority between the power lost by the nanoparticle-free body part and the power lost by the nanoparticle-free body part. The number of degrees lost is especially per second, especially per mg of nanoparticles, especially during the cooling step. It is estimated that

[0528] In one embodiment of the present invention, the cooling capacity of the nanoparticles is in particular per second, in particular per mg of nanoparticles. 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 10, , 10 -1 , 10 -3 Also is 10 -5 °C or lower.

[0529] In another embodiment of the invention, the cooling capacity of the nanoparticles is in particular per second, in particular per mg of nanoparticles 10 ―50 , 10 ―10 , 10 ―5 , 10 ―1, 1, 5, 10, or more than 10°C expensive.

[0530] In yet another embodiment of the present invention, the cooling capacity of the nanoparticles is in particular 1 / 2 of the nanoparticles per second. 10 mg per -50 ~10 50 , 10 -10 ~10 10 , or 10 -5 ~10 5 °C That is.

[0531] In another embodiment of the present invention, the nanoparticle cooling capacity is determined by the amount of the nanoparticles, especially or during the cooling step. is the cooling rate.

[0532] In some cases, heating capacity is the same as heat capacity.

[0533] In some cases, at least one property of the nanoparticle or frozen system is -200, - Measured at temperatures above 100, -50, -20, -10, -5, 0, 5, 10 or 40°C It is determined or observed.

[0534] In some other cases, at least one property of the nanoparticles or frozen system is 0 5 , 10 3 ,500,200,100,50,37,20,10,5,2,1,0,- Measure or observe at temperatures below 5, -10, -20, -40, -100, or -200°C It is measured.

[0535] A freezing system for use according to the present invention, wherein the penetrating segment is selected from the group consisting of: and having at least one characteristic selected from: i) at least one dimension less than 10cm; ii) less than 10cm in length; iii) width less than 5cm; iv) the ratio of the longest dimension to the smallest dimension is greater than 2; v) occupies less than 50%, 25%, 15%, 10%, 5%, or 1% of the volume of the body part; vi) at least 1 / 20, 1 / 50, 1 / 100, 1 / 500 of the maximum volume of the body part; or less than 1 / 1000, vii) biocompatible and / or biodegradable; and viii) rigid or with a shear modulus greater than 1 GPa; ix) Flexible or with a shear modulus of 1 GPa or less.

[0536] In one embodiment of the present invention, the segments, preferably the through segments, have at least 1 having one dimension, surface, volume, length, and / or width, and specifically included in a body part; 1 0 , 10 5 , 10 3 , 500, 100, 50, 10, 5, 2, 1, 0.5, 10 -3 , 1 0 -5 or 10 -10 cm or cm 2 or cm 3 In some cases, the patient To avoid causing pain to the patient, and especially -10 , 1, 5, 10, 30 or longer periods Smaller segments are preferred to maintain the segment size, 60 minutes or 10 minutes. 3 minutes, body parts, and / or allowing a segment to be reintroduced several times in a body part .

[0537] In another embodiment of the invention, the segments, preferably the penetrating segments, have a maximum dimension of The ratio between the dimension and the minimum dimension is 10 -10 , 10 -5 , 10 -1 , 1, 2, 5, 10 or 10 3 Greater than.

[0538] In another embodiment of the invention, the segments, preferably the penetrating ones, have a length of about 1 / 2" between their longest dimension and their maximum length. The ratio between the short dimension and 10 , 10 5 , 10, 5, 2, or less than 1.

[0539] In one embodiment, the dimensions of the segments are the normal or most commonly used dimensions of the segments. The dimensions are those used or those of the segments indicated in the frozen system notice.

[0540] In some cases, the segment may be a freezing system or a cooling probe, or a freezing system or or may be part of a cooled probe.

[0541] In one embodiment of the present invention, the segment, preferably the penetrating segment, is Accounting for 100%, 50%, 25%, 15%, 10%, 5% or 1% or less by volume or mass do.

[0542] In another embodiment of the invention, the segment, preferably the penetrating segment, of the body part 10 by volume or mass -5 %, 0%, 1, 10, 25% or more than 50% do.

[0543] In one embodiment of the present invention, the segments, preferably the penetrating ones, are smaller or is at least 1, 1 / 5, 1 / 20, or 1 / 20 of the maximum volume or largest dimension of the body part At least one dimension smaller than 50, 1 / 100, 1 / 500 or 1 / 1000 It has.

[0544] In one embodiment of the present invention, the segment, preferably the penetrating segment, is the most At least 1 / 100,000, 1 / 1000, 1 / 10, 1 / 10 of the volume or dimensions of a large / 5, 1 / 2 or 1 Larger or having at least one dimension that is larger.

[0545] In one embodiment of the present invention, the segments, preferably the penetrating segments, are biocompatible and and / or biodegradable.

[0546] In some cases, the segments and / or nanoparticles may be fused to the body part. may be introduced, especially causing death or illness or fever or cardiac shock in individuals It is biocompatible.

[0547] In some cases, the segments and / or nanoparticles may be separated by a single particle. If it can be decomposed or is decomposed, for example in the method or freezing system according to the invention, Parts of a body part or its components such as lysosomes, particularly according to their use in If the dissolves the segments and / or nanoparticles, they are biodegradable.

[0548] In some embodiments, the segments, preferably the penetrating ones, may be rigid or curved. or preferably at 90, 45, 20, 10, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 45, 20, 10, 5, 65, 70, 8 Do not bend more than 2 or 1°, or 10 -50 , 10 -20 , 10 -5 , 10 -1 , 0, 1, 5, 10, or greater than 50 GPa. Thus, rigid segments prevent the segments from moving during, for example, cryotherapy. Useful for.

[0549] In some embodiments, the segments, preferably the penetrating ones, are flexible or or preferably 10 minutes before and after administration to the body part. -10 , 10-1, 0, 1, 5, 10, Bending of 45° or more or shear modulus of elasticity of 10 50 , 10 20 , 10 5 , 10, 5 , 2, 1, 10 -1 or 10 -3 In some cases, flexible segments The device prevents segments from becoming stuck in the body part during cryotherapy, for example. It helps to avoid.

[0550] The present invention also relates to a freezing system for use in accordance with the present invention, wherein the non-penetrating segment , has no solid or immovable parts that come into contact with the body part, or are not in continuous contact.

[0551] In one embodiment of the invention, the non-permeable segment is 1, 10, 10 minutes from the surface of the body part 3 or 10 10 Located at a distance of more than nm or segmenting cryogenic liquids or gases that are in contact with or penetrate body parts. When producing or expelling substances, they have no solid or immovable parts that come into contact with body parts. .

[0552] The present invention relates to a refrigeration system for use according to the invention, wherein the cooling source comprises: i) a cooling gas; ii) a iii) a cryogenic liquid, and iv) a cryogenic fuel. The cooling source can be a cryogenic solid.

[0553] The present invention also relates to a refrigeration system for use in accordance with the present invention, wherein the cooling source comprises: Helium 3, helium, hydrogen, neon, nitrogen, air, fluorine, argon, oxygen, methane The cryogenic gas is selected from the group consisting of:

[0554] The present invention also relates to a refrigeration system for use according to the invention, wherein the cooling source is 0, have a boiling point or boiling point higher than 1, 5, 10, 50, 100, 200 or 300 K .

[0555] In some other cases, the cooling source is 5 , 10 3 , 500, 200, 100, 50, It may have a boiling point lower than 20, 10, 5, 2, or 1 K.

[0556] The present invention also relates to a freezing system for use according to the invention, the cooling source of which is a cooling system for freezing the body. is in direct contact with the part.

[0557] In some cases, the cooling source is expelled from the cooling probe or segment and diffuses into the body part. Sometimes the cooling source is in direct contact with the body.

[0558] In some cases, when the cooling source is on the body part or 10 10 , 10 5 , 10 3 , the cooling source comes into direct contact with the body part when it is at a distance of 10 or 1 nm or less.

[0559] In some other cases, the cooling source is located at least in part of the cooled probe, particularly in the segment. Therefore, if the cooling source is particularly separated from the body part, or if the distance between the cooling source and the body part is 10 -1 , 1, 5, 10, 10 3 , or 10 5If the cooling source is larger than 100 nm, the The contact is indirect.

[0560] The present invention provides a method for treating a body part of an individual by cryotherapy, comprising at least one of the following steps: The present invention relates to a freezing system for use in accordance with the present invention in a method of placing a a) administering nanoparticles to a body part of an individual, particularly during the nanoparticle administration time, specified as a given step, b) exposing a body part of an individual to a cooling probe during a particular exposure time. are specified as steps. c) particularly during the cooling period, using a cooling probe to initially detect the body part of the individual, particularly containing nanoparticles; and cooling the body part from a temperature to a cooling temperature of the body part, wherein the cooling and / or maintaining temperature is initially This step is specifically designated as the cooling step. d) during the rise of body temperature, from the cooling temperature of said body part to the final temperature of said body part; or increasing the temperature of the body part from a cooling temperature of said body part to a maintenance temperature of said body part. The nanoparticles are heated or caused to heat the body part containing the nanoparticles by either heating or increasing the temperature. This step is preferably designated as the warming step. e) if necessary, then maintain the temperature of the body part, particularly the part containing the nanoparticles, during the maintenance period; or Maintain: i) the cooling temperature or ii) a temperature between the cooling temperature and the initial or final temperature. This step is specifically designated as the maintain step.

[0561] In one embodiment, the nanoparticle administration time is the duration of nanoparticle administration or the nanoparticle administration step. is the duration of the loop or t0.

[0562] In one embodiment, the exposure time is determined specifically when the cooled probe is switched on or activated. the duration of exposure of the body part by the cooling probe, or the exposure step or duration In some cases, t0' is the time between the administration of the cooling probe at the body part and the time when the cooling probe is applied to the body part. The time during which the cooling probe is switched on or active is divided into It can be either, include, or sum up.

[0563] In one embodiment, the cooling time is the duration of cooling the body part or the duration of the cooling step. between or t1.

[0564] In one embodiment, the heating time is the duration of heating a body part or the duration of a heating step. Or t2.

[0565] In one embodiment, the maintenance time is the time to maintain or maintain the temperature of the body part in maintenance or cooling. duration, or minimum temperature or duration or t3 of the maintenance step.

[0566] In one aspect, the present invention relates to a nanoparticle or a freezing system for use according to the present invention, There are at least three steps: administration, cooling, maintaining, and warming. A sequence of 1, 2, 3, 5, 6, 10, or 10 3 times, preferably six times The above steps are most preferably repeated three or more times.

[0567] The present invention relates to a refrigeration system for use in accordance with the present invention, in which the initial temperature and and / or the final temperature and / or the maximum temperature are physiological temperatures;

[0568] The present invention also relates to nanoparticles for use according to the invention, wherein the physiological temperature is The temperature is selected from the group consisting of: i) the body part before or after it has been treated by the method of the freezing system according to the invention Minute temperature. ii) body temperature of individuals without fever; iii) Temperatures of 35-45°C, 25-45°C, or 10-100°C iv) the temperature of an individual or a body part or its blood, and The average temperature of that body part or parts measured over the course of this individual's life at temperatures not exceeding 5°C, and v) the temperature of an individual or a body part or blood of this individual or its blood or body A temperature not more than 5°C lower than the average temperature of the body part.

[0569] In some cases, physiological temperature is the temperature of a body part or of an entire living organism. or the temperature of at least one eukaryotic or prokaryotic cell.

[0570] In some cases, physiological temperatures are -200, -150, -100, -50, -40, -2 0, -10, -5, -2, -1, 0, 2, 5, 10, 50, 100, 150, 200, 4 00 or can be higher than 500°C.

[0571] In some other cases, the physiological temperature is 10 5 , 10 3 , 500, 200, 100, It can be lower than 50, 42, 41, 20, 10, 5 or 0°C.

[0572] The present invention also relates to a refrigeration system for use in accordance with the present invention, wherein the cooling temperature is , having at least one property selected from the group consisting of: i) The difference ΔT1 between the initial temperature and the cooling temperature is, in particular, 105 , 10 3 , 100, 57 or 10° smaller than C, and ii) The difference ΔT2 between the final temperature and the cooling temperature is, in particular, 10 5 , 10 3 , 100, 57 or 10 Less than °C.

[0573] In one aspect, the present invention relates to nanoparticles or freezing systems for use in accordance with the present invention. wherein the cooling temperature has at least one characteristic selected from the group consisting of: : i) The difference T1 between the initial temperature and the cooling temperature is, in particular, 10 5 , 10 3 , 100, 57 or 10°C Smaller than and / or ii) The difference T2 between the final temperature and the cooling temperature is 10 5 , 10 3 , 100, 57, or 10°C More particularly small, and preferably, as the nanoparticle concentration in the body part increases, the difference ΔT1 and / or ΔT2 decreases.

[0574] In one embodiment of the present invention, the difference ΔT1 between the initial temperature and the cooling temperature is 10 10 , 10 5 , 1 0 3 , 100, 90, 80, 60, 57, 50, 40, 30 or lower than 20°C, preferably Preferably 10 3 or 100, more preferably 57°C or less.

[0575] In one embodiment of the present invention, the difference ΔT2 between the final temperature and the cooling temperature is 10 10 , 10 5 , 10 3 , 100, 90, 80, 60, 57, 50, 40, 30 or 20°C or less, and Preferably 10 3 or 100°C or less, more preferably 57°C or less.

[0576] In one embodiment of the present invention, the method is performed in order to perform multiple cycles and / or to avoid side effects. To avoid reaching ice-ball temperatures or too low temperatures that can cause ice melting, Small values ​​of T1 and / or ΔT2 are reached or desired.

[0577] In another embodiment of the present invention, the difference ΔT1 between the initial temperature and the cooling temperature or minimum temperature is 10 - 50 , 10 -10 , 10 -5 , 10 -1 , 1, 5, 10, 20, 30, 50, 70, 80 , greater than 100 or 1000°C, preferably greater than 1 or 5°C, more preferably or greater than 10°C.

[0578] In one embodiment of the present invention, the difference ΔT2 between the final temperature and the cooling or minimum temperature is 10 - 50 , 10 -10 , 10 -5 , 10 -1 , 1, 5, 10, 20, 30, 50, 70, 80 , greater than 100 or 1000°C, preferably greater than 1 or 5°C, Preferably greater than 10°C.

[0579] In some embodiments of the present invention, the number of cycles to be performed and / or the cure Ice bulb therapy can particularly enhance the medical, cosmetic, therapeutic or diagnostic activity of therapies. To reach temperatures below 0°C or 0°C, large values ​​of ΔT1 and / or ΔT2 are required. To be reached or desired.

[0580] In another embodiment of the present invention, the difference ΔT1 between the initial temperature and the cooling temperature or minimum temperature is 1 0 -50 and 10 50 , 10 -10 and 10 10 , 10 -5 and 10 5 , 10 -3 and 10 3 , 1 0 -2 and 10 2 , 10 -1 and 100, preferably between 1 and 70°C, more preferably Between 2 and 50°C

[0581] In one embodiment of the present invention, the difference ΔT1 is increased by increasing the nanoparticle concentration in the body part. and / or ΔT2. This is particularly useful for administering nanoparticles to body parts. 0 -50 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 10, 10 3 ,or 10 5 This means introducing nanoparticles at concentrations higher than mg / cm of body part. 3 Atata and medical or cosmetic or therapeutic or diagnostic activities of treatment must be at least 0.5 , 1, 1.1, 1.5, 2, 5, 10, 10 3 , or 10 5 ΔT1 and / or can be arrived at by using the value of ΔT2, and the Δ Smaller than the T1 and / or ΔT2 values.

[0582] The present invention also relates to a freezing system for use according to the present invention, wherein the method steps A top is characterized by at least one of the following properties: i) steps a), b), c), d) and / or e) of the method according to the invention comprise at least Tomo 1, 2, 3, 5, 10, 15, 20, 50, 10 2 , 10 3 , or 10 5 times or repeated, and ii) Step c) precedes step d).

[0583] In some other cases, at least one step a), b), c), d) or or e) are not repeated or 10 , 10 5 , 10 3 , 500, 100, 50 , repeated 20, 10, 5, 2, or 1 or less times.

[0584] In yet some other cases, at least one of steps a), b), c), d) ) or e) may be performed in any order or in the following order: Steps b), c), d), e) followed by step a); Steps a), c), d), e) followed by step b); Steps a), b), d), e) followed by step c); Steps a), b), c), e) followed by step d); Steps a), b), c), d) followed by step e).

[0585] The present invention also relates to a freezing system for use in accordance with the present invention, wherein a body part The cooling or minimum temperature of the body part is higher than that of the cooling probe alone without nanoparticles. If the minutes are cooled in a freezing system, at least 1.01, 1.1, 1.5, 2, 5, 1 Cooled to 0 or 100 degrees lower, This comparison is made possible by using the same operating conditions in both cases, especially the cooled tip. It will be held.

[0586] The invention also relates to a freezing system for use according to the invention, wherein the cooling time t1 and and the heating time t2 is characterized by at least one property selected from the group consisting of: It can be attached. i) t1 is at least 10 times longer than t2 3 , 100, 50, 20, 10, 5, 2, 1.5 or is 1.1 shorter i) t1 is 10 -9 , 10 -6 , 10 -3 , 10 -1 , 1, 5, 10 or 100 seconds long. ii) t2 is 10 -9 , 10 -6 , 10 -3 , 10 -1 , 1, 5, 10 or 100 seconds Long. iii) t2-t1 is 10 -9 , 10 -6 , 10 -3 , 10 -1 , 1, 5, 10 or 1 Longer than 00 seconds. iv) t1 is the same with or without nanoparticles. v) t2 is longer in the presence of nanoparticles than in their absence.

[0587] In some cases, t1 in the presence of nanoparticles is 3 10 per -20 , 1 0 -5 , 10 -3 , 10 -1 , 0, 1, 5, 10, or 10 3 mg of nanoparticles is t measured in the presence of t 11 It is also called.

[0588] In some other cases, t1 in the absence of nanoparticles is cm of the body 3 10 per20 , 10 10 , 10 5 , 100, 10, 5, 2, 1, 10 -3 or 10 -6 mg or less t measured in the presence of γ particles, and t 12 It is also called.

[0589] In some cases, t 11 / t 12 is 10 -3 From 10 3 , or 10 -2 From 10 2 ,Ma or 10 -1 Between and 10, t1 is similar with and without nanoparticles.

[0590] In some cases, t2 in the presence of nanoparticles is 3 0 per 10 -20 , 10 -5 , 10 -3 , 10 -1 , 0, 1, 5, 10, or more than 103 mg of nanoparticles t2 measured in the presence of the child, and t 21 It is also called.

[0591] In some other cases, t2 in the absence of nanoparticles is the cm of nanoparticles in the body part. 3 10 per 20 , 10 10 , 10 5 , 100, 10, 5, 2, 1, 0, 10 -3 or 10 -6 t2 measured in the presence of 0.05 mg or less, and t 22 It is also called.

[0592] In some cases, t 21 t 22 At least 0, 0.5, 1, 1.1, 1.2, 1 .5, 2, , 10, 102 , 10 3 , or 10 5 Long, or t 21 / t 22 1, 1 .1, 1.5, 2, 5, 10, or 10 3 Greater than.

[0593] The present invention also relates to a freezing system for use according to the invention, wherein t1 and t2 is characterized by at least one property selected from the group consisting of: i) t1 is 10 20 , 10 9 , 10 6 , 10 3 , 1, 0.1, 10 -2 or 10 -3 seconds Smaller than. ii) t2 is 10 20 , 10 9 , 10 6 , 10 3 , 1, 0.1, 10 -2 or 10 -3 Less than a second. iii) t2-t1 is 10 20 , 10 9 , 10 6 , 10 3 , 1, 0.1, 10 -2 or 10 -3 Less than a second.

[0594] In some cases, the cooling time t1 is the duration of the cooling step.

[0595] In some cases, the warming time t2 is the duration of the warming step.

[0596] In some cases, t0, t0', t1, t2, and / or t3 are 10 50 , 10 20 , 10 10 , 10 5 , 10 3 , 102 , 50, 20, 10, 5, 2, 1, or 10 -3 Less than a second.

[0597] In some other cases, t0, t0', t1, t2, and / or t3 are 10 -5 0 , 10 -10 , 10 -5 , 10 - , 10-1, 0, 1, 5, 10, 10 3 or 10 5 longer than a second.

[0598] In one aspect, the present invention also provides nanoparticles or freezing systems for use in accordance with the present invention. Also relates to. i) in particular in step d), cooling or maintaining or reaching a final or maximum temperature from a maintaining temperature The heating time for the nanoparticles to be absorbed increases with increasing nanoparticle concentration in the body part. and / or ii) In particular in step b), cooling or minimizing from the initial temperature or the holding temperature or the maximum temperature The cooling time to reach temperature is primarily independent of the nanoparticle concentration in the body part.

[0599] In another embodiment of the present invention, the temperature is increased from either the initial or cooling or maintaining or minimum temperature to the maximum. The time to reach the final or maximum temperature is determined by the nanoparticle concentration in the body part, especially if it is at least 0.0. 5, 1, 1.1, 2, 5, 10, 10 3 , or 10 5 Especially if it increases by at least 2 times Also 0, 0.5, 1, 1, 1.1, 2, 5, 10, 10 3 , or 10 5 double increase is increased.

[0600] In the example experiment, PC3-Luc was cultured in the presence (or absence) of 1 mg / mL N-CMD. Cool and warm the cells from RT (room temperature) to 10°C or 0°C. or from 0°C to RT, the duration of the warming step increases as follows: i) At a cooling temperature of 0°C, the results were as follows: 311 seconds without N-CMD to 1 mg / mL N-CMD Up to 461 seconds ii) At a cooling temperature of 10°C, NCs were obtained from 256 seconds without N-CMD to 1 mg / mL. Up to 393 seconds with MD. In some embodiments, the warm-up time of the cell with N-CMD The difference between the heating time of the cell with and without N-CMD is the increase in nanoparticle concentration and the decrease in cooling temperature. may decrease and / or increase as the final temperature increases.

[0601] In some embodiments, the warm-up time of the cell with N-CMD and the warm-up time of the cell without N-CMD are The difference between the heating time and the cooling time is the decrease in nanoparticle concentration, the increase in cooling temperature, and / or It can decrease if the final temperature is reduced.

[0602] In another embodiment of the present invention, the temperature is cooled or maintained or reached to a minimum temperature from an initial or maximum temperature. The cooling time to be achieved does not depend primarily on the nanoparticle concentration in the body part. In this embodiment, the nanoparticle concentration in the body part is preferably at least 0, 0.5, 1, 1.1, 1 .5, 2, 5, 10 or 10 3 fold increase, or preferably cm of body part 3 1 per 0 10 , 10 5 , 10 3 , 10, 5, 2 or 1 mg or less of nanoparticles to the body part c m 3 10 nanoparticles per -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 10, 1 If the amount of water increases to 0, 5, 20, or 500 mg or more, the cooling time is varied as follows: , 10, 5, 2, or 1% or less. This is a cooling step for cooling a body part. It may be the case that a temperature regulator or cooled probe is used during tapping.

[0603] In the example experiment, PC3-Luc was cultured in the presence (or absence) of 1 mg / mL N-CMD. Cool and warm the cells from RT (room temperature) to 10°C or 0°C. or from 0°C to RT, the duration of the cooling step is The difference between 25 seconds and 45 seconds is the temperature. This may be due to the conditions under which the regulator (URGO) is used.

[0604] In one aspect, the present invention relates to a nanoparticle or a freezing system for use according to the present invention, In step b), the temperature is cooled from the initial, maintained or maximum temperature to the cooling step. or a reduction in temperature to a minimum temperature by at least one of the following: i)10 -6 °C / sec to 10 6 °C / sec, preferably 10 -3 °C / sec to 10 3 °C Cooling rates in the range of / sec, ii) The cooling rate with nanoparticles differs from that without nanoparticles by less than 10°C / sec. There is a iii) varies with the concentration of nanoparticles, or 10 -6 °C / sec or less to 10 6 °C / sec, preferably 10 -3 °C / sec to 10 3 Cooling rate varies by a factor in the °C range degree, which means that the concentration of nanoparticles is preferably at least 1.1 times or3 From concentrations lower than 100 μg nanoparticles per cm of body part 3 100μg of na This is when the concentration increases to a level exceeding that of argon particles. iv)10 -6 seconds to 10 6 seconds, preferably 10 -3 seconds to 10 3 Cooling time in seconds, v) The rate at which the temperature is increased in the heating step d) is 10 times faster than -10 From 10 6 , preferably 10 -5 From 10 3 Small cooling rates with coefficients in the range of vi) The heating time of heating step d) is 10 times longer than that of heating step d). -6 From 10 6 , preferably 10 -3 from 10 3 Shorter cooling times by a factor in the range of

[0605] In one embodiment of the present invention, the temperature of a particular body part is cooled or maximized from an initial or maximum temperature. Cooling or cooling from the initial or maximum temperature to the holding temperature or from the holding temperature to the minimum temperature, especially within or during the cooling step, especially as the rate of temperature reduction or cooling The voltage is decreased or reduced at a specified rate.

[0606] In yet another embodiment of the present invention, the cooling rate is determined in particular by the cm 3 Around, especially Nano 10 per mg of particles -20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 1 0, 10 3 or 10 5 Greater than °C (degrees Celsius) per second or °C per minute.

[0607] In yet another embodiment of the present invention, the cooling rate is preferably 1 / cm of the body part. 3 Around, good Preferably 10 mg of nanoparticles 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10 , 5, 2, 1, 10 -1 , 10 -5 or 10 -10 °C / sec or °C / min do.

[0608] In yet another embodiment of the present invention, the cooling rate is preferably 1 / cm of the body part. 3 Around, good Preferably 10 mg of nanoparticles -100 ~10 100 , 10 -50 ~10 20 , 10 ‐1 ~10 5 , between 1 and 100 °C / sec or °C / min.

[0609] In the example experiment, PC3-Luc cells were cultured in the presence (or absence) of 1 mg / mL N-CMD. The mixture was cooled from RT (room temperature) to a cooling temperature of 10°C or 0°C, and then cooled to a temperature of 10°C or 0°C. When warming up from 0°C to RT, 0°C or 10°C cooling temperature, N-CM With or without D, the rate is relatively the same, between 0.6 and 1°C / sec. The difference between 1°C / sec and 1°C / sec may be due to the conditions of use of the temperature regulator (URGO). In some embodiments, the temperature regulator may allow the cooling temperature to be reached more quickly. , the cooling rate can be greater.

[0610] In some other embodiments, the temperature regulator cools or reaches the minimum temperature more slowly. When / if this is possible, the cooling rate may be lower.

[0611] In yet another embodiment of the present invention, the cooling rate is higher in the presence of ice balls than in the absence of ice balls. is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 10 times lower.

[0612] In yet another embodiment of the present invention, the cooling rate is higher in the presence of ice balls than in the absence of ice balls. is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 10 times higher.

[0613] In yet another embodiment of the present invention, the cooling rate is greater in the presence of nanoparticles than in the absence of nanoparticles. Especially when it is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 10 Twice as low.

[0614] In yet another embodiment of the present invention, the cooling rate is greater in the presence of nanoparticles than in the absence of nanoparticles. Especially when it is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 1 0 times larger.

[0615] In yet another embodiment of the present invention, the cooling rate is similar in the presence and absence of nanoparticles. do.

[0616] In yet another embodiment of the present invention, the cooling rate of the body part having nanoparticles is 10 times faster than the cooling rate of the body parts that do not contain 100 , 10 50 , 10 3 , 10, 10 -1 , 10 -3 °C / sec lower.

[0617] In yet another embodiment of the present invention, the cooling rate of the body part having nanoparticles is The cooling rate of the body part is 10 times faster than that of the ―100 , 10 ―50 , 10 ―3 , 10 -1 , 1, 10 or 10 3 °C / sec or more difference.

[0618] In yet another embodiment of the present invention, the cooling rate of a body part containing nanoparticles is determined by the concentration of the nanoparticles. Degrees at least 0, 0.5, 1, 1.1, 2, 5, 10 or 10 3 If it increases by a factor of two, or the concentration of nanoparticles in cm of a body part 3 10 nanoparticles per 3 , 10 2 , 10, 1 , 10 - 1, 10 -3 , 10 -6 or 10 -9 From concentrations below mg to cm of the body 3 Atata 10 nanoparticles -9 , 10 -6 , 10 -3 , 10 -1 , concentrations greater than 1 or 10 mg If it increases to 10 20 , 10 10 , 10 5 , 10, 5, 2, 1, 10 -3 or 10 -5 Changes at less than °C / sec.

[0619] In one embodiment of the present invention, the temperature of the body part is designated as a period of temperature reduction or cooling time. During the elapsed time specified, the temperature is increased from the initial, hold, or maximum temperature to the cooling or Specifically reduced or reduced to a minimum temperature.

[0620] In yet another embodiment of the present invention, the cooling time is 10 -100 , 10 -50 , 10 -10 , 10 -5, 10 -3 , 10 -1 , 1, 5, 10 or 10 2 longer than a second.

[0621] In yet another embodiment of the present invention, the cooling time is 10 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2, 1, 10 -1 or 10 -2 Less than a second.

[0622] In yet another embodiment of the present invention, the cooling time is 10 -100 ~10 100 , 10 -50 ~10 50 , 10 -10 ~10 10 , 10 -5 ~10 5 , 10 -3 ~10 3 or 10 - 3 ~10 seconds.

[0623] In one embodiment of the present invention, the temperature is adjusted during the warming step, in particular from the cooling or minimum temperature to the final or to the maximum temperature, or from the minimum temperature to the maintenance temperature, or from the maintenance temperature The temperature rise or heating rate is increased to the final or maximum temperature. To be or rise.

[0624] In one embodiment of the present invention, the cooling rate is preferably less than the warming rate by : i) at least 10 -50 , 10 -10 ,0,0.5,1,1.1,1.5,2,5,1 0, 10 3 or 10 5 by a factor of, or ii)10-50 , 10 -10 , 10 -5 , 10 -1 , 0, 0.5, 1, 1.1, 1.5 , 2, 5, 10, 10 3 , or 10 5 °C / sec or faster.

[0625] In one embodiment of the present invention, the cooling rate is preferably faster than the warming rate by: small: i)10 10 , 10 5 ,10,5,5,2,1,1.1,1,0.5,10 -3 or 1 0 -10 by a factor of: ii)10 50 , 10 10 , 10 5 ,10,5,2,1.1,1,0.5,0,10 -3 or 10 -5 °C / sec or less.

[0626] In one embodiment of the present invention, the cooling rate is less than the warming rate, in particular: i)10 -100 From 10 100 , 10 -10 From 10 10 , 10 -5 From 10 5 , 10 -3 From 10 3 , or 10 -1 by a factor between 0 and 10, or ii)10 -100 From 10 10 , 10 -10 From 10 10 , 10 -5 from 105 , 10 -3 et al. 10 3 , or 10 -1 at between 10 and 10 °C / sec.

[0627] In the example experiment, PC3-Luc cells in the presence (or absence) of 1 mg / mL N-CMD When cells are cooled from room temperature to 10°C or 0°C, When warming from 0°C to RT, the temperature rise rate or RTI is 0.05 to 0.08°C / sec, the temperature decrease rate or cooling rate RTD is between 0.6 and 1°C / sec. Therefore, the ratio RTD / RTI is between 7.5 and 20. Lower or higher values ​​of this ratio Values ​​may vary depending on other experimental conditions (different temperature regulators, nanoparticle types or concentrations, or different cells) It can also be obtained using the

[0628] In one embodiment of the present invention, the temperature is preferably maintained at or between the warming steps. The temperature rises from the minimum or maximum temperature within the time specified as the duration of the cup or the warm-up time. The temperature is raised or increased from the initial temperature to a final or maximum temperature.

[0629] In one embodiment of the present invention, the cooling time is preferably: i) at least 10 -50 , 10 -10 ,0,0.5,1,1.1,1.5,2,5,1 0, 10 3 , or 10 5 shorter than the heating time by a factor of . ii)10 -50 , 10-10, 10-5, 10-1, 0, 0.5, 11, 1.1, 1. 5, 2, 5, 10, 10 3 , or 10 5 More than a second.

[0630] In one embodiment of the present invention, the cooling time is shorter than the warming time, in particular by: i)10 10 , 10 5 ,10,5,2,1.1,1,0.5,0,10 -3 or 10- 10 by a factor of, or ii)10 50 , 10 10 , 10 6 ,10,5,2,1.1,1,0.7,0,10 -3 or 10 -5 Less than seconds.

[0631] In one embodiment of the present invention, the cooling time is shorter than the warming time, preferably by: stomach: i)10 100 , 10 -10 From 10 10 , 10 -5 From 10 5 , 10 -3 From 10 3 , or 10 -1 Between and 10, or ii)10 -100 From 10 100 , 10 -10 From 10 10 , 10 -5 From 10 5 , 1 0 -3 From 10 3 , or 10 -1 Between 10 and 10 seconds.

[0632] In the example experiment, PC3-Luc was cultured in the presence (or absence) of 1 mg / mL N-CMD. Cool the cells from RT (room temperature) to a cooling temperature of 10 °C or 0 °C, then When heating from C to RT, the temperature rise time t TI Temperature drop from 256 seconds to 469 seconds Time t TD is between 12 and 46 seconds. Therefore, the ratio t TI / t TD is 6 to 39 It is between.

[0633] In some embodiments, the temperature regulator or cooling probe cools the body part at a slower rate. and / or when the heating step is performed and / or the temperature during the heating process. In the presence of larger amounts of nanoparticles, radiation, or media than would allow for increased rates of rise When this is done, the ratio t TI / t TD and / or R TD / R TI to a smaller value of Reach.

[0634] In some embodiments, the temperature regulator or cooling probe cools the body part at a faster rate. and / or the heating step is performed in a manner that minimizes the presence of nanoparticles, radiation, or vehicles. The rate of temperature rise in the heating step can be reduced when the ratio t TI / t TD and / or reaching larger values ​​of RTD / RTI.

[0635] In yet another embodiment of the present invention, the cooling time is longer in the presence of ice balls than in the absence of ice balls. is at least 0, 0.5, 1.001, 1.1, 1.5, 2, 5, or 10 times shorter .

[0636] In yet another embodiment of the present invention, the cooling time is longer in the presence of ice balls than in the absence of ice balls. is at least 0, 0.5, 1.001, 1.1, 1.5, 2, 5, or 10 times longer .

[0637] In one aspect, the present invention relates to nanoparticles or freezing systems for use in accordance with the present invention. wherein the maintaining step is performed according to at least one of the following: i) preferably at least 1.5 times longer than the cooling time and / or warming time, more preferably at least 1.5 times longer than the cooling time and / or warming time is at least a factor of 10 shorter, and ii) a coefficient of preferably at least 1.5 higher than DT1 and / or DT2 according to the invention c) Keep the temperature fluctuations during the step small in number.

[0638] In one embodiment of the present invention, the body part containing the nanoparticles is cooled to a temperature of preferably 10 50 , 10 20 , 10 3 , 10 2 , 10, 5, 2, 1, 10 -1 Seconds or 10 -3 longer than a second The step that is maintained for a period of time is designated as the maintain step.

[0639] In one embodiment of the present invention, the temperature is maintained at or above the temperature of the maintenance step, particularly during or during the maintenance step. Maintained at a maintenance or cooling temperature for a period of time specified as the time or hold time. .

[0640] In one embodiment of the present invention, the maintenance time is 10 20 , 10 10 , 10 5 , 10 3 , 10, 5 , 2, 1, 0, 10 -1 , 10 -3 or 10 -6 Less than a second.

[0641] In another embodiment of the present invention, the maintenance time is 10 -50 , 10 -20 , 10 -6 , 10 -3 , 10 -1 , 0, 1, 2, 5, 10, 10 3 , 10 5 or 10 10 longer than a second.

[0642] In yet another embodiment of the present invention, the maintenance time is 10 -50 From 1050 , 10 -10 mosquito et al. 10 10 , 10 -5 From 10 5 , 10 -3 From 10 3 , or 10 -1 From 10 3 Between is seconds.

[0643] In the experimental example, the duration of the maintenance step was less than 1 second for short cycles and less than 1 second for long cycles. In the case of the model, the time is longer than 1 second. By starting the heating step earlier after the cooling step, This shortens the maintenance time. A temperature regulator and a cooling probe that can maintain the cooling temperature for a long time are used. This allows the retention time to be extended.

[0644] In yet another embodiment of the present invention, the maintenance time is longer than the cooling time and / or the warming time. At least 0, 1, 1.001, 1.1, 2, 3, 5, 10, 15, 20, 50, 10 2 , 10 3 , 10 5 or 10 10 In some cases, the temperature may be at the lowest or coolest temperature. temperature for a long period of time, especially when an instrument or cold probe is used to maximize the temperature of a body part for a long period of time. When maintaining at a lower temperature, the duration of the maintenance step may be longer.

[0645] In yet another embodiment of the present invention, the temperature is maintained at a cooling temperature for a specific period of time, preferably Preferably, there is an improvement in efficacy and / or reduction in side effects due to the presence of nanoparticles. It may be useful to mimic the usual cryotherapy treatments.

[0646] In yet another embodiment of the present invention, the duration of the maintaining step is determined by the duration of the cooling step and and / or the duration of the heating step should be at least 0, 1, 1.001, 1.1, 2, 3, 5, 10, 15, 20, 50, 10 2 , 10 3 , 10 5 or 10 10 It's just shorter. In some embodiments, the temperature is not maintained at the minimum temperature or at the maintenance or cooling temperature for an extended period of time. If the device or cooling probe has not been used to maintain a minimum temperature for an extended period of time, Therefore, the duration of the maintenance step can be short. This method creates a significant number of cycles. This can be used when necessary, and is more efficient than maintaining the temperature by cooling or This method does not require temperature measurement during treatment and is efficient for cooling and / or warming. It is also easy to implement, since all you need to know is the time or duration of the step.

[0647] In yet another embodiment of the present invention, the maintaining step comprises maintaining the temperature of the body part during or between The temperature is maintained at a cooling or maintaining temperature, wherein the cooling or maintaining temperature is, in particular, is the temperature the body part reaches during the maintenance step.

[0648] In some other embodiments, temperature fluctuations within or during the maintenance step are particularly Specifically designated as a step temperature fluctuation maintained at (T cool -T min ) / T min , ( T BP -T min ) / T min , T BP / T min , T cool / T min , (T M -T min ) / T min or T M / T minIt is estimated as the absolute value of T BP , T cool , T M and T min especially for body parts that are reached during or during the maintenance step. The minute temperature, cooling temperature, hold temperature, and minimum temperature.

[0649] In yet some other embodiments, the variation in the maintained temperature is 10 100 , 10 50 , 10 1 0 , 10 5 , 10 3 , 10 2 , 50, 10, 5, 2, 1, 0.5, 0, 10 -1 , 10 ― 3 , 10 -5 , or 10 -10 % or less.

[0650] In still other embodiments, the variation in the maintenance temperature is 10 -100 , 10 -50 , 1 0 -10 , 10 -5 , 10 -3 , 10 -1 , 0, 1, 5, 10, 10 3 or 10 5 %Yo It's bigger.

[0651] In yet some other embodiments, the variation in the maintained temperature is 10 -20 %~10 20 %, 1 0 -5 % and 10 5 %, 10 -3 %~10 3 %, or 10 -1 Within %~10% be.

[0652] In some other embodiments, the variation in the maintained temperature is small or the cooling step and / or The temperature gradient DT1 and / or DT2 of the heating step should be at least 0, 0.1, 0 .5, 1, 1.1, 1.5, 2, 5, 10, 10 2 , 10 3 or 10 5 Small by a factor of .

[0653] In the experimental example, the temperature fluctuations in the holding step are typically 0°C to 1°C, and the cooling and / or The temperature fluctuation during the heating step is usually 15 to 65°C.

[0654] In one aspect, the present invention relates to a nanoparticle or a freezing system for use according to the present invention, In particular in step d) or in the warming step, the temperature is increased from the cooling temperature to the final temperature or From the cooling temperature to the holding temperature or from the holding temperature to the final temperature, at least one of the following must be performed: Therefore, it rises: i)10 -6 °C / sec to 10 6 °C / sec range, preferably 10 -3 °C / sec to 10 3 Heating rates in the °C / sec range, ii) The heating rate is different from or 10 times that of the case without nanoparticles. -3 by a factor of over °C heating rate, including large nanoparticles; iii) Cooling rate is 10 -10 ~10 5 , preferably 10 -5 ~10 3 Coefficients in the range heating rate is smaller by iv)10 -6 seconds to 10 6 seconds, preferably 10 -3 seconds to 10 3 Heating time in seconds and v)10 -6 From 10 6 coefficient in the range of 10 -3From 10 3 Cooling coefficient in the range Heating time longer than cooling time.

[0655] In one embodiment of the present invention, the temperature of the body part in particular is preferably controlled within the warming step or Between, from the cooling or minimum temperature to the final or maximum temperature, or from the cooling or minimum temperature The rate of temperature increase or heating to the holding temperature or from the holding temperature to the final or maximum temperature To be raised or rise at a speed specified as

[0656] In yet another embodiment of the invention, the heating rate is determined in particular by the cm 3 Around, especially Nano 10 per mg of particles -20 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 1 0, 10 3 or 10 5 Greater than °C (Celsius) / second or °C / minute.

[0657] In yet another embodiment of the present invention, the heating rate is preferably 1 / cm of the body part. 3 Around, good Preferably 10 mg of nanoparticles 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10 , 5, 2, 1, 10 -1 , 10 -5 or 10 -10 °C / sec or °C / min or less .

[0658] In yet another embodiment of the present invention, the heating rate is determined in particular by the cm 3 Around, especially Nano 10 per mg of particles ―100 ~10 100 , 10 ―50 ~1020 , 10 ―3 ~10 3 , 10 ~1 ~10 5 , or 1 to 100 °C / sec or °C / min.

[0659] In yet another embodiment of the present invention, the warming rate is greater in the presence of ice balls than in the absence of ice balls. The combination is at least 1.001, 1.1, 1.5, 2, 5 or 10 times lower.

[0660] In yet another embodiment of the present invention, the warming rate is greater in the presence of ice balls than in the absence of ice balls. The conjunction is at least 1.001, 1.1, 1.5, 2, 5, or 10 times larger.

[0661] In yet another embodiment of the present invention, the heating rate is increased in the presence of nanoparticles compared to when they are absent. Especially when it is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or In some cases, the presence of nanoparticles in body parts can lead to When a child captures or absorbs heat from a body part without specifically releasing it, or when nanoparticles When acting as an isolating material, it may slow down the rate at which the temperature rises during the warming step. be.

[0662] In yet another embodiment of the present invention, the heating rate is increased in the presence of nanoparticles compared to when they are absent. Especially when it is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 1 In some cases, the presence of nanoparticles in body parts can increase the Heat may be released during the warming step to increase the rate at which the temperature increases during the warming step.

[0663] In yet another embodiment of the present invention, the heating rates in the presence and absence of nanoparticles are similar. is.

[0664] In yet another embodiment of the present invention, the rate of temperature increase in a body part having nanoparticles is The rate at which the temperature of the particle-free body part rises from the cooling temperature to the final temperature is calculated as 10 100 , 1 0 50 , 10 3 , 10 -2 , 10 -1 , or 10 -3 °C / min.

[0665] In yet another embodiment of the present invention, the rate of temperature increase in a body part containing nanoparticles is The rate at which the temperature of the unborn body part rises from the cooling temperature to the final temperature is calculated by 10 -100 , 1 0 -50 , 10 -3 , 10 -1 , 1, 10, or 10 3 °C / sec or more difference.

[0666] In yet another embodiment of the present invention, the rate of temperature increase in a body part containing nanoparticles is determined by the nanoparticle concentration. Degrees at least 0, 0.5, 1, 1.1, 2, 5, 10 or 10 3 If it increases by a factor of two, or nanoparticle concentration cm of body part 3 10 per 3 , 10 2 , 10, 1, 10 -1 , 1 0 -3 , 10 -6 , or 10 -9 From concentrations below mg to cm of body part 3 10 per - 9 , 10 -6 , 10 -3 , 10 -1 , increasing to concentrations greater than 1 or 10 mg nanoparticles If you do, 10 20 , 10 10 , 10 5, 10, 5, 2, 1, 10 -3 or 10 -5 ° C / sec.

[0667] In one embodiment of the present invention, the temperature of the body part is measured from a cooling or minimum temperature to a final or maximum temperature. or from the cooling or minimum temperature to the holding temperature, or from the holding temperature to the final or maximum The heating step is performed within a specified time period, either as the duration of the temperature rise or as the heating time. To be raised or elevated in or among steps.

[0668] In yet another embodiment of the present invention, the heating time is 10 -100 , 10 -50 , 10 -10 , 10 -5 , 10 -3 , 10 -1 , 1, 5, 10 or 10 2 longer than a second.

[0669] In yet another embodiment of the present invention, the heating time is 10 100 , 10 50 , 10 10 , 10 5 , 10 3 , 10, 5, 2, 1, 10 -1 or 10 -2 Less than a second.

[0670] In yet another embodiment of the present invention, the heating time is 10 -100 ~10 100 , 10 -50 ~10 50 , 10 -10 ~10 10 , 10 -5 ~10 5 , 10 -3 ~10 3 or 10 - 3 ~10 seconds.

[0671] Experimentally, various processing parameters (initial, cooling, final temperature, and temperature drop and temperature The duration and rate of increase were measured using PC3-Luc cells alone or 1 mg of nanoparticles (N-MC D) PC3-Luc cells mixed with HCl were cooled during the cooling step and were cooled during the warming step. Warmed. Cooling temperature is just above 0°C (>0°C) or just below 0°C (<0°C) The rate of temperature increase is usually smaller in the presence of nanoparticles than in their absence. Therefore, the presence of nanoparticles allows: i) the heating stage and / or ii) increasing the temperature rise rate during the warming step. To make someone do something.

[0672] In one embodiment, nanoparticles can be heated by laser, sound waves, magnetic fields, especially alternating magnetic fields, etc. In the absence of radiation, the temperature rise rate during the warming step is significantly slower than in the absence of nanoparticles. In the presence of at least 0, 0.5, 1, 1.5, 2, 5, 10, 10 3 ,or 10 5 It is small by a factor of .

[0673] In one embodiment, nanoparticles can be heated by laser, sound waves, magnetic fields, especially alternating magnetic fields, etc. In the presence of radiation application, the temperature increase rate of the warming step is larger, and the nanoparticles are present. Especially when present than when absent, at least 0, 0.5, 1, 1.5, 2, 5, 10, 10 3 , or 10 5 It is large by a coefficient of .

[0674] In one embodiment of the present invention, the heating rate is smaller than the cooling rate, in particular: i) at least 10 -50 , 10-10 ,0,0.5,1,1.1,1.5,2,5,1 0, 10 3 or 10 5 by a factor of, or ii)10 -50 , 10 -10 ,0,0.5,1,1.1,1.5,2,5,10,10 3 or 10 5 °C / sec or faster. This is because no radiation is applied during the heating step or During the cooling step, the material or device or the cooling probe adjusts the temperature during this step. This can occur when the device is used for

[0675] In one embodiment of the present invention, the heating rate is smaller than the cooling rate, in particular: i)10 10 , 10 5 ,10,5,2,1,1.1,1,0.5,0,10 -3 or 1 0 -10 by a factor of, or ii)10 50 , 10 10 , 10 5 ,10,5,2,1.1,1,0.5,0,10 -3 or 10 -5 °C / sec or less. This is because radiation is applied during the warming step and / or Or substances or equipment are used during the cooling step to regulate the temperature during this step. This can occur if the probe is not properly installed or if a cooled tip is not used.

[0676] In one embodiment of the present invention, the heating rate is smaller than the cooling rate, in particular: i)10 -100 and 10 100 Between 10 -10 and 10 10 Between 10 -5 and 10 5 Between , 10 -3 and 103 Between . or 10 -1 by a factor between 10 and 10, or ii)10 -100 From 10 100 , 10 -10 From 10 10 , 10 -5 From 10 5 , 1 0 -3 From 10 3 , or 10 -1 between 10 and 10 °C / sec.

[0677] In one embodiment of the present invention, the warming time is longer than the cooling time, in particular: i) at least 10 ―50 , 10 ―10 ,0,0.5,1,1.1,1.5,2,5,1 0, 10 3 , or 10 5 by a factor of . or ii)10 -50 , 10 -10 , 10 -5 , 10 -1 , 0, 0.5, 1, 1.1, 1.5 , 2, 5, 10, 10 3 or 10 5 More than a second.

[0678] In one embodiment of the present invention, the heating time is longer than the cooling time, in particular: i) 10 10 , 10 5 ,10,5,2,1.1,1,0.5,0,10 -3 or 10 -10 by a factor of, or ii)10 50 , 10 10 , 10 5 ,10,5,2,1.1,1,0.5,0,10 -3 or 10 -5 In less than a second.

[0679] In one embodiment of the present invention, the heating time is longer than the cooling time, in particular: i) 10 -100 and 10 100 Between 10 -10 and 10 10 Between 10 -5 and 10 5 of Between, 10 -3 and 10 3 Between or 10 -1 Between and 10, or ii)10 -100 From 10 100 , 10 -10 From 10 10 , 10 -5 From 10 5 , 1 0- 3 From 10 3 , or 10 -1 10 seconds from now.

[0680] In yet another embodiment of the present invention, the warming time is longer in the presence of ice balls than in the absence of ice balls. The match is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 10 And it's short.

[0681] In yet another embodiment of the present invention, the warming time is longer in the presence of ice balls than in the absence of ice balls. The match is at least 0, 1, 1.001, 1.1, 1.5, 2, 5, or 10 And it's long.

[0682] In one aspect, the present invention relates to a nanoparticle or a freezing system for use according to the present invention, comprising: wherein the temperature is specifically controlled or adjusted during the cooling step b) and / or the maintaining step c). In this case, the temperature is not specifically controlled or adjusted during the heating step d), preferably , temperature control or regulation, especially using equipment or substances or temperature regulators or cooling probes is executed.

[0683] In some embodiments, adjusting the temperature or temperature fluctuations or temperature gradients Any device or substance or cooling probe used for the treatment, especially before or in the absence of treatment, Especially designated as a thermoregulator or cooling probe, for use in a living body, body part, or its environment In some cases, it is not part of the blood, the surrounding air, tissues, organs, body parts, or cells. different.

[0684] In some embodiments, the temperature regulator or cooling probe is connected to a cryotherapy unit or cryotherapy device. surgical unit, more specifically gynecology or oncology or medical or dermatology or neurosurgery This is equipment used during cryosurgery in the unit.

[0685] In some embodiments, the temperature regulator or the cooling probe or a portion of the cooling probe is: i) a freezing liquid, ii) cooling gas, iii) NO2 gas, iv) nitrous oxide gas, v) liquid nitrogen, and and vi) dimethyl ether gas.

[0686] In some embodiments, the temperature regulator or cooling probe is a liquid, gas, or solid. .

[0687] In some embodiments, the temperature regulator or cooling probe is a metal rod, preferably a metal A rod or piece of metal that is specifically connected to a unit that controls the heat of the rod or metal .

[0688] In some embodiments, the temperature regulator or cooling probe is irradiated with radiation, preferably electromagnetic radiation, light or laser radiation, magnetic fields, in particular alternating magnetic fields, sound waves, in particular ultrasound or radio frequency waves, It is a device that produces or generates radiation that generates heat, such as

[0689] In some embodiments, the temperature regulator or cooled probe is a device that generates or produces radiation. isn't it.

[0690] In some embodiments of the present invention, the temperature regulator or cooling probe maintains a temperature such that R: i) In some embodiments, 10 10 , 10 5 , 10 3 , 10 2 , 10, 10, 5, 2 , 1, 0, -10, -20, -50, -100, -150 or -200°C, ii) In some other embodiments of the above, −200, −150, −100, −50, − 20, -10, 0, 2, 5, 10, 20, 50, 10 2 or 10 3 °C, iii) In still other embodiments, -200 to 10 3 , -100 to 10 3 ,- 50 to 100, or -10 to 100°C (Celsius). The temperature is preferably controlled by a temperature regulator or a cooling probe during at least one step of the method. In some other embodiments, the temperature is the temperature of the body part that is in thermal equilibrium. The temperature of the thermostat or cooling probe before contact or spreading heat towards the body part. degrees.

[0691] In one embodiment of the present invention, a temperature regulator or cooling probe is not used during at least one step of the method. If needles are used, initial, cooling, and / or final temperatures of the procedure are reached. If a temperature regulator or cooling probe is not used during at least one step of the process, The initial, cooling, and / or final temperatures are not reached.

[0692] In one embodiment of the present invention, the temperature regulator or cooling probe does not include a body part, and preferably Preferably, the nanoparticles are introduced into the body without changing the temperature of the rest of the organism. regulates the temperature of the body part containing the body part. The temperature of the rest of the organism not containing the body part is 10 -5 0 , 10 -10 , 10 -3 , 10 -1 , 1, 5, 10, or 10 3 Changes of more than °C It will never happen.

[0693] In one embodiment of the present invention, the method comprises determining the temperature or generation of ROS or NOS or nanoparticles. an instrument or substance, specifically called a sensor, that measures the release of at least one compound from or using or including a cooled probe.

[0694] In some embodiments, the sensor may be a thermometer, a thermocouple, or an infrared camera. In some other embodiments, the sensor may be a fluorescent probe. The temperature or amount of ROS or NOS generated by nanoparticles can be adjusted, and in particular to effectively regulate the release of at least one of the compounds in a particularly desirable or targeted manner. The most effective treatment and / or the least side effects and / or the best benefit-to-risk ratio of the treatment. It can be used to adjust or control the value.

[0695] In one embodiment of the present invention, the method comprises imaging nanoparticles within a body part and / or uses or includes a device or substance or a cooled probe to image a body part. The device or material or cooling probe is also called an imaging device, and is used for MRI (Magnetic Resonance Imaging), scanning, Scanner, CT scanner, PET (positron emission tomography), biopsy, fluorescence, luminescence, absorption, tissue Histology, Microscopy, Transmission or Scanning Electron Microscopy, X-rays, Electrons, Neutrons, Particles, Elemental Particles , light diffusion or diffraction or scattering.

[0696] In one aspect, the present invention also relates to a method or a freezing system according to the present invention, in which the temperature control Cooling, holding, and warming steps without the use of a valve or cooling probe During at least one of the temperature is controlled.

[0697] In one embodiment of the present invention, for example, when a living organism enters a hypothermic state that reduces the temperature of a body part. In this case, the cooling step is performed without the use of a temperature regulator or cooling probe to reduce the body temperature. .

[0698] In one embodiment of the present invention, for example, the body part is in contact with air or blood circulation. Therefore, they are left to heat up and use thermostats and cooling probes that do not belong to living organisms or body parts. Warming without the use of thermoregulators or cold probes to warm body parts when not necessary The step is performed.

[0699] In one aspect, the present invention relates to nanoparticles or freezing systems for use in accordance with the present invention. and at least one of the cooling step, the maintaining step, and the warming step is in the presence of: It is held at. i) Percentage of nanoparticles internalized into cells in a part of the body (10 -10 From 90%, from 10-3 90%, or 10 -10 to 50%, or 10 -5 20% from this point. -Percentages are specifically related to the number or amount of nanoparticles internalized by cells in a body part and the number or amount of nanoparticles internalized by cells in a body part. The ratio is the ratio between the total number or amount of nanoparticles contained in and / or ii) The concentration of nanoparticles in the body part is determined by the cm 3 10 per -9 , 10 -5 , 10 -3 , 1 or 5 mg of nanoparticles to cm of body part 3 10 per -3 , 10 -1 ,1, 5, 10, 10 3 , 10 6 , or 10 9 nanoparticles ranging from mg nanoparticles, or 10 per cell specifically contained in or arising from a body part -10 , 10 -5 , 1 0 -3 , 10 -1 , 1 or 10 to 1, 10, 10 3 , 10 6 , or 10 10 pg Nanoparticles in.

[0700] In another embodiment of the present invention, the cooling zone is a volume, surface, or length that is cooled to a cooling temperature. That is true.

[0701] In some embodiments, the nanoparticle region is at least 0, 1, 1.01 times colder than the cooling region. , 1.1, 1.2, 1.5, 2, 5, 10, 10 3 or 10 5 Possibility of being smaller by a factor of There is.

[0702] In some other embodiments, the nanoparticle region is at least 0, 1, 1. 01, 1.1, 1.2, 1.5, 2, 5, 10, 10 3 , or 10 5 twice as likely be.

[0703] In another embodiment of the invention, at least one step of the method comprises administering to cells of the body part endogenously This was done in the presence of a certain percentage of nanoparticles that were oxidized, which was -50 , 10 -20 , 10 -10 , 10 -5 , 10 -1 , 0, 1, 5, 10, 50, 75, 80, 90 , or greater than 99%.

[0704] In another embodiment of the present invention, at least one step of the method comprises: 70, 50, 20, 10, 5, 2, 1, 10 -1 , 10 -5 , or 10 -10 %below The method is carried out in the presence of nanoparticles internalized by cells of the body part in a proportion.

[0705] In another embodiment of the invention, at least one step of the method comprises intracellularly injecting the cells of the body part. The results were obtained in the presence of localized nanoparticles, the percentage of which was 10 -50 from 100%, 10 -10 From 99% to 10 -5 From 95%, 10 -3 to 90%, or 10 -1 from It is 70%.

[0706] In Experiment No. 2, the percentage of N-CMD internalized into PC3-Luc cells was PC3-Luc cells cultured in the presence of N-CMD at various concentrations of NC MD (0, 62, 250, 1000 μg / mL N-CMD), and various cultures Measured over time (5 min, 30 min, 3 hr, 6 hr, 24 hr, 96 hr), where The percentage of internalized N-CMD is the amount of nanoparticles or N-CMD inside the cells. and the amount of nanoparticles or N-CMD cultured in PC3-Luc cells or body parts. The proportion of internalized N-CMD varies from 6% to 26% (Fig. 1(b) This ratio increased with increasing N-CMD concentration and incubation time (Fig. 1(b) In some embodiments, this percentage varies depending on the concentration of nanoparticles or the incubation time. , preferably at least 0, 0.5, 1, 1.5, 2, 5, 10, or 10 3 Coefficient of by increasing the concentration of α-glucan, or by using different cell types, and / or by radiation. Preferably, by performing internalization in the presence of at least 0, 0.5, 1, 1.5, 2, 5, 10 or 10 3 Larger values ​​are obtained by a factor of . This percentage is determined by adjusting the nanoparticle concentration or incubation time, preferably at least 0. 0.5, 1, 1.5, 2, 5, 10, or 10 3 By reducing it by a factor of , or By using a cell type having a cell number of preferably at least 0, 0.5, 1, 1.5, 2, 5, 10, or 10 3 Lower values ​​can be obtained by a factor of .

[0707] In one aspect, the present invention relates to a nanoparticle or a freezing system for use according to the present invention, There, the nanoparticles occupy a portion of the body part, which is smaller than the maximum volume of the body part. or the whole body part, or 10% of the whole body part by mass or volume -1 0 , 10 -5 , 10 -1 % to 1, 10, 50, 70% or 90% Then, at least one of a cooling step, a maintaining step, and a warming step is performed.

[0708] In some cases, the entire body part or its largest volume is the portion of the body part that contains the nanoparticles. (also called part of the body part) and part of the body part that does not contain nanoparticles (other than the body part). (also called part of the

[0709] In one embodiment of the present invention, the cooling step, maintaining step, and / or warming step are , 99.9, 90, 80, 70, 60, 50, 30, 2 in mass or volume of the whole body part performed on nanoparticles that occupy less than 0, 10, 5, 2 or 1% of the body mass can be.

[0710] In one embodiment of the present invention, the cooling step, maintaining step, and / or warming step are , 10 in mass or volume of the entire body part -10 , 10 -5 , 1, 2 5, 10, 20, Occupying a body part that is greater than 30, 50, 60, 70, 80, 90, or 99% is performed on nanoparticles.

[0711] In one embodiment of the present invention, the cooling step, maintaining step, and / or warming step are , 99.9, 90, 80, 70, 60, 50, 30, 20 in mass or volume of whole body parts , performed on nanoparticles that occupy less than 10, 5, 2, or 1% of the body mass. do.

[0712] In one embodiment of the present invention, the cooling step, maintaining step, and / or warming step are , 10 in mass or volume of the whole body part -10 , 10 -5 , 1, 2, 5, 10, 20, 3 occupying a portion of the body greater than 0, 50, 60, 70, 80, 90, or 99% This is performed on particles.

[0713] In another embodiment of the present invention, the cooling zone is a volume, surface, or length that is cooled to a minimum temperature. That is true.

[0714] In some cases, the nanoparticle region is at least 0, 1, 1.01, 1.1 , 1.2, 1.5, 2, 5, 10, 10 3 , or 10 5 It is possible that the coefficient is small.

[0715] In some other cases, the nanoparticle region is at least 0, 1, 1.0 times larger than the cooling region. 1, 1.1, 1.2, 1.5, 2, 5, 10, 10 3 , or 10 5 It is likely twice as large do.

[0716] The present invention also relates to a freezing system for use according to the invention, wherein the nanoparticles are Body parts |T BPWNP (xt)-T BPWNP (xt)| It has the ability to maintain -5 , 10-2, 0.1, 0.5, 1, 5, or 10 °C higher, where: i)T BPWNP (xt) is the cooling temperature of the body part containing the nanoparticles. ii) T BPWONP (xt) is the cooling temperature of the body part without nanoparticles. iii) T BPWNP (xt) and T BPWONP (xt) is the temperature at which the body part is cooled by the cooling probe. The temperature is cooled to Tx and then measured after a certain time xt. iv)|T BPWNP (xt)-TBPWNP (xt)| is the temperature at which nanoparticles cool a body part. This allows us to estimate the ability to maintain the BPWNP (xt)-T BPWNP (xt) The ability of the freezing system to maintain the body part at a cooling temperature increases. It will get better.

[0717] The present invention also relates to a freezing system for use in accordance with the present invention, wherein Δt is 0 -3 , 10 -2 , 1, 5, 10, 20, 50, 10 2 , 10 3 or 10 5 Greater than seconds Hey.

[0718] The present invention also relates to a freezing system for use according to the invention, wherein xt is 10 1 0 , 10 5 , 10 3 , 10 2 , 5, 5, 1, 10 -2 , 10 -3 or 10 -5 More than seconds small.

[0719] The invention also relates to a freezing system for use in accordance with the invention, in particular designated Tx. The cooling temperatures available are -273°C, -250°C, -200°C, -100°C, and 50°C. , -40°C, -20°C, -10°C, -5°C, -3°C, -2°C, -1°C, 0 .2°C, 5°C, 10°C, 20°C, 30°C, 0K, 1K, 2K, 5K, 10 K, 50K, 70, 100K, 200K, 250K, 273K, 300K, 350K Or greater than 400K.

[0720] In some cases, the cooling temperature Tx is 10 5 °C, 10 3 °C, 200°C, 100°C, 5 0°C, 40°C, 20°C, 10°C, 0°C, -5°C, -10°C, -15°C, -20°C, -30°C, -40°C, -50°C, -100°C, -200°C, 10 00K, 500K, 200K, 100K, 50K, 40K, 20K, 10K, 5K, 3K , 2K, 1K or 0.1K or less.

[0721] The present invention also relates to a freezing system for use in accordance with the present invention, wherein the nanoparticles , |T BPWNP (t2)-T BPWONP Defined as (t1)| / (t2-t1) It has the ability to slow down the heating or warming up of the body part, which can be as fast as 10 times per minute. -5 , 1 0 -3 , greater than 0.5 or 5°C, where: i)T BPWNP (t1) is the cooling temperature of the body part containing the nanoparticles, The cooling temperature T x After the temperature is cooled to 1000 K, the temperature is measured at a specific time t1. ii) T BPWNP (t2) is the cooling temperature of the body part containing the nanoparticles, and The cooled probe cools to a temperature T x After the temperature is cooled to 1000 K, the temperature is measured at a specific time t2. iii) t2 is different from t1; and iv)|T BPWNP (t2)-T BPWONP (t1)| / (t2-t1) is the body part Slow down the heating or warm-up time by |T BPWNP (t2)-T BPW ONP The larger the value of (t1)| / (t2-t1), the better the estimation of the capacity of the freezing system. The greater the freezing system's ability to slow down the heating or warming up of a body part, the greater the are.

[0722] The present invention also relates to a freezing system for use according to the invention, wherein the nanoparticles are Has the ability to slow down the heating or warming up of a body part defined as: [|T BPWONP (t2)-T BPWONP (t1)| / (t2-t1)]-[|T BPWN P (t2)-T BPWNP (t1)| / (t2-t1)], which is 10 per minute -5 , 10 -3 , 10 -1 0.5 1 or greater than 10°C, where i)T BPWNP (t1) is the cooling temperature of the body part containing the nanoparticles, The cooling temperature T x After the temperature is cooled to 1000 K, the temperature is measured at a specific time t1. ii) T BPWNP (t2) is the cooling temperature of the body part containing the nanoparticles, and The cooled probe cools to a temperature T x After the temperature is cooled to 1000 K, the temperature is measured at a specific time t2. iii) T BPWONP (t1) is the cooling temperature of the body part that does not contain nanoparticles, The body part is cooled to temperature T x After the temperature is cooled to 1000 K, the temperature is measured at a specific time t1. iv) T BPWONP (t2) is the cooling temperature of the body part that does not contain nanoparticles, The part is cooled to temperature T x After the temperature is cooled to 1000 K, the temperature is measured at a specific time t2. v) t2 is different from t1; and vi)[|T BPWONP (t2)-T BPWONP(t1)| / (t2-t1)]-[ |T BPWNP (t2)-T BPWNP (t1)| / (t2-t1)] is the time course of the body part. The ability of a freezing system to slow down heat or heating can be estimated, i.e., [|T BPWONP (t2)-T BPWONP (t1)| / (t2-t1)]-[|T BPWNP (t2)- T BPWNP (t1)| / (t2-t1)], the larger the value, the more the body part of the freezing system The ability to heat or slow down the heating of the food is also greater.

[0723] The present invention relates to a freezing system for use according to the invention, wherein the freezing system comprises Cooling volumes greater than either half of the entire body or the cooling volume without nanoparticles The cooling temperature T achieved by the freezing system x Cool until simmering.

[0724] The present invention relates to a refrigeration system for use according to the invention, in which the cooling temperature T x teeth Higher than: i)-200, -100, -70, -40, -20, -10, -5, -2, -1, 0, 2 , 5, 10 or 20°C, or ii) Cooling temperature reached without nanoparticles.

[0725] The present invention also relates to a freezing system for use in accordance with the present invention, in which the concentration of nanoparticles is Cools body parts at a temperature-independent rate.

[0726] The present invention also relates to a refrigeration system for use in accordance with the present invention, the refrigeration system comprising: The particles heat the body part at a rate that decrea...

Claims

1. 1. A freezing system for treating a body part of an individual, comprising: α) a first part which is a cooled probe, 1) the cooling probe is in communication with a cooling source and has a volume that is at least 10% of the maximum volume of the body part; It has a penetration part smaller than one or at least one dimension of 1 cm or less, and Suitable for cooling effect or 2) The cooling probe has a non-penetrating portion that communicates with a cooling source and is suitable for external cooling. 、 and β) a second portion, 1) An assembly of at least two nanoparticles, the assembly being capable of binding together or binding to one another. The nanoparticles may include at least two nanoparticles bound to each other via a tether or a binding material. A collection of features, or 2) α) iron and at least one other metal other than iron, or β) more than 50% by mass at least one nanoparticle comprising iron or iron oxide; Here, the at least two nanoparticles or at least one aggregate of nanoparticles are cooled. Meaning it is cooled by needles, Either The freezing system includes two parts:

2. 13. A method of treating a body part of an individual using the freezing system of claim 1, comprising the steps of: Steps a) administering nanoparticles to a body part of an individual; b) exposing a body part of the individual to said cooling probe; c) cooling the body part of the individual containing the nanoparticles from an initial temperature to a temperature lower than the initial temperature using a cooling probe. a cooling step of cooling said body part to a cooling temperature; d) changing the temperature of a body part, in particular containing nanoparticles, from the cooling temperature of said body part to the final temperature of the body part; or increasing the temperature of a body part from a cooling temperature of said body part to a body temperature. a warming step by either heating the part to a final temperature; e) Optionally, adjusting the temperature of the body part containing the nanoparticles by: i) cooling temperature or ii) Hold or cause to be held at a holding temperature between the cooling temperature and the initial or final temperature. a holding step, A freezing system comprising at least one of the steps:

3. A freezing system for use according to claim 1, characterized in that the initial temperature and / or the final The temperature is physiological, and the physiological temperature is in the following group: 1) The temperature of the body part before or after it has been treated by the method of claim 2; 2) the temperature of an individual not suffering from a fever; 3) Temperature between 25°C and 45°C 4) of an individual or a body part or the blood of that individual or the blood of that individual or the blood of that A temperature not exceeding 5°C above the average temperature of any part of the body measured over the individual's lifetime; 5) of an individual or a body part or the blood of that individual or the blood of that individual or the blood of that A temperature not more than 5°C below the average temperature of that part of the body measured over the individual's lifetime; A freezing system that is at a selected temperature.

4. A refrigeration system for use according to any of claims 2 or 3, in which the cooling Temperature is a group consisting of 1) the difference between the initial temperature and the cooling temperature is less than or equal to 57° C.; and 2) The difference between the final temperature and the cooling temperature is less than or equal to 57°C; A freezing system having at least one characteristic selected from:

5. A freezing system for use according to any one of claims 2 to 4, in which The steps of the method have the following characteristics: 1) Steps a), b), c), d) and / or e) of claim 2 are repeated; and 2) step c) precedes step d); A freezing system characterized by at least one of the following:

6. A refrigeration system for use according to any one of claims 2 to 5, in which during cooling Between 1 and heating time t 2 The next group is 1) t 1 is at least 1.1 times t 2 Shorter, 2) t 1 is 10 -6 More than a second 3) t 2 is 10 -6 More than a second 4) t 2 -t 1 is 10 -3 More than a second 5) t 1 is similar in the presence and absence of nanoparticles, and 6) t 2 is longer in the presence of nanoparticles than in their absence, The freezing system is characterized by at least one selected from the following:

7. A refrigeration system for use according to any one of claims 2 to 6, in which the cooling temperature A freezing system with a temperature higher than -40°C.

8. A freezing system for use according to any one of claims 1 to 7, comprising: 1) A cooling probe that is a medical device, apparatus or instrument; and 2) at least one nanoparticle that is a compound, drug, or medical device; A freezing system that is a set or combination of.

9. 10. A device according to any one of claims 1 to 8 for storing or maintaining coldness in a body part of an individual during cryotherapy.

2. Use of a freezing system according to any one of claims 1 to 11.

10. 10. Use of a freezing system according to claim 9, wherein 1) The temperature gradient is less than 150°C; or 2) The cooling temperature is -100°C or higher; Use of freezing systems to reach body parts.

11. Use of a freezing system according to any of claims 9 or 10, wherein 1) 1% or more of the mass or volume of the body part is cooled; and / or 2) A greater volume, surface area, or length of a body part is cooled in the presence of nanoparticles than in their absence. 、 use.

12. Use of a freezing system according to any one of claims 9 to 11, in which the second part The next group is 1) at least one nanoparticle is an ice nucleation site; and 2) at least two nanoparticles bound or attached to each other through a binding or bonding material; The size of the ice nucleation sites of the particles are not connected to each other, or are connected or bound or ice nucleation sites of at least two nanoparticles that are not bonded to one another via a bonding material Larger than the size of and,

13. Use of the freezing system according to any one of claims 9 to 12, in which cryotherapy is Non-ice ball cryotherapy or nanoparticle ice ball cryotherapy, 1) Non-ice sphere cryotherapy is ice therapy that does not contain or embed metal spheres or iron oxide nanoparticles. Cryotherapy is not just about balls. and 2) Nanoparticle iceball cryotherapy uses iceballs embedded or containing nanoparticles of metal or iron oxide. Cryotherapy, which includes Use characterized by.

14. 14. The composition according to claim 9, 10, 11, 12 or 13 for stimulating or activating the immune system. Use of freezing systems.

Citation Information

Patent Citations

  • Medical systems, methods, and devices for reducing pigmentation by cooling treatment

    JP2018526179A

  • Skin Freezing System for Treating Acne and Skin Conditions

    JP2019514616A

  • Cryoprobe with Integral Agent Delivery Device

    US20080027419A1

  • Method and apparatus for use of ice crystals in aesthetic and cosmetic procedures

    US20180310979A1

  • Cryotherapy device flow control

    WO2018142411A1

Cited By

  • Photoelastic sample crystallinity multi-modal data fusion analysis method and system

    CN121994795A